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1. Introduction 
1.1. Stroke 
It is estimated that around 15 million people become victim of this deadly disease every year 
all around the world, with one third destined to death and another one third left with lifelong 
disabilities (Corbyn, 2014). Strokes can be broadly classified as ischemic stroke and 
hemorrhagic stroke. Approximately 80% of the strokes are ischemic and are characterized by 
blockage of the cerebral blood vessels supplying brain, while remaining 20% are 
hemorrhagic, involving rupture of the blood vessels, with two major subcategories, i.e., 
intracerebral hemorrhage and subarachnoid hemorrhage (Murray et al., 2015). 
1.2. Subarachnoid hemorrhage 
Subarachnoid hemorrhage is a specific subtype of hemorrhagic stroke that is characterized by 
extravasation of the blood from a ruptured aneurysm into the subarachnoid space and also 
sometimes involves ventricles and deeper brain parenchyma (Suarez  et al., 2006; 
Macdonald, 2014). Although it accounts for only 5% of all the stroke events, but the 
mortality inflicted by it is around 50% (32% to 67%) and affects at relatively younger age 
compared to ischemic stroke with 27.3% of stroke related years of productive life lost (van 
Gijn et al., 2007; Macdonald, 2014; Fanizzi et al., 2017; Grasso et al., 2017). The incidence is 
estimated around 10.5 per 100,000 persons per year, but varies geographically with higher 
incidence in Japan (22.7) and Finland (19.7) (de Rooij et al., 2007; Grasso et al., 2017). In 
approximately 85% of the cases, rupture of the intracranial aneurysm is the underlying cause 
of subarachnoid hemorrhage (Macdonald and Schweizer, 2017), while the remaining cases 
with relatively good clinical outcome belong to non-aneurysmal SAH. The fatality of the 
disease is reflected by 20% deaths occurring before any medical attention, 30% within 24 
hours of onset and 40% - 60% within a month after subarachnoid hemorrhage (Korja and 
Kaprio, 2016; Grasso et al., 2017).  Among the survivors, one third remains lifelong 
dependent and those with good recovery still have neurological and/or cognitive deficits 
(Suarez  et al., 2006; van Dijk et al., 2016). 
1.3. Intracranial aneurysms and risk factors 
Aneurysms are the weak bulging lesions or abnormal dilatations present in almost 3.2% of 
our population. Aneurysms are formed due to the hemodynamic shear stress in the arterial 
wall at the bifurcation of arteries and are marked by chronic inflammation and degeneration 
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in the arterial wall (Etminan and Rinkel, 2016; Aoki et al., 2017). Majority of the aneurysms 
have a saccular or berry morphology (90%) and fusiform aneurysms occurring in posterior 
circulation account for only 10% (Drake and Peerless, 1997). The risk factors for the 
aneurysm development are hypertension, smoking, chronic alcohol consumption, aging, 
female gender, and family history of aneurysmal subarachnoid hemorrhage (aSAH) in first 
degree relatives (D’Souza, 2015). A few genetic disorders such as autosomal dominant 
polycystic kidney disease, Marfan syndrome, Ehlers-Danlos syndrome type IV, 
neurofibromatosis type 1, and fibromuscular dysplasia have been found to be associated with 
intracranial aneurysms formation (D’Souza, 2015) . Single nucleotide gene polymorphisms 
(SNPs) in or near the genes CDKN2B-AS1, SOX17 transcription regulator gene, endothelin 
receptor gene, HDAC9 and the gene encoding elastin have been revealed in genome wide 
association studies (GWAS) and linkage analysis to be strongly associated with intracranial 
aneurysms (Etminan and Rinkel, 2016). An exome wide association study has identified SNP 
of collagen type XVIIα1 chain gene to be significantly associated with aneurysmal 
subarachnoid hemorrhage (aSAH) (Yamada et al., 2017). 
1.4. Aneurysm treatment and post-aSAH complications 
The obliteration of the bleeding aneurysm from the arterial circulation is achieved by 
neurosurgical clipping and endovascular coiling in majority of the cases (Cahill and Zhang, 
2009), but still outcome of the patients is not improved. This is mainly due to the post-aSAH 
complications occurring mainly over the first two weeks  after initial bleed (Macdonald and 
Schweizer, 2017). The brain injury following aSAH occurs in two phases. An early brain 
injury occurring within initial 72 hours of the insult results from transient global cerebral  
ischemia and toxic effects of the extravasated blood (Cahill et al., 2006; Cahill and Zhang, 
2009; Macdonald and Schweizer, 2017). This may be followed by a secondary delayed phase 
of brain damage over a period of 3 – 14 days and is the time frame where post-aSAH 
complications can develop and cause neurological deterioration (Macdonald and Schweizer, 
2017). The major post-aSAH complications include rebleeding, cerebral vasospasm (CVS), 
hydrocephalus, seizures, delayed ischemic neurological deficits (DIND), cortical spreading 
depression, delayed cerebral ischemia (DCI), infections, cardiomyopathy and pulmonary 
edema (Suarez  et al., 2006). The research in the past was maligned by a sole focus on 
cerebral vasospasm and strategies aimed at its reversal were developed. The failure of the 
endothelin antagonists to improve the outcome despite reversing the cerebral vasospasm has 
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recognized that clinical outcome after aSAH is determined by multiple factors. These 
conflicting results led to change the direction of aSAH research to early brain injury with 
profound stress laid on the role of inflammation that plays crucial and central role in the 
development of post aSAH complications (Macdonald, 2014; Savarraj et al., 2017a; Savarraj 
et al., 2017b).  
1.5. Inflammation and subarachnoid hemorrhage 
Acute inflammation is the sentinel host defense response for protection against infection or 
injury and has been historically defined by the cardinal features such as redness (rubor), 
swelling (tumor), pain (dolor), heat (calor) and loss of function (functio laesa) (Galea and 
Brough, 2013; Murray et al., 2015; Basil and Levy, 2016). However, prolonged and 
dysregulated inflammation could be devastating and even detrimental following CNS insult 
(Murray et al., 2015). Inflammation occurring in the absence of pathogens (as in case of 
aSAH) is usually ascribed as sterile inflammation, however, involves similar cascades of 
mechanisms mounted against pathogens (Chen and Nuñez, 2010). This is owing to the 
pattern recognition receptors (PRRs) which respond to the evolutionarily conserved danger 
molecular motifs, which may either be exogenous ‘pathogen associated molecular patterns 
(PAMPs)’ derived from pathogens or endogenous ‘damage associated molecular patterns 
(DAMPs)’ molecules derived from injured, stressed and necrotic cells (Matzinger, 1994; 
Chen and Nuñez, 2010; Takeuchi and Akira, 2010).  Immediately after acute brain injury, 
local and systemic inflammatory response leads to  trigger inflammatory signaling cascades 
accompanied by the activation and infiltration of immune cells at the site of injury (Murray et 
al., 2015). A great body of evidence supports the critical role of inflammation in the aSAH 
(Provencio, 2013; Lucke-Wold et al., 2016; Savarraj et al., 2017a; Savarraj et al., 2017b). 
Moreover, evidence support that early inflammation after aSAH leads to poor outcomes 
(Provencio, 2013). Release of DAMPS might be critical to initiate and sustain the 
inflammation. 
1.6. Damage associated molecular patterns (DAMPs) and aSAH 
Any type of injury either ischemic or traumatic can potentially release damage associated 
molecular patterns from injured or stressed cells leading to inflammation without presence of 
any pathogens. During sterile inflammation DAMPs bind to the PRRs on immune cells, lead 
to activation of subcellular signaling pathways including NFκB and finally, upregulate the 
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expression of multiple genes including the transcription and release of pro-inflammatory 
mediators (Chen and Nuñez, 2010; Takeuchi and Akira, 2010; O'Neill et al., 2013). Over the 
past years, an ever expanding list of DAMPs along with their cognate receptors has been 
identified including HMGB1, HSPs (Heat Shock Proteins), S100 proteins, SAP130, ATP, 
mitochondrial DNA, formyl peptides, heparan sulphate, β-amyloid, biglycan, versican, IL-1α, 
IL-33, cholesterol and uric acid crystals (Chen and Nuñez, 2010). There is sufficient evidence 
that support the involvement of DAMPs in the pathophysiology of SAH. 
1.6.1. High mobility group box 1 (HMGB1) and aSAH 
HMGB1 (High mobility group box 1) is a well characterized prototypical protein DAMP. 
HMGB1 is expressed in all eukaryotic cells as a non-histone DNA binding nuclear 
transcription factor, but signifies danger upon its extracellular release from necrotic cells 
(Bianchi and Manfredi, 2009). Extracellularly released HMGB1 is then recognized by TLR-
2, TLR-4, TLR-9 and receptor for advanced glycation end products (RAGE) (Bianchi and 
Manfredi, 2009). Evidence on the role of HMGB1 after aSAH is increasing continuously in 
the recent years.  Release of HMGB1 in cerebrospinal fluid of patients after aSAH was found 
by Nakahara et al. (2009). Interestingly, the elevated HMGB1 levels were higher in the CSF 
of patients with a poor clinical outcome after aSAH and HMGB1 levels correlated with TNF-
α, IL-6 and IL-8, suggesting an indispensable role of HMGB1 in ongoing inflammation 
(Nakahara et al., 2009). King and colleagues also found significant associations of CSF 
HMGB1 levels with poor Hunt and Hess (H&H) grades and the disability and dependence 
among aSAH patients (King et al., 2010). A subsequent study employing a rabbit model of 
SAH has shown that HMGB1 was upregulated and translocated in the cytosol of the 
microglia for active secretion (Murakami et al., 2011). Zhu et al. (2012a) evaluated HMGB1 
levels in systemic circulation and demonstrated an association with CVS, poor functional 
outcomes and mortality after one year of aSAH, highlighting the prognostic value of on 
admission plasma HMGB1 determination.  
Sun et al. (2014b) found as early as 2 h post SAH release of HMGB1 from the neurons and 
intraventricular injection of recombinant HMGB1 upregulated the inflammation as assessed 
by upregulation of TLR-4, NF-κB, IL-1β and cleaved Caspase-3. Furthermore, in-vitro 
application of hemoglobin (Hb) led to the upregulation and translocation of HMGB1 from 
nucleus to cytoplasm in neuronal cultures. Interestingly, application of Glycyrrhizic acid, a 
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natural inhibitor of HMGB1, downregulated IL-1β and thus, prevented activation of glial 
cells upon conditioned medium application from Hb primed neurons (Sun et al., 2014b).  
Thereafter, two other natural compounds, Purpurogallin, a natural phenol and 4′-O-β-d-
glucosyl-5-O-methylvisamminol were demonstrated to attenuate HMGB1 expression in 
double hemorrhagic SAH rat model and intriguingly, were also effective in decreasing the 
cerebral vasospasm and its associated changes in basilar arteries (Chang et al., 2014; Chang 
et al., 2015a). A similar study employing Rhinacanthin-C, an extract from Rhinacanthus 
nasutus, ameliorated SAH associated increase in HMGB1 mRNA and protein as well as pro-
inflammatory cytokines and cleavage of Caspase-3 and Caspase 9 (Chang et al., 2016). 
Another clinical study described elevated CSF HMGB1 levels in acute hydrocephalus after 
aSAH and strong correlations with H&H score, WFNS (World Federation of Neurological 
Surgeons) score, GCS (Glasgow Coma Scale), days on intensive care unit and poor outcome 
after 3 months (Sokol et al., 2015). Wang and colleagues confirmed the association of CSF 
HMGB1 levels and poor outcome after 3 months in a relatively larger cohort of aSAH 
patients. Further, they revealed in SAH rat model that both HMGB1 and its receptor RAGE 
are upregulated and application of post-SAH CSF either from patients or rats induced RAGE 
expression and reduced viability of neuronal cultures. Interestingly, administration of 
recombinant soluble form of RAGE to interfere with RAGE and HMGB1 signaling reduced 
the neuronal cell death both in-vitro and in-vivo (Wang et al., 2016). The first evidence that 
HMGB1 may be involved in the inflammatory response leading to CVS, the most feared 
complication after aSAH, came from the observations of Zhao and colleagues. They observed 
increased expression of HMGB1 in the vasospastic rat basilar arteries at day 3, 5 and 7 after 
SAH (Zhao et al., 2016). Li et al. (2017) have shown increased basilar artery thickness and 
reduced luminal diameter with increased expression of HMGB1 protein and mRNA of pro-
inflammatory cytokines, and all these changes were ameliorated after glycyrrhizic acid 
supplementation for 3 days (Li et al., 2017). Finally, administration of anti-HMGB1 antibody 
prevented basilar artery vasospasm, decreased extracellular translocation and expression of 
HMGB1 in smooth muscle cells, decreased the expression of contractile and inflammation 
associated molecules, decreased plasma HMGB1 levels, improved the morphology and 
decreased the number of cerebral cortex microglia, and lastly recovery from the neurological 
deficits (Haruma et al., 2016). 
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Delayed cerebral ischemia (DCI) is seen in approximately 30% of the aSAH patients 
(Francoeur and Mayer, 2016). A case series of three aSAH patients with DCI has shown 
significant elevation of HMGB1 compared to controls, but did not show significant changes 
in both CSF and plasma HMGB1 levels as compared to baseline. Interestingly, there was a 
trend towards increase in plasma and decrease in CSF HMGB1 levels (Bell et al., 2017). 
Another study defined DCI as cerebral infarction and interestingly, found the presence of 
minor allele G of rs2249825 as an independent predictor of DCI. This single nucleotide 
polymorphism (SNP) of HMGB1 (C/G at 3814) may lead to enhanced HMGB1 expression 
and consequently result in DCI (Hendrix et al., 2017). The above discussed evidence suggests 
that HMGB1 not only plays a distinct role during early brain injury, but also in post aSAH 
sequelae with prominent involvement in CVS, DCI and thereby, impact the clinical outcome. 
1.6.2. IL-1α and IL-33 
IL-1α and IL-33 are both members of the IL-1 family of cytokines and are synthesized as 
pro-forms requiring cleavage of around 100 amino acid residues at the N-terminal to give 
mature forms (Kim et al., 2013). IL-1α and IL-33 share a unique feature that they have a dual 
role as intracellular transcriptional regulators and as extracellular potent regulators of 
inflammation (Hirsiger et al., 2012). Interestingly, both pro- and mature forms of IL-1α are 
active in inducing inflammation, whereas pro-IL-33 not and probably requires processing by 
serine proteases extracellularly into mature form (Kim et al., 2013). IL-1α, signaling via IL-
1R, is constitutively expressed in endothelial cells, keratinocytes and fibroblasts, but in 
monocytes/macrophages its synthesis occurs de novo (Hirsiger et al., 2012). IL-1α binds not 
only to cellular receptors, but also functions as a transcription factor in the presence of pro-
inflammatory stimuli such as LPS or TNF and promotes production of NF-κB (p65), IL-6 and 
IL-8 (Buryskova et al., 2004; Werman et al., 2004). Moreover, IL-1α can mediate recruitment 
of neutrophils via increased secretion of CXCL-1 by mesenchymal cells (Eigenbrod et al., 
2008). 
As discussed above, in a rat filament model of SAH, IL-1α was expressed mainly in 
microglia/macrophages after 12 hours with higher expression in basal structures adjacent to 
hemorrhage site in addition to cortex, striatum and hippocampus and co-localize with HO-1 
in activated microglia (Greenhalgh et al., 2012). Moreover, application of heme upregulated 
the secretion of active form of IL-1α from organotypic slice cultures and mixed glial cell 
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cultures and the administration of IL-1R antagonist reduced BBB breakdown and brain 
damage (Greenhalgh et al., 2012). Interestingly, IL-1α gene expression was highest at day 7 
and correlated with decreased vessel caliber in canine vasospastic basilar arteries isolated at 
different days after intracisternal blood injections (Aihara et al., 2001). Inhibition of p38-
MAPK signaling reduced IL-1α gene and protein expression in human VSMCs in vitro and 
downregulated IL-1α mRNA expression in canine basilar arteries showing reversal of 
vasospasm (Sasaki et al., 2004). Bowman et al. (2004) showed increased IL-1α levels in rat 
femoral arteries displaying vasospasm. 
IL-33 is known to have anti-inflammatory activity via promoting Th2 type response. IL-33 
can stimulate cells of innate and adaptive immunity via binding to ST2 membrane receptors 
(Chackerian et al., 2007). ST2 receptor is a member of TLR/IL-1R superfamily and its 
heteromer with IL-1R accessory protein (IL-1RAcP) is responsible for IL-33 signaling, while 
soluble ST2 (sST2) act as a decoy receptor (Jiang et al., 2012a). Interestingly, monocytes/ 
macrophages are polarized towards alternate type (M2) phenotype in the presence of IL-33 
(Kurowska-Stolarska et al., 2009). However, IL-33 has been assigned to play an 
inflammatory role in CNS reflecting its pleiotropic nature (Hudson et al., 2008; Jiang et al., 
2012a). Huang et al. (2014) have observed an increased expression of IL-33 mRNA and 
protein in the cerebral cortex of the rats after experimental SAH. Intriguingly, IL-33 
expression co-localized with neuronal and astrocytic markers and mRNA expression of IL-33 
correlated with that of IL-1β after SAH (Huang et al., 2014). So, IL-1α and IL-33 represent 
important DAMPs implicated in neuroinflammation after experimental SAH and therefore, 
needs further investigations. 
1.6.3. Mitochondrial DAMPs 
In recent years, mitochondria have been recognized as a host of different DAMPs including 
TFAM (mitochondrial transcription factor A), N-formyl peptides, cardiolipin and 
hypomethylated/non-methylated mitochondrial DNA which are released upon cell stress, 
injury and necrosis (Galluzzi et al., 2012). Mitochondrial DNA (mtDNA) has been identified 
a long time ago to induce TNF secretion from splenocytes and arthritis in mice joints (Collins 
et al., 2004). Zhang et al. (2010) have shown that circulating mtDNA, acting via TLR-9, 
elicits MAPK-signaling based migration and degranulation of neutrophils leading to organ 
injury. There are now evidences that mtDNA can upregulate innate immune responses 
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through several PRRs, most importantly TLR-9, NLRP3-, NLRC4-, AIM2-inflammasome 
complex and cGAS-STING (West and Shadel, 2017). Several studies have shown elevated 
circulating cell free mtDNA and its biomarker and prognostic potential in connection to 
diseases involving CNS pathology (Lu et al., 2010; Mathew et al., 2012; Podlesniy et al., 
2013; Sondheimer et al., 2014; Perez-Santiago et al., 2016; Podlesniy et al., 2016b; Podlesniy 
et al., 2016a; Varhaug et al., 2016). Wang and colleagues have evaluated plasma and CSF 
mtDNA levels from 21 aSAH patients and found significant elevation of mtDNA in the CSF 
on admission, which was associated with poor clinical outcome. However, plasma mtDNA 
levels showed a delayed elevation at day 8 in poor clinical outcome patients (Wang et al., 
2013). 
1.6.4. Hemoglobin and its derivatives 
The extravasated blood and its degradation products acutely trigger neuroinflammation in 
addition to global ischemic insult in aSAH (Macdonald, 2014; Miller et al., 2014). 
Erythrocyte hemolysate degradation yields methemoglobin, heme, hemin and 
oxyhemoglobin, which are described as TLR-4 ligands and as DAMPs (Piazza et al., 2011; 
Gladwin and Ofori-Acquah, 2014; David B. Kurland, 2015; Kwon et al., 2015). 
Methemoglobin leads to increased TNF-α secretion through its interaction with not only 
TLR-4 homodimers, but also TLR-2/TLR-4 heterodimers (Kwon et al., 2015). Heme 
promotes increased formation of Neutrophil Extracellular Traps (NETs) from neutrophils and 
heme activated TLR-4 only upregulates MyD88 dependent substream pathway leading to 
NFκB and MAPK activation with resultant TNF-α secretion (Gladwin and Ofori-Acquah, 
2014). Hemin (iron (III)-protoporphyrin IX) acts additively to endotoxin with a mechanism 
of TLR-4 activation distinct from endotoxin (Piazza et al., 2011). Oxyhemoglobin, which 
might spontaneously oxidize to methemoglobin, leads to increased TNF-α secretion from 
vascular smooth muscle cells (VSMCs) via increased TLR-4 expression and activation (Wu 
et al., 2010; David B. Kurland, 2015). 
It is well established that the degree of bleeding on initial CT scan correlates with poor 
clinical outcome (Suarez  et al., 2006). Hemoglobin and its derivatives released after 
erythrocyte hemolysis can induce contraction of cerebral arteries both in-vitro and in-vivo 
(Macdonald and Weir, 1991). Induction of basilar artery vasospasm by application of either 
LPS (TLR-4 ligand) or blood in the subarachnoid space indicated a common shared pathway 
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upregulating inflammation after SAH (Recinos et al., 2006). Furthermore, intra-subarachnoid 
administration of methemoglobin activates microglia with enhanced TNF-α and TLR-4 
upregulation (Kwon et al., 2015). Heme has demonstrated cytotoxic effects on macrophages, 
microglia, astrocytes and brain endothelial cells (Dutra and Bozza, 2014). It has also been 
shown that heme has the potential to induce IL-1β secretion via NLRP3 inflammasome in 
macrophages (Dutra et al., 2014). However, in a rat filament model of SAH, it was shown 
that heme upregulated the expression of HO-1 around the hemorrhage site and IL-1α, which 
was confirmed in-vitro by application of heme to organotypic slice cultures preferentially 
releasing IL-1α over IL-1β (Greenhalgh et al., 2012). So, hemoglobin and its degradation 
products play a role of DAMPs and strategies aimed at their early removal or neutralization 
may help to reduce the pathophysiological events triggered by subarachnoid blood hemolysis 
to prevent complications and improve clinical outcome. 
1.6.5. S100B 
S100B is the founding member of calgranulins, a family of small intracellular calcium 
binding proteins and is majorly expressed in astrocytes, with limited expression in neurons 
(Bianchi, 2007; Sorci et al., 2010). Passively released S100B by necrotic and damaged cells, 
has diagnostic and prognostic value in different CNS pathologies (Sen and Belli, 2007). At 
higher micromolar concentrations, extracellular S100B behaves as DAMP with neurotoxic 
effects mediated by RAGE and is involved in many neurodegenerative and inflammatory 
brain diseases (Bianchi et al., 2011). It can induce neuronal death, pro-inflammatory 
cytokines (IL-1β) and stress related inflammatory enzymes such as inducible nitric oxide 
synthase (iNOS) (Huang et al., 2010). 
S100B measured on admission or on various days post aSAH at both CNS and systemic 
levels has been shown to significantly rise after aSAH and found to be associated with 
severity of aSAH (H&H, WFNS grades), hematoma on CT (Fischer grades), neurosurgical 
clipping, CVS, intracranial hypertension, hydrocephalus and VP-shunt placement, cerebral 
infarcts, size of ischemic lesions, short-term survival and mortality, neuropsychological 
evaluation tests, and  functional outcome assessed at various intervals after aSAH (Masakazu 
Takayasu et al., 1985; Persson et al., 1987; Hardemark et al., 1989; Wiesmann et al., 1997; 
Petzold et al., 2003; Weiss et al., 2006; Pereira et al., 2007; Stranjalis et al., 2007; Sanchez-
Pena et al., 2008; Moritz et al., 2010; Brandner et al., 2012; Jung et al., 2013; de Azua Lopez 
et al., 2015; Kellermann et al., 2016; Lai and Du, 2016). 
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S100B release in the periphery has been found to be independent of BBB dysfunction and 
higher S100B serum/CSF ratio associated with better neurological function highlight a repair 
role for active stimulated release of S100B (Kleindienst et al., 2010). Lower serum levels of 
S100B observed after administration of magnesium sulphate and atorvastatin signifies its 
potential to monitor the therapeutic efficacy in aSAH patients (Hassan et al., 2012; Sanchez-
Pena et al., 2012). These lines of evidence clearly highlight the DAMP role of S100B in 
aSAH pathophysiology. 
1.6.6. Other DAMPs 
Components of the extracellular matrix (ECM), released upon proteolysis following tissue 
injury in soluble form can act as DAMPs (Schaefer, 2014). These normally ECM sequestered 
components such as biglycan, decorin, versican, tenascin-C, hyaluronan, and heparan sulfate 
are recently recognized as rapid activators of innate immune response by interacting with 
PRRs after their release (Moreth et al., 2012; Schaefer, 2014). Among these several of ECM 
released DAMPs have been investigated in preclinical and clinical investigations both at CNS 
and systemic levels after SAH and include hyaluronic acid, syndecan-1 (SDC-1, a heparan 
sulfate proteoglycan), sCD44 (hyaluronan receptor), Tenascin-C, Periostin, Fibronectin and 
Galectin-3 (Heula et al., 2015). 
Heat shock proteins (HSP) are highly conserved chaperones aiding in protein folding and 
represent another potential subgroup of DAMPs which can activate PRRs such as TLR-2 and 
TLR-4 leading to MyD88 dependent upregulation of NFκB (Kang et al., 2015). Numerous 
heat shock proteins such as HSP10, HSP20, HSP27, HSP32 (HO-1), HSP47, HSP60, HSP70, 
HSP72, and HSP90α have been shown to be implicated in SAH pathophysiology (Satoh et 
al., 2003; Matz et al., 1996b; Matz et al., 1996a; Turner et al., 1999; Macomson et al., 2002; 
Nikaido et al., 2004). Table 1 below represents some important DAMPs with their receptors. 
1.6.7. Significance of DAMPs investigation 
All the evidences described above suggest the involvement and importance of DAMPs in the 
context of aSAH pathophysiology. Since, DAMPs are the initiators of inflammation and 
therefore, their early blockage or sequestration may be helpful to reduce the ongoing 
inflammation and reduce the severity of the disease with protection against ensuing 
complications and poor outcomes. HMGB1 represent an excellent example, where pre-
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clinical approaches to neutralize HMGB1 by administering anti-HMGB1 monoclonal 
antibody or other molecules (ethyl pyruvate, glycyrrhizic acid, ghrelin, purpurogallin, 
siRNA) that inhibit the release of HMGB1 have been shown to be beneficial (Sun et al., 
2014b). Recombinant soluble form of RAGE to interfere with RAGE and HMGB1 signaling 
has been shown to be neuroprotective in experimental SAH (Wang et al., 2016). RAGE is 
implicated in the signaling of multiple DAMPs and represents a potential therapeutic target. 
Similarly, sST-2 administration to abrogate IL-33 signaling in SAH needs to be investigated 
(Boyapati et al., 2016). Since TLRs are implicated in the signaling of numerous DAMPs, 
therefore, they represent important modulatable targets to culminate DAMP signaling during 
brain injury (Downes and Crack, 2010). Furthermore, the other DAMP receptors and the 
downstream signaling pathways represent potential modulatable targets.  
Finally, investigation of the time course of various DAMPs may have a diagnostic and 
prognostic potential and will be helpful for early identification of the patients at increased 
risk of developing different complications and achieving poor clinical outcome. Therefore, it 
will aid in addressing early and aggressive treatment and management in these patients. 
Further, DAMPs may be used as treatment response markers. Systemic S100B and HMGB1 
represent interesting DAMP molecules that have been investigated in aSAH associated 
complications and may serve as potential biomarkers. Our knowledge, regarding DAMPs and 
their implication in complex pathophysiological events triggered after brain injury is still in 
infancy and further investigations aimed at combined multifaceted role of DAMPs in brain 
injury after aSAH are required. 
Table 1. List of some important DAMPs members and their receptors (Boyapati et al., 
2016) 
Sr. # DAMPs Receptors 
1. HMGB1 TLR-2, TLR-4, TLR-9, RAGE 
2. IL-1α IL-1R 
3. IL-33 ST2 (IL-1RL1) 
4. Heme, Hemin, Oxyhemoglobin, 
methemoglobin 
TLR-4 
5. mtDNA TLR-9, NLRP3, NLRC4, AIM-2, cGAS-
STING 
6. TFAM RAGE, TLR-9 
7. N-formyl peptides FPR1, FPRL1 
8. S-100 proteins TLR-4, RAGE 
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9. Fibrinogen TLR-4 
10. Fibronectin TLR-2, TLR-4 
11. Hyaluronan TLR-2, TLR-4 
12. Biglycan TLR-2, TLR-4, P2X4, P2X7, NLRP3 
13. Versican TLR-2, TLR-6, CD14 
14. Heparan sulfate TLR-4 
15. Tenascin C TLR-4 
16. Galectin-3 TLR-2, TLR-4 
 
1.7. Cytokine response and aSAH 
Interactions between the nervous system and immune system are becoming increasingly an 
important concern to be further explored in recent years and have been known to take place 
not only during homeostasis, rather during acute or chronic inflammation as well (Veiga-
Fernandes and Mucida, 2016). Apart from cell to cell contacts, soluble mediators such as 
cytokines and chemokines represent an important mode of communication at proximal and 
distal sites (Ordovas-Montanes et al., 2015). Circulating cytokines play an important role in 
determining the status of health in individuals and due to their involvement in immuno-
inflammatory responses after injury, they are increasingly implicated in potential immuno-
neuromodulatory effects in CNS diseases (Osuka et al., 1998; Oke and Tracey, 2009). As 
already mentioned above, the interest in the role of inflammation after aSAH has been fueled 
after the failure of endothelin antagonists to improve outcome despite successful reversal of 
vasospasm (Macdonald, 2014). Inflammation during early brain injury after aSAH is 
associated with secondary brain injury (Helbok et al., 2015). A great body of evidence 
supports the upregulation of different cytokines at both CNS and systemic levels (Kwon and 
Jeon, 2001; Takizawa et al., 2001; Niwa and Osuka, 2016; Chaudhry et al., 2017; Savarraj et 
al., 2017a; Savarraj et al., 2017b). Increased cytokines after aSAH mediate damage to the 
brain tissue and also upregulate the recruitment of inflammatory cells in a complex and 
vicious cycle (Macdonald, 2014). Pro-inflammatory cytokines have been known to contribute 
to early brain injury via increasing brain edema due to BBB disruption and inducing neuronal 
apoptosis (Ostrowski et al., 2006; Sozen et al., 2009). Systemic inflammatory response 
occurring in 75% of the cases after aSAH may have its roots in elevated levels of cytokines 
(Macdonald et al., 2014). The section below briefly reviews some important cytokines in the 
context of aSAH, post-aSAH complications and outcome. 
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1.7.1. IL-1β 
IL-1β represents one of the leading cytokines that remained the subject of intensive 
investigation in the context of CNS diseases as it is considered as a master cytokine 
regulating inflammation locally and systemically (Allan et al., 2005; Dinarello et al., 2012; 
Murray et al., 2015). IL-1 was identified as potent endogenous pyrogen and is known to be 
comprised of IL-1α and IL-1β as products of different genes (Allan et al., 2005; Murray et al., 
2015). Both are secreted as pro-forms, only IL-1α is active in pro-form, but pro-IL-1β is 
inactive and requires caspase-1 mediated activation to a 17 kDa mature form (Thornberry et 
al., 1992; Allan et al., 2005). IL-1β signals via engaging type-I IL-1 receptor (IL-1R1) and 
IL-1 receptor accessory protein (IL-1RAcP), while type-II IL-1R (IL-1R2) acts as a decoy 
receptor, devoid of any intracellular signaling domain (Sims et al., 1988; Korherr et al., 1997; 
Subramaniam et al., 2004; Boraschi and Tagliabue, 2013). All of these three receptors can be 
shed from the membrane and are also present as soluble forms (Subramaniam et al., 2004). A 
third ligand of IL-1 receptor acts as an antagonist (IL-1RA) and antagonizes the effects of IL-
1 competitively at IL-1R1 (Allan et al., 2005; Murray et al., 2015). 
Preclinical and clinical studies in the setting of ischemic stroke have shown elevation of IL-
1β (Allan et al., 2005; Murray et al., 2015). Similarly, several preclinical studies have shown 
upregulation of IL-1β in the cerebral cortex, basilar arteries and in the peripheral circulation 
after SAH (Keiichi Iseda et al., 2007; Sozen et al., 2009; Kooijman et al., 2014b; Zhou et al., 
2015; Chen et al., 2016; Wu et al., 2016b; You et al., 2016; Huang et al., 2017). IL-1β levels 
have been shown to increase at both CNS and systemic levels in aSAH patients (Hirashima et 
al., 1997; Kwon and Jeon, 2001; Muroi et al., 2008; Hopkins et al., 2012; Zhou et al., 2015). 
A significant upregulation of IL-1β was seen in CSF of aSAH patients with higher H&H 
grades and non-significant 3 folds higher levels were observed in patients developing DIND 
(Kwon and Jeon, 2001). However, IL-1β levels were found to be non-significantly very low 
in CSF of aSAH patients either with higher Fischer grades or poor clinical outcome (Kwon 
and Jeon, 2001). IL-1β levels were found to be higher in CSF of aSAH patients showing CVS 
and poor clinical outcomes and levels in plasma were low, suggesting an intrathecal origin 
(Fassbender et al., 2001). IL-1β is known to induce toxicity in cerebral endothelial cells in-
vitro and preclinical studies also show an upregulation of IL-1β during CVS (Kimura et al., 
2003; Keiichi Iseda et al., 2007). Moreover, LPS stimulation of monocytes showed increased 
IL-1β activation index in aSAH patients who later on developed CVS (Nam et al., 2001). In a 
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rat-SAH model, administration of intracerebroventricular anti-IL-1β antibody conferred 
protection against vasospasm (Jedrzejowska-Szypułka et al., 2009). 
Interestingly, serum levels of soluble form of IL-1RA have been found to be upregulated 
after aSAH (Gruber et al., 2000). Elevation of IL-1RA in CSF has been shown to associate 
with DCI and poor clinical outcome (Mathiesen et al., 1997). Administration of sIL-1RA to 
interfere with IL-1 signaling has shown neuroprotective effects in SAH model (Greenhalgh et 
al., 2012). Administration of Anakinra, a recombinant form of IL-1RA has shown decreased 
levels of neutrophils, CRP and IL-6 with improvement of clinical scores during 6 hours of 
ischemic stroke. A similar phase II clinical study investigating twice a day subcutaneous 
administration of Anakinra for 21 days after aSAH found reduction of systemic inflammation 
reflected by reduced IL-6 levels and improved functional outcome at 6 months, though non-
significant (Galea et al., 2017a). Due to better tolerance and desirable effects of IL-1RA, 
currently a phase III clinical study in aSAH is underway (Galea et al., 2017a). 
1.7.2. TNF-α 
TNF-α, also called cachectin, was identified to be a factor in blood capable of inducing 
hemorrhagic necrosis in tumors and a macrophage mediator linked to disease associated 
wasting and shock (Probert, 2015). TNF-α is synthesized as a 26 kDa transmembrane protein, 
which is cleaved by metaloprotease, TNF-α converting enzyme (TACE)/ADAM17 to liberate 
soluble trimeric TNF-α (17 kDa), which binds TNF receptor I (TNFR1 – also known as 
p55/p60 and a death domain containing protein) constitutively expressed at low levels or 
TNFR2 (p75/p80); initiating a complex substream signaling, also involving NFκB mediated 
expression of cytokines and chemokines (Sedger and McDermott, 2014; Probert, 2015). 
TNF-α is an acute phase reactant cytokine released by a variety of cells under inflammatory 
clues (Hong et al., 2014). Besides IL-6 and IL-1β, TNF-α is one of the principal cytokines 
secreted by microglia and astrocytes and has also been shown in preclinical SAH studies to 
be released by glial cells (McKeating and Andrews, 1998; van Dijk et al., 2016). TNF-α has 
been known to recruit inflammatory cells and mediate cellular injury (Mathiesen et al., 1997). 
In the CSF of aSAH patients, the CD16
+
 monocytes may be a source of TNF-α (Moraes et 
al., 2015). This pro-inflammatory cytokine is linked with both homeostatic and 
pathophysiological roles and is one of the leading cytokines mediating neuroinflammation. 
The effects of TNF-α are not only restricted to immune cells, but can also mediate 
excitotoxicity by impairing astrocytic glutamate transport and upregulation of Ca
2+
 
Introduction 
15 
 
permeability associated AMPA and NMDA receptors and downregulation of inhibitory 
GABAA receptors in neurons (Olmos et al., 2014).  
TNF-α plays a critical role in intracranial aneurysm formation and their rupture which results 
in SAH (Jayaraman et al., 2005; Jayaraman et al., 2008; Starke et al., 2014).TNF-α has been 
demonstrated in a number of preclinical studies to be upregulated to play an inflammatory 
role and involved in disruption of blood brain barrier (BBB) after SAH (Chen et al., 2016; 
Haruma et al., 2016; Wu et al., 2016a). TNF-α release after aSAH in interstitial fluid has been 
determined by microdialysis (Hanafy et al., 2010b). Increased levels of TNF-α have been 
detected after aSAH, which were correlated with the severity of aSAH assessed by H&H 
grade (Schallner et al., 2015; Zhou et al., 2015; Wu et al., 2016a). Elevated levels of TNF-α 
in CSF have been shown to be associated with CVS (Fassbender et al., 2001; Wu et al., 
2016a). Interstitial levels of TNF-α well correlated with angiographic vasospasm in poor 
grade aSAH patients (Hanafy et al., 2010a). TNF-α has been shown to mediate 
vasoconstrictive properties of hemolyzed blood and is responsible for causing CVS 
(Vecchione et al., 2009). Moreover, TNF-α has shown toxicity in cerebral endothelial cells 
through cleavage of caspase-3 and inducing apoptosis in them (Kimura et al., 2003). A non-
significant two fold higher CSF levels of TNF-α were found in aSAH patients presenting 
with DIND (Kwon and Jeon, 2001). Interestingly, a study evaluating the effect of 
hypothermia and barbiturates on inflammatory cytokines has found elevated levels of TNF-α 
in combined therapy group compared to the other without combined therapy at both CSF and 
plasma level (Muroi et al., 2008). Mathiesen and co-authors (1997) have found a significant 
elevation of CSF TNF-α level during 4 – 10 days after aSAH in patients with poor clinical 
outcome (Mathiesen et al., 1997). Early systemic levels of TNF-α are associated with poor 
functional outcomes (Chou et al., 2012). In a rat SAH model, pretreatment with TNF-α 
blocking antibody significantly protected the hippocampus neuronal loss due to apoptosis 
(Jiang et al., 2012b). So, all these evidences suggest that TNF-α plays an important role in 
inflammation induced after aSAH. 
1.7.3. IL-6 
IL-6 is a pleiotropic cytokine with hormone like activity that can influence vascular and 
metabolic diseases (Bethin et al., 2000; Hodes et al., 2014; Kraakman et al., 2015). IL-6 
signals via IL-6R (CD126, type 1 cytokine α-receptor subunit) and gp130 (CD130, β-receptor 
subunit) and involves downstream pathways such as GTPase Ras-Raf, MAPK and JAK-
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STAT (Scheller et al., 2011; Hunter and Jones, 2015). Three modes of IL-6 signaling have 
been identified: classical involving membrane bound IL-6R and gp130; trans-signaling 
dependent on soluble IL-6R whereby only gp130 expressing cells can gain response to IL-6-
sIL-6R complex; and recently identified cluster signaling in which dendritic cells harboring 
IL-6-IL-6R complex in their membranes engage gp130 on the target cell membranes 
(Scheller et al., 2011; Hunter and Jones, 2015; Quintana, 2017).  Depending on the context of 
disease, IL-6 has both pro-inflammatory and anti-inflammatory effects (Hunter and Jones, 
2015).  
In acute pathological conditions including aSAH, IL-6 stimulates the neuro-inflammatory 
response that may contribute to the disease progression (Suzuki et al., 2009). Both TNF-α and 
IL-1β are elevated in CSF during early inflammatory cascade and induce IL-6 after aSAH 
(Mathiesen et al., 1997). Increased CSF levels of IL-6 correlate with the severity of aSAH 
(Gruber et al., 2000; Kwon and Jeon, 2001; Kiiski et al., 2017). IL-6 levels in cerebrospinal 
fluid (CSF) of patients after aSAH have been shown to be associated with occurrence of 
cerebral vasospasm and poor clinical outcome (Gaetani et al., 1998; Osuka et al., 1998; 
Gruber et al., 2000; Fassbender et al., 2001; Nam et al., 2001; Schoch et al., 2007; 
Sarrafzadeh et al., 2010; Helbok et al., 2015; Niwa and Osuka, 2016; Wu et al., 2016a; Zeiler 
et al., 2017). Increased expression of IL-6 mRNA was observed in canine vasospastic basilar 
arteries at day 7 (Aihara et al., 2001). Patients presenting with DIND post-aSAH display 
significantly higher IL-6 levels, both at CSF and systemic levels (Kwon and Jeon, 2001; 
Muroi et al., 2013). IL-6 measured in CSF has also been shown to predict infection and 
shunt-dependency due to chronic hydrocephalus after aSAH (Hopkins et al., 2012; Wostrack 
et al., 2014; Kiiski et al., 2017). Gruber et al. (2000) have shown a trend towards raised IL-6 
in the CSF of aSAH patients who developed cerebral infarction. Serum IL-6 levels after 
aSAH were associated with the development of DCI, and DCI is a major factor leading to 
poor clinical outcomes (McMahon et al., 2013). Moreover, elevated early serum IL-6 levels 
predict the unfavourable clinical outcome (Muroi et al., 2013; Hollig et al., 2015b; Hollig et 
al., 2015a; Kao et al., 2015).  
IL-6 represents also one of the extensively investigated cytokines in the CSF of aSAH 
patients and development of point of care testing at the patient bedside after aSAH highlight 
its importance in ongoing inflammation (Dengler et al., 2008). IL-6 has also been shown to 
represent a surrogate measure of response monitoring after administration of various 
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therapeutic agents to aSAH patients (Muroi et al., 2008; Kawaguchi et al., 2010; Muroi et al., 
2012; Muroi et al., 2014; Singh et al., 2014; Galea et al., 2017a). Above evidence also 
suggests that IL-6 has an important prognostic potential for aSAH associated complications 
and clinical outcomes and represents an important cytokine in aSAH associated 
inflammation. 
1.7.4. IL-23 
IL-23 is a heterodimeric cytokine composed of p40 (shared with IL-12 p40) and p19 subunits 
and signals by binding to IL-23R and IL-12Rβ1 (Oppmann et al.; Parham et al., 2002). The 
p19 subunit of IL-23 shares structural homology with IL-6 and TNF-α (Oppmann et al., 
2000). The exogenous and endogenous stimuli trigger the release of IL-23 from activated 
dendritic cells and activated macrophages (Uhlig et al., 2006; Lyakh et al., 2008). IL-23 can 
drive the polarization of T helper cells into Th17 cells producing a pro-inflammatory 
cytokine IL-17 and expressing IL-23R (Lyakh et al., 2008; Ghoreschi et al., 2010). Systemic 
IL-23 levels are found to be elevated in a number of diseases including systemic lupus 
erythematosus, psoriasis, urticaria, asthma, rheumatoid arthritis, multiple sclerosis, 
schizophrenia, and Alzheimer’s disease (Ciprandi et al., 2012; Wen et al., 2012; Atwa et al., 
2014; Chen et al., 2014; Du et al., 2014; Borovcanin et al., 2015; Fotiadou et al., 2015; 
Wendling et al., 2015). In a mouse model of ischemic stroke, serum IL-23 as well as IL-23 
mRNA and  protein levels in the brain tissue were raised and contributed to evolution of 
infarct volume (Ma et al., 2013). Mice deficient in IL-23 p19 displayed protection against 
ischemia/ reperfusion injury (I/R) and better behavioural outcomes (Shichita et al., 2009). 
Interestingly, the source of IL-23 were infiltrating macrophages from the peripheral 
circulation (Shichita et al., 2009). Moreover, serum IL-23 levels has been shown to be 
increased in patients with carotid atherosclerosis, which accounts for 20 – 30% of ischemic 
stroke events (Abbas et al., 2015). 
1.7.5. IL-17 
IL-17 or IL-17A is a signature cytokine for Th17 cells which express transcription factor  
RORγt (retinoic acid receptor-related orphan receptor-γt) and require IL-23 for maturation to 
an inflammatory phenotype (Gaffen et al., 2014). In addition to Th17 cells, IL-17 is also 
secreted by other innate immune cells such as γδ T cells, NK T cells and innate lymphoid 
cells (Gaffen et al., 2014). IL-17 signals mainly through heterodimeric complex of IL-17RA 
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and IL-17RC and activates downstream pro-inflammatory pathways NFκB, MAPK and 
C/EBP (Korn et al., 2009; Gaffen et al., 2014). IL-17 can upregulate inflammation by 
inducing secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and 
chemokines for recruiting neutrophils and macrophages (Mills, 2008). IL-17 plays a key role 
in many inflammatory autoimmune diseases such as psoriasis, inflammatory bowel disease, 
multiple sclerosis, rheumatoid arthritis and asthma (Korn et al., 2009; Gu et al., 2013). 
Shichita and co-authors have shown that IL-17 producing cells (mainly γδ T cells) mediate 
ischemic-reperfusion injury (Shichita et al., 2009). IL-17 positive lymphocytes were also 
detected in post stroke autopsies and antibody mediated neutralization of IL-17 in 
experimental stroke reduced infarction and improved outcome (Gelderblom et al., 2012). 
However, detailed investigations of IL-17 in the context of aSAH at both clinical and 
preclinical level are scarce. Very recently, a study investigating network analysis of cytokines 
in the peripheral circulation after aSAH has shown that IL-17A is detectable after aSAH and 
IL-17A was correlated with IFN-γ under different conditions associated with aSAH (Savarraj 
et al., 2017a; Savarraj et al., 2017b).  
1.7.6. IL-10 
IL-10 represents an important anti-inflammatory cytokine that is co-induced with pro-
inflammatory cytokines via pathways which have negative regulatory feedback impact to 
limit damage to the host (Wang et al., 2017). IL-10 is secreted by almost all types of immune 
cells under different conditions including Th cells, Tregs, CD8+ T cells, B cells, DCs, 
macrophages, eosinophils, neutrophils and NK cells (Wang et al., 2017). Interleukin-10 was 
shown to be produced by Th2 cells (anti-inflammatory) and inhibit the pro-inflammatory Th1 
response (Moore et al., 2001; Couper et al., 2008). However, IL-10 has been shown to 
regulate Th2 responses induced by Schistosoma infestation, Aspergillus infection or allergens 
(Wang et al., 2017). IL-10 also limits pro-inflammatory cytokine secretion from macrophages 
and DCs (Moore et al., 2001; Couper et al., 2008). IL-10 inhibits production of pro-
inflammatory cytokines such as IL-1α, IL-1β, IL-6, IL-12, IL-18, G-CSF, TNF-α, PAF, LIF 
and chemokines such as MCP-1, MCP-5, MIP-1α, MIP-1β, RANTES, CXCL8, IP-10, MIP-
2, KC etc. from monocytes/macrophages (Moore et al., 2001). Interestingly, IL-10 promotes 
differentiation of IL-10 secreting Treg cells with immunosuppressive properties 
(Hawrylowicz and O'Garra, 2005). Human IL-10, a homodimer of 35kDa, is encoded by 
chromosome 1 and is secreted after cleavage of an 18 amino acids long signal peptide from a 
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protein comprising 178 amino acids (Sabat et al., 2010). IL-10 signaling is mediated by 
binding to IL-10 receptor (IL-10R) through downstream pathway dependent upon STAT3 
(Sabat et al., 2010; Wang et al., 2017). 
IL-10 has been shown to be upregulated in different CNS pathologies and limit inflammation 
via reduction of pro-inflammatory cytokine synthesis, decreasing cytokine receptor 
expression and also inhibiting receptor activation with a promotion of neuronal and glial cell 
survival (Strle et al., 2001). Pre-clinical studies employing SAH models have shown non-
significant upregulation of IL-10 in the CNS and basilar arteries and it was associated with a 
rise in pro-inflammatory cytokines (Aihara et al., 2001; Kooijman et al., 2014b; Song et al., 
2014; Li et al., 2017). In ruptured intracranial aneurysms, reduction in IL-10 expression has 
been seen with upregulated expression of TNF-α and some SNPs in IL-10 gene have been 
identified to be associated with the formation of intracranial aneurysms (Jayaraman et al., 
2005; Sathyan et al., 2015). In clinical studies, IL-10 levels have been shown to follow a 
constant pattern when present in detectable amounts when determined in extracellular fluid 
by microdialysis or in CSF (Mellergård et al., 2008; Mellergard et al., 2011; Hopkins et al., 
2012). Systemic levels of IL-10 were also shown to reflect similar pattern as observed at CNS 
level (Hopkins et al., 2012). In a study comparing systemic IL-10 levels among 
endovascularly based normothermia and conventional temperature management in aSAH 
patients has not shown any significant difference (Broessner et al., 2010). Serum IL-10 levels 
have been shown to follow a significant decrease after initial rise in SAH patients (Dziurdzik 
et al., 2004). Most of the studies investigating IL-10 levels after aSAH are without 
comparative controls (Dziurdzik et al., 2004; Mellergård et al., 2008; Mellergard et al., 2011; 
Hopkins et al., 2012; Savarraj et al., 2017a; Savarraj et al., 2017b). A study investigating 
plasma IL-10 levels in aSAH patients in comparison to patients with unruptured intracranial 
aneurysms has not shown any significant difference (Chamling et al., 2017). Only a small 
single study has recruited healthy control group and found a significant elevation at day 1 and 
non-significant elevation at day 3 after aSAH of plasma IL-10 levels and furthermore, found 
significant IL-10 release from PBMCs from aSAH patients on LPS stimulation (Kinoshita et 
al., 2007). Systemic IL-10 levels have been found to be significantly higher in aSAH patients 
with poor Hunt and Hess grades (H&H ≥ 4), higher Fischer grades, and contracting 
pneumonia infection (Chamling et al., 2017; Savarraj et al., 2017a; Savarraj et al., 2017b). 
Recently, IL-10 levels measured within 48 hours after aSAH have shown to be elevated 
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significantly in patients with general cerebral edema and higher subarachnoid hemorrhage 
early brain edema score (Savarraj et al., 2017a). The same study with slightly different 
dichotomization of the mRS has shown significantly higher serum IL-10 levels after aSAH in 
patients with poor clinical outcome at discharge (Savarraj et al., 2017a). Previous studies 
investigating IL-10 levels after ischemic stroke, intracerebral hemorrhage and traumatic brain 
injury have shown association of elevated IL-10 levels with poor functional outcomes (Garcia 
et al., 2017). Pre-clinical and clinical studies investigating serum IL-10 levels in detail after 
aSAH are still lacking (Garcia et al., 2017).  
1.7.7. CCL5/RANTES 
Chemokines represent small 8 – 14 kDa soluble cytokines which play a major role in 
chemotaxis and the recruitment of leucocytes (Zlotnik and Yoshie, 2000; Dorner et al., 2002). 
Based on the arrangement of the cysteine residues in the conserved structure from N-
terminal, different chemokine families such as C, CC, CXC and CX3C have been identified 
(Mantovani, 1999; Zlotnik and Yoshie, 2000). In humans, around 50 chemokines are known 
to exist (Rollins, 1997; Mantovani, 1999). Some chemokines are known to be constitutively 
expressed with homeostatic roles in many physiological processes, while several others are 
induced during inflammation in response to inflammatory stimuli with critical role in innate 
and adaptive immune responses (Mantovani, 1999; Dorner et al., 2002; Raman et al., 2011). 
Regulated on activation, normal T cell expressed and secreted (RANTES) or CCL5 is a pro-
inflammatory chemokine from class CC of chemokines and binds several of seven 
transmembrane GPCRs such as CCR5, CCR4, CCR3, CCR1, Syndecan (SDC)-1, SDC-4, 
and CD44 (Rollins, 1997; Xia and Hyman, 1999; Zlotnik and Yoshie, 2000; Suffee et al., 
2017). CCL5 is secreted by T-lymphocytes, endothelial cells, epithelial cells, endometrial 
cells, smooth muscle cells, platelets, eosinophils, fibroblasts, glial cells and neurons (Appay 
and Rowland-Jones, 2001; Terao et al., 2008; Levy, 2009; Tokami et al., 2013). In vitro, 
RANTES is known to be as potent as MCP-1 for monocytes and has also been known to act 
as chemoattractant for CD4
+
 T cells, CD8
+
 T cells, eosinophils, NK cells, and basophils 
(Rollins, 1997). 
 In numerous CNS related pathologies, CCL5 has been known to play an inflammatory role 
(Simpson et al., 2000; Bartosik-Psujek and Stelmasiak, 2005; Cartier et al., 2005; Zaremba et 
al., 2006; Tang et al., 2014; Cerri et al., 2017). Elevated CCL5 has been regarded as a risk 
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factor for stroke in asymptomatic subjects (Canouï-Poitrine et al., 2011). Increased plasma 
levels of CCL5 have been observed after traumatic brain injury and ischemic stroke (Tokami 
et al., 2013; Albert et al., 2017). In a cerebral ischemia model, knockout of RANTES was 
associated with relatively lower infarct volume and reduced plasma levels of IL-6, IL-10 and 
IL-12 and furthermore, circulating blood cells were identified as a potential source of 
RANTES that mediates BBB disruption, cerebral inflammation and infarction (Terao et al., 
2008). In contrast to this, CCR5 knockouts had larger infarcts (Woiciechowsky et al., 1998). 
Tokami et al. (2013) has suggested an autocrine or paracrine role of neuron derived CCL5 
which upregulates neuroprotective growth factors such as BDNF, EGF and VEGF and 
downregulates Caspase-3 in neurons through CCR5 and CCR3 ligation on neurons. 
Furthermore, they speculate that CCR1 expression by endothelial cells and by circulating 
blood cells may underlie the acute detrimental effects of RANTES (Tokami et al., 2013). 
Pedrazzi et al. (2007) have shown that HMGB1 could lead to secretion of CCL5 from 
astrocytes and due to localization of astrocytes in close proximity to BBB, secreted CCL5 
may play an important role in microglial and blood monocyte migration and activation, thus 
enhancing the brain damage. Promotion of leucocyte infiltration at the inflammation site is a 
well established effect of RANTES (Appay and Rowland-Jones, 2001). CCL5 has been 
shown to mediate the brain damage through increasing the infiltration of mononuclear cells 
through BBB and lead to secondary brain injury via induction of potent inflammatory 
cytokines (Mirabelli-Badenier et al., 2011). Furthermore, CCL5 produced by DCs lead to a 
Th1 polarized response (Lebre et al., 2005; Ma et al., 2007). Interestingly, monoclonal 
antibody targeting of CCL5 has shown reduced leucocyte infiltration in CNS and also 
prevented neurological deficits in MS mouse model (Chang et al., 2015b). 
CCL5 expression has been shown to be upregulated in the rat cerebral aneurysm arterial walls 
(Aoki et al., 2008). In a study focused on identifying expression of long non-coding (lnc)-
RNAs identified 17 lnc-RNAs targeting CCL5 in cerebral aneurysms on resections (Li et al., 
2016). Recent preclinical investigations in the context of SAH have demonstrated the 
involvement of CCL5 in ongoing inflammation (Smithason et al., 2012; Chang et al., 2015b). 
Analysis of multiple systemic cytokines after aSAH has already shown that CCL5 levels 
peaked 6-8 days after aSAH, but were the part of the cluster of platelet associated cytokines 
that were correlated at all the times of assessment after aSAH and included platelet derived 
growth factor (PDGF)-AA, PDGF-AB/BB, sCD40L, CXCL1P1 and TNF-α (Savarraj et al., 
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2017b). Interestingly, the CCL5 levels were shown to be negatively correlated with FLTL3 in 
less severe grade aSAH patients (Savarraj et al., 2017b). 
1.8. Immune cell response after aSAH 
1.8.1. Monocyte response 
Monocytes represent important members of the mononuclear phagocyte system comprised of 
myeloid derived cells (Jakubzick et al., 2017). Increased infiltration of monocytes has been 
observed in the stem and frontal parts of the brain at 90 minutes and 24 hours after 
experimental SAH, which was significantly reduced after antibody mediated IL-1β 
neutralization (Jedrzejowska-Szypułka et al., 2009). It was interesting to note that application 
of CSF from aSAH patients led to increased monocyte transmigration through human 
endothelial cell layers in in-vitro migration assay (Schneider et al., 2012). Monocytes have 
been regarded as a source of IL-1β and IL-6 in CSF of aSAH patients (Takizawa et al., 2001). 
Rat basilar arteries showing vasospasm highly express CD34 after SAH and play a major role 
in monocyte/ macrophage recruitment in addition to others (Wang et al., 2010). Increased 
adventitial infiltration of monocytes was seen after SAH in rat basilar arteries and that was 
abrogated by 6-mercaptopurine supplementation (Chang et al., 2010). Chang and colleagues 
have described increased perivascular MCP-1
+
 (Monocyte Chemoattractant Protein-1/ CCL2) 
monocytes in double hemorrhagic SAH model (Chang et al., 2015a). Mice carrying negative 
mutations of  PPARγ in smooth muscle cells express increased monocyte/macrophage marker 
CD68 in cerebral arteries along with CXCL1, MCP-1 and TNF-α and increased incidence of 
aneurysm formation and rupture (Hasan et al., 2015). Aoki et al. (2017) have demonstrated 
that macrophage infiltration led by MCP-1 and activation of NFκB involving PGE2-PGEP2 
(PGE receptor subtype 2) signaling in arterial wall leads to aneurysm formation, suggesting 
that inflammation is not only present after aneurysm rupture, rather also drives aneurysm 
formation. 
Yang and co-authors have found a significant increase in blood monocytes after aSAH and 
increased expression of leucocyte adhesion molecules PSGL-1 and Mac-1 (Yang et al., 
2012). Interestingly, PSGL-1 expression on admission was significantly associated with the 
development of DCI (Yang et al., 2012). Monocytes harvested from aSAH patients showing 
vasospasm when stimulated with LPS ex-vivo has shown increased IL-1β release (Nam et al., 
2001). Another compelling evidence for the role of monocytes in post-aSAH inflammation 
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came from the findings of Ma et al., (2015), who found increased TLR-4 expression on 
monocytes after aSAH. TLR-4 expression on PBMCs was highest on day1 and low on day 7. 
Furthermore, it was associated with aSAH severity (H&H IV-V), Fischer score, CVS, DCI, 
infarction and poor clinical outcome (Ma et al., 2015). Transcriptomic analysis of the 
peripheral blood revealed upregulation of genes pertinent to monocytes after aSAH (Pera et 
al., 2013). Intriguingly, decreased HLA-DR expression on monocytes and reduced TNF-α 
secretion from monocytes in LPS stimulation ex-vivo functional assay was seen in aSAH 
patients presenting with DIND and contracting pneumonia infection, implicating an 
impairment of immune cell function (Sarrafzadeh et al., 2011). 
Mills et al. (2000) described for the first time M1/M2 paradigm similar to Th1/Th2, where 
M1 represent pro-inflammatory monocytes/macrophages, whereas M2 as anti-inflammatory 
ones. Ruptured intracerebral aneurysms from patients were shown to possess increased M1 
(HLA-DR
+
) cells opposed to M2 (CD163
+
) cells as revealed by immunohistochemical 
analysis of aneurysm dome resections (Hasan et al., 2012). However, human monocytes have 
been characterized into three subgroups based on differential cell surface expression of CD14 
and CD16 as classical CD14
++
CD16
-
, intermediate CD14
+
CD16
+
 and non-classical 
CD14
+
CD16
++ 
(Ziegler-Heitbrock et al., 2010; Ziegler-Heitbrock and Hofer, 2013; Guilliams 
et al., 2014). A flow cytometric analysis from aSAH patients showed increased 
CD14
++
CD16
+
 monocytes in CSF compared to peripheral blood, but their reduced counts in 
the peripheral blood of aSAH patients compared to healthy controls (Moraes et al., 2015).  
CD16+ monocytes have already been described as pro-inflammatory, since they represent 
activated state owing to CD16 expression, upregulated expression of pro-inflammatory 
cytokines, and enhanced antigen presentation potency (Moraes et al., 2015). 
1.8.2. T cell response 
Lymphocytes upon activation also release different cytokines mediating damaged cells 
clearance, infected cell killing and microbial neutralization (Zhou et al., 2017). Lymphocyte 
infiltrations have been observed in CVS affected arteries on autopsies (Hughes and 
Schianchi, 1978). Aneurysmal tissue harvested during aneurysm clipping contained 
numerous T cells, while B cells were rare (Chyatte et al., 1999). Increased infiltration of T 
cells has been observed in subarachnoid space in close proximity to cerebral blood vessels 
after experimental SAH and numbers of T cells and helper T cells (CD4+) have been shown 
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to peak after two days of SAH induction and persist significantly in higher numbers till day 7 
compared to shams (Kubota et al., 1993). Of note, peripheral T cells showed significant 
elevation at day 3, but not the helper T cells (Kubota et al., 1993). Moreover, T cells 
expressing IL-1β were also detected in the CSF from aSAH patients (Takizawa et al., 2001). 
Impairments in proliferative properties of suppressor lymphocytes (now known as Treg cells) 
were documented in the peripheral blood of aSAH patients and later on, (Chrapusta et al., 
2000) have shown significant decrease in CD4+ T cells in dexamethasone treated aSAH 
patients compared to controls and decreased proliferative response, while enhanced T cell 
adhesion and T cell co-stimulatory properties in the peripheral blood of aSAH patients (Ryba 
et al., 1993). Interestingly, patients presenting with CVS had increased CD4+ T helper cells 
in the peripheral blood and more aggressive T cell adhesion and co-stimulatory properties 
(Chrapusta et al., 2000). 
Several studies have investigated CD4+ T helper cells in the peripheral blood after aSAH 
(Chrapusta et al., 2000; Sarrafzadeh et al., 2011; Moraes et al., 2015; Zhang et al., 2015; 
Zhou et al., 2017). Over the past different subsets of CD4+ T helper cells have been 
characterized, more importantly Th1, Th2, Th17 and Treg cells. Naïve CD4+ T helper cells 
can differentiate into interferon (IFN)-γ secreting, expressing T-bet signature transcription 
factor Th1 cells in response to IL-12 induced STAT4 signaling and mediate cell based 
response against intracellular pathogens (Chrapusta et al., 2000; Sarrafzadeh et al., 2011; 
Moraes et al., 2015; Zhang et al., 2015; Zhou et al., 2017). Th2 cell polarization occurs under 
the influence of IL-4 upregulated STAT6 signaling and expression of master transcription 
factor GATA3 and these cells produce cytokines such as IL-4, IL-5 and IL-13 and mediate 
extracellular immune responses against parasitic infestations and contribute to allergic 
responses (Murphy and Reiner, 2002). Th17 cells secrete IL-17, express master transcription 
factor RORγt and involve STAT3 signaling in response to various cytokines such as IL-6, 
TGF-β and IL-23; and play critical role in antibacterial, antifungal responses and autoimmune 
diseases (Acosta-Rodriguez et al., 2007; Gaffen et al., 2014). T regulatory (reg) cells express 
FOXP3 as a signature transcription factor and secrete immunosuppressive cytokines such as 
IL-10, TGF-β and IL-35 and have the capability to suppress nearly all immune cell subtypes. 
Therefore, they play an indispensable role in immune tolerance and prevention against 
autoimmune diseases (Sakaguchi et al., 2010). 
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A lymphopenic response has been observed after aSAH, but interestingly it was shown to be 
associated with increased CD4+ T cells expressing transient activation marker CD69 (Moraes 
et al., 2015). Acute focal neurological deficits in aSAH patients can lead to an early 
significant reduction in CD4+ T cells, which may underlie the observed immunosuppression 
after aSAH (Sarrafzadeh et al., 2011). A very recent study has shown significant reduction of 
CD4+ T cells and Treg cells after aneurysmal obliteration surgery and even in patients 
presenting with fever and poor prognosis (Zhou et al., 2017). Regarding CD4+ T cell subsets, 
only limited studies have been done so far. A preclinical study investigated the polarization 
of Th1 cells to Th2 upon administration of statins in endovascular puncture model of SAH 
(Ayer et al., 2013). A single clinical study has investigated T helper cell subsets in patients 
with both ruptured and unruptured intracranial aneurysms and has found significant elevation 
of Th17 cells and reduction of Th2 cells compared to controls (Zhang et al., 2015). Detailed 
studies investigating the dynamics of these different CD4+ T cell subsets along with their 
activation states after aSAH are lacking. These studies are highly encouraged as they would 
not only help in understanding the interplay between different T helper cell subtypes during 
the course of the disease, but would be advantageous from biomarker and therapeutic point of 
view. 
1.9. Role of systemic inflammation after aSAH 
A systemic inflammatory response has been observed in 75% of the aSAH patients 
presenting with pyrexia, tachypnea, tachycardia and leucocytosis and the inflammatory 
cytokines have been blamed for this response (Macdonald et al., 2014). Cytokines released as 
a consequence of intrathecal inflammation after aSAH may eventually enter the systemic 
circulation owing to post-aSAH compromised BBB and upregulate systemic inflammatory 
cascades and may explain peripheral organ system failures (Gruber et al., 2000). 
Interestingly, development of systemic inflammatory response syndrome and extracerebral 
organ-system damage after aSAH is accompanied by a significant systemic upregulation of 
sTNFR1 and sIL-1RA (Gruber et al., 2000). Blockage of IL-1 signaling via sIL-1RA has 
been shown to abrogate the brain injury (Greenhalgh et al., 2012). Systemic levels of 
different pro-inflammatory molecules such as CRP, TNF-α, IL-1β and IL-6 have been shown 
to be upregulated and associated with DCI or poor clinical outcome (McMahon et al., 2013; 
Muroi et al., 2013; Miller et al., 2014; Ma et al., 2015; Da Silva et al., 2017). Inflammation 
plays a crucial role in determining the clinical outcome and cognitive function after aSAH 
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(Muroi et al., 2013; Hong et al., 2014; Da Silva et al., 2017). Therefore, investigation of 
systemic inflammation after aSAH represent a potential target that seems promising to 
uncover and provide with not only new therapeutic options, but also with new biomarkers 
and prognostic markers of post-aSAH complications and clinical outcome. A schematic 
representation of the role of inflammation mediated by DAMPs and cytokines after aSAH is 
represented in Fig. 1. 
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Figure 1: Schematic representation of the role of inflammation mediated by DAMPs and 
cytokines after aSAH and their possible association with post-aSAH complications and 
clinical outcome (modified from: https://www.nature.com/articles/cddis201663) 
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2. Aims of the study 
Since, inflammation is known to play a major role in aSAH and post-aSAH complications 
and can affect the clinical outcome of the aSAH patients. Therefore, the aim of this study was 
to investigate the role of molecules that can initiate and drive inflammation after aSAH, 
during post-aSAH complications and its impact on clinical outcome of the aSAH patients. 
The inflammation driven by aSAH is sterile in nature, hence, we aimed to characterize 
DAMPs after aSAH, their association with post-aSAH complications and their impact on 
clinical outcome. We investigated the role of main DAMPs such as HMGB1, IL-1α, IL-33 
and mitochondrial DNA in the systemic circulation of patients after aSAH, post-aSAH 
complications and their impact on clinical outcome.  
To characterize the mediators of systemic inflammation after aSAH, this study aimed to 
investigate some selective cytokines which are either not previously investigated or lack 
comprehensive and detailed investigations. We selected pro-inflammatory molecules 
including IL-6 and RANTES, anti-inflammatory molecule IL-10 and Th17 response 
molecules including IL-23 and IL-17. The secondary aim of the study was to highlight the 
diagnostic or prognostic potential of these DAMPs molecules and cytokines for aSAH, post-
aSAH complications and clinical outcome. 
Additionally, the aim of the study was to characterize monocyte and CD4+ T cell subsets 
response during early and delayed brain injury phases after aSAH. 
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3. Materials and Methods 
3.1. Ethics statement 
This study was performed according to the guidelines of the Helsinki declaration and was 
approved by the local ethics committee of the medical faculty of the University of Bonn, 
Germany (Reference Number: LfD 138/ 2011). Informed consent was obtained by the 
treating neurosurgeon. 
3.2. Patient population 
This retrospective study included 80 consecutive patients unless otherwise stated after 
aneurysmal SAH with Hunt and Hess grade I – V, who were admitted to the department of 
Neurosurgery, University Hospital Bonn, the University of Bonn, Germany. The patients 
presenting to our neurosurgery unit within 24 hours of aSAH were considered for sampling. 
Patients with age ≤ 18 years, ischemic stroke, traumatic brain injury, onset of symptoms 
beyond 24 hours, SAH due to arteriovenous malformations or vasculitis, pregnancy, signs of 
eminent death and those who did not provide informed consent were excluded from the 
study. Blood samples were collected at seven different time points including on day 1 (within 
the first 24 hours), day 3, 5, 7, 9, 11 and 13. Patients whose blood samples were available less 
than four time points (due to death etc.) were excluded from analysis. Twenty-eight control 
patients with spinal stenosis without any known cerebral pathology were enrolled in the study 
unless otherwise stated. 
3.3. Clinical monitoring and aneurysm treatment 
Institutional standardized diagnostic and treatment regimen was followed. SAH was 
ascertained by computed tomography (CT) scan. CT angiography (CT-A) and digital 
subtraction angiography (DSA) were performed for further evaluation of the aneurysm. The 
aneurysm treatment decision (neurosurgical clipping or endovascular coiling) was based on 
an interdisciplinary approach. An early treatment strategy (within 24 hours of admission) was 
followed. The treatment protocol at the neuro-intensive care unit (NICU) included hourly 
neurological monitoring, continuous invasive blood pressure and body temperature 
measurements, daily transcranial Doppler (TCD) and the administration of nimodipine for 21 
days starting from the day of admission. Generally, patients who were not clinically 
assessable were screened for vasospasm by daily TCD and DSA on day 7 after ictus. CT-A 
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and CT perfusion (CT-P) were performed upon suspicion of CVS to confirm the presence of 
the latter. The patients having significant perfusion deficits with a difference in mean 
transient time (MTT) above 2 seconds in comparison to the contralateral hemisphere in CT-P 
were considered to be treated. CVS patients were treated with induced hypertension using 
catecholamines, maintaining a target mean arterial blood pressure (MAP) at around 110 mm 
Hg until resolution of CVS. Hypertensive treatment was stopped after final CT-A and CT-P 
showed no further evidence of CVS with perfusion deficits. 
3.4. Assessment of clinical severity and degree of bleeding 
The clinical severity of aSAH patients was assessed by Hunt and Hess grades (H&H grades) 
with dichotomization into two groups: aSAH patients with H&H I-II grades were considered 
to be having less severe aSAH or good grades, whereas patients presenting with H&H grades 
III-V were considered to be having severe aSAH and poor grades (Mathiesen et al., 1997). 
The degree of bleeding after aSAH was assessed by the volume of hematoma on CT-scans as 
according to Fischer scale. 
3.5. Clinical outcome assessment 
The clinical outcome of the patients was assessed at discharge by well known and commonly 
used clinical outcome assessment scales i.e., Glasgow Outcome Scale (GOS) and Modified 
Rankin Scale (mRS). In order to characterize the patients into good outcome and poor 
outcome patients for the ease of comparison, both the scales were dichotomized to represent 
poor outcomes and good outcomes at discharge. Glasgow Outcome Scale scores were 
dichotomized as GOS score 1 – 3 represented poor clinical outcome and GOS score 4 – 5 
represented good clinical outcome as described previously (Chaudhry et al., 2017). Patients 
presenting with a mRS 0 – 2 were grouped into good outcome, while those with a score of 3 – 
6 were regarded as with a poor outcome as described by others (Broessner et al., 2010).  
3.6. Peripheral blood sampling and retrieval of serum 
Blood samples of aSAH patients were collected on days 1, 3, 5, 7, 9, 11 and 13 after aSAH. 
Blood samples from spinal stenosis control patients or healthy controls were available at a 
single time point. The peripheral venous blood was withdrawn in monovette serum gel tubes 
(Sarstedt, Germany), allowed to clot for 15 minutes at room temperature and then, spun at 
3500 rpm in a benchtop centrifuge (Sigma Laborzentrifugen, Osterode am Harz, Germany) 
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for 10 minutes to obtain serum. The serum was aliquoted into 500 µl clean polypropylene 
microtubes (Axygen
TM
, USA) and they were immediately frozen at -80 °C until analysis. 
Peripheral blood leukocytes count and other hematological parameters were recorded from 
daily laboratory tests. 
3.7. Analysis of serum DAMPs and cytokines 
In order to investigate the questions posed by the proposed hypothesis, we have adopted the 
two well known molecular and cell biology techniques including ELISA and qPCR to 
quantify DAMPs and cytokines in aSAH patients and controls. The details of these are given 
below: 
3.7.1. Enzyme Linked Immunosorbent Assays (ELISAs) 
HMGB1 and selective cytokines were quantified using pre-coated sandwich ELISA kits by 
following the instructions of the manufacturers. The detailed procedures for every ELISA kit 
are mentioned in section 3.7.1.1 below. Serum HMGB1 was analyzed using Shino test 
ELISA kit obtained from IBL International (Catalog no. ST51011, Hamburg, Germany). 
Serum IL-17 and IL-23 levels were quantified using pre-coated Platinum ELISA kits 
purchased from eBioscience (Catalog no. BMS2017 and BMS2023/3, Bender MedSystems 
GmbH, Vienna, Austria). For serum IL-10 determination, pre-coated BD OptEIA Human IL-
10 ELISA Kit II was purchased from BD (Catalog no. 550613, Becton Dickinson 
Biosciences, San Jose, CA, USA). Quantikine ELISA kits purchased from R&D Systems 
were used for the measurement of IL-1α and IL-33 (Catalog no. DLA50 and D3300, R&D 
Systems, Minneapolis, USA). RANTES/CCL5 ELISA kit was also purchased from R&D 
Systems (Catalog no. DRN00B, R&D Systems, Minneapolis, MN, USA). Serum IL-6 levels 
were measured using Immulite immunoassay as a part of routine diagnostics service available 
at the central lab. facility of the department of Clinical Chemistry and Clinical Pharmacology, 
University of Bonn. The detailed procedures of the ELISAs are presented as following: 
3.7.1.1. HMGB1 ELISA 
All the components of the kit were brought to the room temperature before use. Lyophilized 
standard was diluted with an appropriate amount of the provided standard diluent to yield a 
final concentration of 320 ng/mL. Seven microcentrifuge tubes were labeled as 80 ng/mL, 40 
ng/mL, 20 ng/mL, 10 ng/mL, 5 ng/mL, 2.5 ng/mL and 0 ng/mL. In the first tube 300 µL 
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while in the rest of the tubes 100 µL of the diluent buffer was dispensed. The standard stock 
solution was left for at least 10 minutes at room temperature to allow complete reconstitution.  
The stock solution was gently swirled and 100 µL of it was added to the tube labeled 80 
ng/mL. After a brief vortex mixing, 100 µL was transferred to the next tube labeled 40 
ng/mL. In this way, serial dilutions were made up to 2.5 ng/mL and last tube labeled 0 ng/mL 
contained only diluent buffer and served as blank.  The wash buffer was diluted 1:5 with the 
deionized distilled water.  
A volume of 100 µL of diluent buffer was added to the wells of the microtiter plate. Blank 
wells were supplied with 10 µL of the diluent buffer (0 ng/mL). Then, 10 µL of the standards, 
positive control and the samples were pipetted into the respective wells and the microplate 
was shaken briefly for 30 secs. The plate was sealed with an adhesive foil and incubated at 
37°C for 20 – 24 hours. Afterwards the adhesive foil was removed and the contents of the 
wells were discarded. Each well was washed 5 times with 400 µL of the diluted wash buffer 
using an automatic washer (HydroFlex
TM
 microplate washer, Tecan, Groedig, Austria). 
Enzyme conjugate diluted with an enzyme conjugate diluent was added into the wells in a 
volume of 100 µL. The plate was sealed again and incubated for 2 hrs at +25°C. Later on, 
plate was washed again as mentioned above and 100 µL of the colour solution consisting of 
colouring reagent A and B was added in each well. The plate was again incubated at room 
temperature for 30 minutes covered with an aluminium foil to protect it from the light. 
Afterwards, 100 µL stop solution was added and after cleaning the back of the wells, optical 
density of each well at 450 nm was determined with the help of a multiwellplate reader 
(Thermoscientific Multiskan
TM
 Go, microtiterplate spectrophotometer, Vantaa, Finland). The 
results were then computed from the calibration curve generated from the standards. The 
limit of detection of the assay was 1 ng/mL. 
3.7.1.2. IL-1α ELISA 
The components of the kit were brought to the room temperature. The washing buffer was 
prepared by adding 20 mL of wash buffer concentrate to deionized distilled water to prepare 
500 mL of wash buffer. The human IL-1α standard was reconstituted with calibrator diluent 
RD6C to produce a stock solution of 250 pg/mL. The standard was allowed to equilibrate for 
a minimum of 15 minutes with gentle agitation prior to making dilutions. Then, 6 
microcentrifuge tubes were labelled as 125 pg/mL, 62.5 pg/mL, 31.3 pg/mL, 15.6 pg/mL, 7.8 
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pg/mL, and 3.9 pg/mL, respectively. Each tube was supplemented with 500 µL of the 
calibrator diluent RD6C. Then, 1:2 serial dilutions were prepared by pipetting 500 µL of the 
reconstituted standard stock solution to the first tube labelled as 125 pg/mL. After gently 
vortexing, 500 µL from 125 pg/mL tube was transfered to the 2nd tube labelled as 62.5 
pg/mL and the same process was repeated until the last tube labelled as 3.9 pg/mL. The 
undiluted human IL-1α standard stock solution (250 pg/mL) served as the highest standard. 
The calibrator diluent RD6C served as the blank.  
The microplate was removed from the sealed pouch and 50 μL of assay diluent RD1-83 was 
pipetted into each well. About 200 μL of the calibrator diluent RD6C was added to each of 
the blank wells. An aliquot of 200 μL of standards, controls, or samples were added to the 
appropriate wells of the microplate. After covering with the adhesive strip provided, the 
microplate was incubated for 2 hours at room temperature. The contents of the microplate 
were decanted or aspirated after 2 hours of incubation. The wells of the microplate were then 
washed 3 times with approximately 400 µL of wash buffer per well with thorough aspiration 
of microwell contents between washes using an automatic washer (HydroFlex
TM
 microplate 
washer, Tecan, Groedig, Austria). Care was taken not to scratch the surface of the 
microwells. After the last wash step, the wells were emptied and microplate was tapped on 
absorbent pad or paper towel to remove excess wash buffer. Added 200 μL of human IL-1α 
conjugate to each well and covered with a new adhesive film for incubation for 2 hours at 
room temperature. After repeating the washing step as described above, 200 μL of substrate 
solution consisting of equal volumes of colouring reagents A and B, was added to each well 
and incubated the microplate for 20 minutes at room temperature protected from light. After 
adding 50 μL of stop solution to each well, the optical density was measured at 450 nm as 
primary wavelength and 540 nm or 570 nm as reference wavelength using Thermoscientific 
Multiskan
TM
 Go, microtiterplate spectrophotometer (Vantaa, Finland). The absorbance values 
were then corrected by subtracting the reference wavelength (540 nm or 570 nm) values from 
primary wavelength (450 nm) absorbance values. The results were then computed from the 
standard curve obtained from standards. The sensitivity of the assay kit was 1 pg/mL. 
3.7.1.3. IL-33 ELISA 
The components of the kit were brought to the room temperature. The calibrator diluent RD5-
26 was diluted 1:5 by adding 4 mL of calibrator diluent RD5-26 to 16 mL of deionized 
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distilled water to prepare 20 mL of calibrator diluent RD5-26. The washing buffer was 
prepared by adding 20 mL of wash buffer concentrate to deionized distilled water to prepare 
500 mL of wash buffer. The human IL-33 standard was reconstituted with deionized distilled 
water to produce a stock solution of 4000 pg/mL. The standard was allowed to equilibrate for 
a minimum of 15 minutes with gentle agitation prior to making dilutions. Then, 7 
microcentrifuge tubes were labelled as 400 pg/mL, 200 pg/mL, 100 pg/mL, 50 pg/mL, 25 
pg/mL, 12.5 pg/mL, and 6.25 pg/ml respectively. In the first tube 900 µL of the calibrator 
diluent RD5-26 (1:5 diluted) was added, while in remaining tubes 500 µL of the calibrator 
diluent RD5-26 (1:5) was pipetted. In the first tube labelled as 400 pg/mL, 100 µL of the 
stock solution was added and briefly vortexed. Then, 1:2 serial dilutions were prepared for 
the rest of the tubes by pipetting 500 µL from the first tube to the next tube labelled as 200 
pg/mL. After gently vortexing, 500 µL from 200 pg/mL tube was transfered to the 3rd tube 
labelled as 100 pg/mL and the same process was repeated until the last tube labelled as 6.25 
pg/mL. The calibrator diluent RD5-26 (1:5) served as zero standard.  
The microplate was removed from the sealed pouch and 100 μL of assay diluent RD1-77 was 
pipetted into each well. About 200 μL of the calibrator diluent RD5-26 (1:5) was added to 
each of the blank wells. Approximately, 200 μL volumes of standards, controls, or samples 
were added to the appropriate wells of the microplate. After covering with the adhesive strip 
provided, the microplate was incubated for 2 hours at room temperature on an orbital 
microplate shaker set at 500 rpm ± 50 rpm. The contents of the microplate were decanted or 
aspirated after 2 hours of incubation. The wells of the microplate were then washed 4 times 
with approximately 400 µL of wash buffer per well with thorough aspiration of microwell 
contents between washes using an automatic washer (HydroFlex
TM
 microplate washer, 
Tecan, Groedig, Austria). Care was taken not to scratch the surface of the microwells. After 
the last wash step, the wells were emptied and microplate was tapped on absorbent pad or 
paper towel to remove excess wash buffer. Added 200 μL of human IL-33 conjugate to each 
well and covered with a new adhesive film for incubation for 2 hours at room temperature on 
the shaker. After repeating the washing step as described above, 200 μL of substrate solution 
consisting of equal volumes of colouring reagents A and B, was added to each well and 
incubated the microplate for 30 minutes at room temperature protected from light. After 
adding 50 μL of stop solution to each well, the optical density was measured at 450 nm as 
primary wavelength and 540 nm or 570 nm as reference wavelength using Thermoscientific 
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Multiskan
TM
 Go, microtiterplate spectrophotometer (Vantaa, Finland). The absorbance values 
were then corrected by subtracting the reference wavelength (540 nm or 570 nm) values from 
primary wavelength (450 nm) absorbance values. The results were then computed from the 
standard curve obtained from standards. The sensitivity of the assay kit was 1 pg/mL. 
3.7.1.4. IL-23 ELISA 
The components of the kit were brought to the room temperature. The wash buffer 
concentrate (50 mL) was diluted 20 times with deionized distilled water to a final volume of 
1000 mL in a volumetric flask. Similarly, assay buffer concentrate (5 mL) was diluted 20 
times with deionized distilled water to a final volume of 100 mL. Human IL-23 standard was 
reconstituted with a sample diluent volume specified on the vial to provide a concentration of 
4000 pg/mL. The vial was gently swirled and the mixture was allowed to stand for 10 – 30 
minutes. Then, 8 microcentrifuge tubes were labelled as 2000 pg/mL, 1000 pg/mL, 500 
pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.3 pg/mL, and 15.6 pg/mL respectively. Each 
tube was supplemented with 225 µL of the sample diluent. Then, 1:2 serial dilutions were 
prepared by pipetting 225 µL of the reconstituted standard to the first tube labelled as 2000 
pg/mL. After gently vortexing, 225 µL from 2000 pg/mL tube was transferred to the 2nd tube 
labelled as 1000 pg/mL and the same process was repeated until the last tube labelled as 15.6 
pg/mL. The sample diluent served as the blank.  
The microwell strips were washed twice with approximately 400 µL of wash buffer per well 
with thorough aspiration of microwell contents between washes using an automatic washer 
(HydroFlex
TM
 microplate washer, Tecan, Groedig, Austria). The wash buffer was allowed to 
sit in the wells for about 10 – 15 seconds before aspiration. Care was taken not to scratch the 
surface of the microwells. After the last wash step, the wells were emptied and microwell 
strips were tapped on absorbent pad or paper towel to remove excess wash buffer. The 
microwell strips were then used immediately after washing.  
The blank wells were then pipetted in with 100 µL of the sample diluent and 100 µL of each 
standard was added in duplicate to the standard wells. The sample wells were supplemented 
with 50 µL of sample diluent followed by addition of 50 µL of each serum sample into 
respective sample wells. The plate was covered with an adhesive film and incubated at room 
temperature (18° to 25°C) for 2 hours. A 1:250 dilution of the concentrated biotin-conjugate 
solution (48 µL) with 11.952 mL of assay buffer (1x) was prepared in a clean plastic tube 
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immediately before use. After 2 hours of incubation, adhesive film was removed and wells 
were emptied. The microwell strips were washed 5 times as described above. A volume of 
100 µL of biotin-conjugate (1x) prepared as described above was added to all the wells and 
the microplate was covered with an adhesive film and incubated at room temperature (18° to 
25°C) for 1 hour. Similar to biotin-conjugate, a 1:250 dilution of the concentrated avidin-
horse reddish peroxidase (HRP) solution (48 µL) with 11.952 mL of assay buffer (1x) was 
prepared in a clean plastic tube. After 1 hour of incubation, the adhesive film was removed 
and the emptied wells were washed 5 times as described above. A volume of 100 µl of 
diluted avidin-HRP was supplied to all the wells and the microplate was covered with an 
adhesive film and incubated at room temperature (18° to 25°C) for 30 minutes. The 
incubation was followed by adhesive film removal, emptying of the wells and washing for 5 
times as described above. After washing, 100 µL of the tetramethyl benzidine (TMB) 
substrate solution was immediately added to the microplate wells and incubated in dark at 
room temperature (18° to 25°C) for about 15 minutes. The enzyme reaction was then stopped 
by quickly pipetting 100 µl of the stop solution into each well. It was made sure that the stop 
solution was spread quickly and uniformly throughout the microwells to completely 
inactivate the enzyme. The absorbance of each microwell was read on a spectrophotometer 
using 450 nm as the primary wavelength and 620 nm as the reference wavelength 
Thermoscientific Multiskan
TM
 Go, microtiterplate spectrophotometer (Vantaa, Finland). The 
absorbance values were then corrected by subtracting the reference wavelength (620 nm) 
values from primary wavelength (450 nm) absorbance values. The results were then 
computed from the standard curve obtained from standards and since, the samples were 
diluted 1:2, therefore, the concentration values of the samples were multiplied by a dilution 
factor of 2 to yield final serum IL-23 concentrations in the samples. The sensitivity of the 
assay kit was 4 pg/mL. 
3.7.1.5. IL-17 ELISA 
The components of the kit were brought to the room temperature. The wash buffer 
concentrate (50 mL) was diluted 20 times with deionized distilled water to a final volume of 
1000 mL in a volumetric flask. Similarly, assay buffer concentrate (5 mL) was diluted 20 
times with deionized distilled water to a final volume of 100 mL. Human IL-17 standard was 
reconstituted with a volume of deionized distilled water specified on the vial to provide a 
concentration of 200 pg/mL. The vial was gently swirled and the mixture was allowed to 
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stand for 10 – 30 minutes. Then, 7 microcentrifuge tubes were labelled as 100 pg/mL, 50 
pg/mL, 25 pg/mL, 12.5 pg/mL, 6.3 pg/mL, 3.1 pg/mL, and 1.6 pg/mL, respectively. Each 
tube was supplemented with 225 µL of the sample diluent. Then, 1:2 serial dilutions were 
prepared by pipetting 225 µL of the reconstituted standard to the first tube labelled as 100 
pg/mL. After gently vortexing, 225 µL from 100 pg/mL tube was transferred to the 2nd tube 
labelled as 50 pg/mL and the same process was repeated until the last tube labelled as 1.6 
pg/mL. The sample diluent served as the blank.  
The microwell strips were washed twice with approximately 400 µL of wash buffer per well 
with thorough aspiration of microwell contents between washes using an automatic washer 
(HydroFlex
TM
 microplate washer, Tecan, Groedig, Austria). The wash buffer was allowed to 
sit in the wells for about 10 – 15 seconds before aspiration. Care was taken not to scratch the 
surface of the microwells. After the last wash step, the wells were emptied and microwell 
strips were tapped on absorbent pad or paper towel to remove excess wash buffer. The 
microwell strips were then used immediately after washing.  
The blank wells were then pipetted in with 100 µL of the sample diluent and 100 µL of each 
standard was added in duplicate to the standard wells. The sample wells were supplemented 
with 50 µL of sample diluent followed by addition of 50 µL of each serum sample into 
respective sample wells. A 1:100 dilution of the concentrated biotin-conjugate solution (60 
µL) with 5.94 mL of assay buffer (1x) was prepared in a clean plastic tube immediately. A 
volume of 50 µL of biotin-conjugate (1x) was added to all the wells and the microplate was 
covered with an adhesive film and incubated at room temperature (18° to 25°C) for 2 hours 
on a microplate shaker set at 400 rpm. Similar to biotin-conjugate, a 1:200 dilution of the 
concentrated streptavidin-horse reddish peroxidase (HRP) solution (60 µL) with 11.94 mL of 
assay buffer (1x) was prepared in a clean plastic tube in order to be used within 30 minutes 
following preparation. After 2 hours of incubation, adhesive film was removed and wells 
were emptied. The microwell strips were washed 4 times as described above. A volume of 
100 µl of diluted streptavidin-HRP (1x) was supplied to all the wells and the microplate was 
covered with an adhesive film and incubated at room temperature (18° to 25°C) for 1 hour on 
a microplate shaker set at 400 rpm. The incubation was followed by adhesive film removal, 
emptying of the wells and washing for 4 times as described above. After washing, 100 µL of 
the tetramethyl benzidine (TMB) substrate solution was immediately added to the microplate 
wells and incubated in dark at room temperature (18° to 25°C) for about 10 minutes. The 
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enzyme reaction was then stopped by quickly pipetting 100 µl of the stop solution into each 
well. It was made sure that the stop solution was spread quickly and uniformly throughout the 
microwells to completely inactivate the enzyme. The absorbance of each microwell was read 
on a spectrophotometer using 450 nm as the primary wavelength and 620 nm as the reference 
wavelength Thermoscientific Multiskan
TM
 Go, microtiterplate spectrophotometer (Vantaa, 
Finland). The absorbance values were then corrected by subtracting the reference wavelength 
(620 nm) values from primary wavelength (450 nm) absorbance values. The results were then 
computed from the standard curve obtained from standards and since, the samples were 
diluted 1:2, therefore, the concentration values of the samples were multiplied by a dilution 
factor of 2 to yield final serum IL-17 concentrations in the samples. The sensitivity of the 
assay kit was 0.5 pg/mL. 
3.7.1.6. IL-10 ELISA 
The components of the kit were brought to the room temperature. The wash buffer 
concentrate (25 mL) was diluted 20 times with deionized distilled water to a final volume of 
500 mL in a volumetric flask. Lyophilized IL-10 standard was reconstituted with a volume of 
standard/sample diluent specified on the vial to prepare a 500 pg/mL stock standard. The vial 
was gently swirled and the stock standard was allowed to equilibrate for 15 minutes followed 
by a gentle vortex mixing. Then, 6 microcentrifuge tubes were labelled as 250 pg/mL, 125 
pg/mL, 62.5 pg/mL, 31.3 pg/mL, 15.6 pg/mL, and 7.8 pg/mL, respectively. Each tube was 
supplemented with 300 µL of the standard/sample diluent. Then, 1:2 serial dilutions were 
prepared by pipetting 300 µL of the reconstituted stock standard to the first tube labelled as 
250 pg/mL. After gently vortexing, 300 µL from 250 pg/mL tube was transferred to the 2nd 
tube labelled as 125 pg/mL and the same process was repeated until the last tube labelled as 
7.8 pg/mL. The standard stock solution served as the highest standard. The standard/sample 
diluent served as the blank.  
A volume of 50 µL of elisa diluent was pipetted into each well of the microplate. The blank 
wells were then pipetted in with 100 µL of the standard/sample diluent. About 100 µL of 
each standard and sample was added to the appropriate wells. The microplate was gently 
shaken or tapped for 5 seconds to mix and then, was covered with a plate sealer and 
incubated at room temperature (18° to 25°C) for 2 hours. Within 15 minutes prior to use, 
working detector was prepared by pipetting 12 mL of the detection antibody to a clean plastic 
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tube and adding in 48 µL of the enzyme concentrate. The contents of the microwell strips 
were decanted or aspirated after 2 hours of incubation. The wells were then washed 5 times 
with approximately 300 µL of wash buffer per well with thorough aspiration of microwell 
contents between washes using an automatic washer (HydroFlex
TM
 microplate washer, 
Tecan, Groedig, Austria). Care was taken not to scratch the surface of the microwells. After 
the last wash step, the wells were emptied and microwell strips were tapped on absorbent pad 
or paper towel to remove excess wash buffer. The microwell strips were then used 
immediately after washing. Afterwards, 100 µL of working detector was added to each well 
and the microplate was covered with a plate sealer and incubated at room temperature for 1 
hour. After incubation, adhesive plate sealer was removed and wells were emptied. The 
microwell strips were washed 7 times as described above with an additional soaking step for 
1 minute. After washing, 100 µL of the tetramethyl benzidine (TMB) one step substrate 
reagent was immediately added to the microplate wells and incubated in dark at room 
temperature (18° to 25°C) for about 30 minutes. The enzyme reaction was then stopped by 
quickly pipetting 50 µl of the stop solution into each well. The absorbance of each microwell 
was read on a spectrophotometer using 450 nm as the primary wavelength and 570 nm as the 
reference wavelength Thermoscientific Multiskan
TM
 Go, microtiterplate spectrophotometer 
(Vantaa, Finland). The absorbance values were then corrected by subtracting the reference 
wavelength (570 nm) values from primary wavelength (450 nm) absorbance values. The 
results were then computed from the standard curve obtained from standards. The sensitivity 
of the assay kit was 2 pg/mL. 
3.7.1.7. RANTES/CCL5 ELISA 
The components of the kit were brought to the room temperature. The calibrator diluent RD6-
11 was diluted 1:5 by adding 20 mL of calibrator diluent RD6-11 to 80 mL of deionized or 
distilled water to prepare 100 mL of calibrator diluent RD6-11. For this assay, serum samples 
required a 100-fold dilution and were diluted by adding 10 μL of each serum sample into 990 
μL of calibrator diluent RD6-11 in the clean 1.5 mL microcentrifuge tubes. The washing 
buffer was prepared by adding 20 mL of wash buffer concentrate to deionized distilled water 
to prepare 500 mL of wash buffer. The human RANTES standard was reconstituted with 
calibrator diluent RD6-11 (1:5 diluted) to produce a stock solution of 2000 pg/mL. The 
standard was allowed to equilibrate for a minimum of 15 minutes with gentle agitation prior 
to making dilutions. Then, 6 microcentrifuge tubes were labelled as 1000 pg/mL, 500 pg/mL, 
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250 pg/mL, 125 pg/mL, 62.5 pg/mL, and 31.3 pg/mL, respectively. Each tube was 
supplemented with 500 µL of the calibrator diluent RD6-11 (1:5 diluted). Then, 1:2 serial 
dilutions were prepared by pipetting 500 µL of the reconstituted stock standard to the first 
tube labelled as 1000 pg/mL. After gently vortexing, 500 µL from 1000 pg/mL tube was 
transferred to the 2nd tube labelled as 500 pg/mL and the same process was repeated until the 
last tube labelled as 31.3 pg/mL. The undiluted human RANTES standard stock solution 
(2000 pg/mL) served as the highest standard. The calibrator diluent RD6-11 (1:5 diluted) 
served as the blank.  
The microplate was removed from the sealed pouch and 100 μL of assay diluent RD1W was 
pipetted into each well. About 100 μL of the calibrator diluent RD6-11 (1:5 diluted) was 
added to each of the blank wells. About 100 μL volumes of standards, controls, or samples 
were added to the appropriate wells of the microplate. After covering with the adhesive strip 
provided, the microplate was incubated for 2 hours at room temperature. The contents of the 
microplate were decanted or aspirated after 2 hours of incubation. The wells of the microplate 
were then washed 3 times with approximately 400 µL of wash buffer per well with thorough 
aspiration of microwell contents between washes using an automatic washer (HydroFlex
TM
 
microplate washer, Tecan, Groedig, Austria). Care was taken not to scratch the surface of the 
microwells. After the last wash step, the wells were emptied and microplate was tapped on 
absorbent pad or paper towel to remove excess wash buffer. Afterwards, added 200 μL of 
human RANTES conjugate to each well and covered with a new adhesive film for another 
incubation of 1 hour at room temperature. After repeating the washing step as described 
above, 200 μL of substrate solution consisting of equal volumes of colouring reagents A and 
B, was added to each well and incubated the microplate for 20 minutes at room temperature 
protected from light. After adding 50 μL of stop solution to each well, the optical density was 
measured at 450 nm as primary wavelength and 540 nm or 570 nm as reference wavelength 
using Thermoscientific Multiskan
TM
 Go, microtiterplate spectrophotometer (Vantaa, 
Finland). The absorbance values were then corrected by subtracting the reference wavelength 
(540 nm or 570 nm) values from primary wavelength (450 nm) absorbance values. The 
results were then computed from the standard curve obtained from standards. The sensitivity 
of the assay kit was 2 pg/mL. 
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3.7.2. Real time quantitative Polymerase Chain Reaction (qPCR) 
The second DAMP member, mtDNA from the healthy controls and aSAH patients was 
quantified using a real time quantitative PCR. Before qPCR quantification, DNA was isolated 
from the serum and mtDNA for standard curves was generated as described below: 
 3.7.2.1. Isolation of serum DNA 
Cell free circulating DNA in the serum of aSAH patients and controls was isolated using 
QIAMP DNA mini kit (Catalog no. 51306, QIAGEN, Germany) by following the 
manufacturer’s instructions with slight modifications. Briefly, the serum samples were 
centrifuged for 2-3 mins at 6000 rpm (Eppendorf, Germany) to get rid of any contaminating 
cellular debris and obtain cell free DNA. A 200 µl aliquot of serum was applied to 20 µl 
proteinase K and 200 µl lysis buffer and incubated for 20 mins at 56 °C. Afterwards, 230 µl 
of absolute alcohol was added and the mixture was applied to the provided columns after a 
brief spin down. The columns were washed twice sequentially with the provided washing 
buffers and finally, DNA was eluted from the column using 50 µl of elution buffer. The 
extracted DNA was stored at -80 °C until qPCR quantification. 
3.7.2.2. Generation of mtDNA for standard curves 
3.7.2.2. A. Normal PCR amplification of mtDNA 
The mtDNA was kindly provided by Dr. Stilla Frede, Department of Anesthesiology, 
University of Bonn. This mtDNA was extracted from the mitochondria that were isolated 
from HepG2 cells as described previously (Schafer et al., 2016). This mtDNA was then used 
as a template to amplify different mitochondrial gene fragments i.e., mt Cytochrome B (mt 
CytB), mt D-Loop (mt D-Loop) and mt Cytochrome c oxidase subunit I (mt COX-1) by using 
following primers: mtCytB Fwd: 5’- CCT CCA AAT CAC CAC AGG A -3’, Rev: 5’- TGA 
GTA GAG AAA TGA TCC GTA ATA -3’ (Eurogentec, Belgium); mtD-Loop Fwd: 5’- ATC 
AAC CCT CAA CTA TCA -3’, Rev: 5’- ACT GTA ATG TGC TAT GTA -3’; and mt COX-
1 Fwd: 5’- TCA TCT GTA GGC TCA TTC -3’, Rev: 5’- GGC ATC CAT ATA GTC ACT -
3’ (Invitrogen, Germany).  A 2 µL of mtDNA template was applied to a 50 µL PCR reaction 
volume containing 40 nM concentrations of the above mentioned primers. The PCR profile 
was initial denaturation at 95 °C for 5 mins followed by 40 cycles of 95 °C for 1 min, 55 °C 
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for 1 min and 72 °C for 1.5 min (Bimoetra T3000 Thermocycler, Biometra GmbH, 
Goettingen, Germany).  
3.7.2.2. B. Gel electrophoresis of mtDNA amplicons 
The amplicons amplified by the above PCR were confirmed by gel electrophoresis on a 2% 
agarose gel. A 2 g amount of agarose (Catalog # 35-1020, PeqGold Universal Agarose, 
VWR, Germany) in 100 mL of the TAE buffer was heated for 2 minutes in a microwave 
oven. Then, 10 µL of the ethidium bromide was added to 100 mL of the gel solution. After a 
brief heating (30 secs) and mixing, the gel solution was poured into the gel casting chamber 
and combs (PEQLAB Biotechnologie GmbH, Erlangen, Germany) were placed to allow the 
formation of wells. Approximately after 20 minutes, when the gel was polymerized and 
combs were removed, TAE buffer was added into the chamber until it reaches the edges of 
the gel. A prestained DNA ladder (15 µL) was loaded into the wells before each mtDNA 
gene fragment and 25 µL of PCR amplicons were loaded into the respective wells. The 
chamber was connected to the power supply (BioRad Power PAC 3000, Munich, Germany) 
and the gel was run for 2 minutes at 100 V. Then, the surface of the gel was completely 
submerged under the additional TAE buffer and the gel was allowed to run further for 45 
minutes at 100 V. After the gel run was complete, the gel was photographed under UV 
illumination (Bio Doc-IT
TM
 Imaging System, Upland, CA, USA) to confirm the PCR 
amplification of the respective mtDNA fragments. 
3.7.2.2. C. mtDNA PCR product purification  
Since for each mt gene fragment, 6 microcentrifuge tubes containing 50 µL of the PCR 
reaction volumes were prepared and 25 µL of the PCR product was loaded onto the gel and 
the remaining was pooled for purification. A volume of 100 µL of the pooled PCR product 
for each mt gene fragment was then purified by High Pure PCR Product Purification Kit 
(Catalog no. 11732668001, Roche, Germany) by following the manufacturer’s instructions. A 
100 µL aliquot of the pooled PCR product was mixed with 500 µL of the binding buffer and 
applied to a high pure filter tube followed by centrifugation at maximum speed for 60 secs. 
The flow through was discarded and 500 µL of the washing buffer was applied to the filter 
tube and centrifuged at 13000 g for 1 min. The flow through was again discarded and a 
similar subsequent wash with 200 µL of the washing buffer was done. The filter tube was 
connected to a clean 1.5 mL microcentrifuge tube and 50 µL of elution buffer was applied. 
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After centrifugation for 1 minute at maximum speed, the highly purified DNA product was 
obtained in the microcentrifuge tube.  
3.7.2.2. D. Preparation of mtDNA standard dilutions 
Purified mitochondrial gene fragments were then quantified by applying 1 µL of the 
respective mtDNA to the nanodrop (Thermoscientific NanoDrop 2000 Spectrophotometer, 
Wilmington, USA) and finally serial dilutions were prepared using sterilized TE buffer (pH 
7.4) ranging from 100 ng/mL to 1 pg/mL. The serially diluted mtDNA standard dilutions 
were then confirmed through normal PCR and gel electrophoresis. 
3.7.3. Real time PCR quantification of mtDNA 
A real time PCR approach based on Taqman probes labelled with 6-carboxyflourescein (6-
FAM) on their 5’ end and a non-fluorescent minor groove binder (MGB) on their 3’ end was 
established to quantify serum mtDNA levels. The following primers were employed for 
qPCR: mt CytB Fwd: 5’- AACCGCCTTTTCATCAATCG -3’, Rev: 5’- 
TAGCGGATGATTCAGCCATAATT -3’; mt D-Loop Fwd: 5’-
TCAACTATCACACATCAACTGCAACT 3’, Rev: 5’-
GGGTAGGTTTGTTGGTATCCTAGTG -3’, and mt COX-1 Fwd: 5’- 
TCATCTGTAGGCTCATTCATTTCTCT -3’, Rev: 5’- 
TCTACTATTAGGACTTTTCGCTTCGA -3’. The sequences of Taqman Probes used were 
as follows: mt CytB 5’-6-FAM-CCACATCACTCGAGACGT-MGB-Eclipse-3’, mt D-Loop: 
5’- 6-FAM-CAAAGCCACCCCTCA-MGB-Eclipse-3’ and mt COX-1: 5’-6-FAM-
TTTTCATGATTTGAGAAGCC-MGB-Eclipse-3’. Both the primers and probes were 
purchased from Eurogentec, Belgium. A qPCR was carried out using a reaction volume of 
12.5 µL consisting of Taqman Universal qPCR mastermix (Life Technologies, Germany), 
900 nM of each primer and 100 nM of the respective probes. All the samples and standards 
were run in triplicates on a 384 microwell plate in a CFX384 Touch
TM
 Real-Time PCR 
detection system (Bio-Rad Laboratries, Inc.). The qPCR conditions were initial heating at 50 
°C for 2 mins, then at 95 °C for 10 mins to activate the Taq Polymerase and finally 50 cycles 
of 95 °C for 15 sec and 60 °C for 1 min. The data was acquired at the end of each cycle. The 
serum mtDNA levels were then computed from the respective standard curves for each 
mitochondrial gene fragment. 
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3.8. Polychromatic cell surface based flow cytometric immunophenotyping 
In addition to DAMPs and cytokine response, we also assessed systemic immune cell 
response by analyzing peripheral blood of 15 aSAH patients at day 1 and day 7, while once 
from 10 healthy volunteers by flow cytometry. Different subsets of monocytes and CD4+ T 
cells were investigated by following the approach described by Maecker et al. (2012) by 
establishing two flow cytometry panels.  
Briefly, the peripheral EDTA anticoagulated blood (3 ml) was lysed with erythrocyte lysis 
buffer (eBioscience, Germany) at room temperature. After erythrocyte lysis, cells were 
centrifuged at 350 g for 5 minutes at 4° C and washed with 2 mL of an ice cold FCS flow 
cytometry buffer (BD Biosciences, Germany) after discarding the supernatant. After washing 
the cells, cells were resuspended in 1 mL of FCS buffer, counted using countess cell counting 
slides (Catalog # C10283, Eugene, Oregon, USA) through Countess
TM
 automated cell counter 
(ThermoFischer scientific, Germany) and adjusted to a final concentration of 1 million cells 
per 100 µL with FCS buffer. Then, 100 µL aliquots of the cells were dispensed into 5 ml flow 
cytometry tubes (Catalog #   55.1578, Sarstedt, Germany) after labelling them for stained 
cells and fluorescence minus one (FMO) controls. For acquisition of single stained 
compensation controls, one drop of Ultracomp eBeads (eBioscience, Germany) was 
suspended in 100 µL of FCS buffer. The cells were incubated with Human Fc block pure 
(Catalog # 564220, BD Biosciences, Germany) for 10 minutes on ice. The panel of anti-
human antibodies for monocytes consisted of CD45 APC-H7, CD14 FITC, CD15 PerCP-
Cy5.5, CD16 APC, CCR2 BV421, HLA-DR PE-Cy7 (BD Biosciences, USA) and CX3CR1 
PE (eBioscience, CA, USA). The panel of anti-human T cell antibodies was comprised of 
CD45 APC-H7, CD3 PE-Cy7, CD4 BV605, CD25 PerCP-Cy5.5, CD127 FITC, CXCR3 
APC, CCR6 BUV737, HLA-DR BV421 and CD38 PE (BD Biosciences, USA). The cells 
were then sequentially stained for chemokine receptors at room temperature allowing at least 
5 minutes interval before next antibody addition as suggested by Jalbert et al. (2013) for both 
the panels.  Afterwards, the cells for both stained samples and FMO controls were stained on 
ice for 20 minutes using respective master mixes of antibodies prepared in Brilliant Violet 
Staining buffer (BV Buffer, BD Biosciences, Germany). The list of antibodies used for both 
panels along with their catalog numbers and clones are given in appendix 10.4. After 
incubation, cells were washed with 2 mL of FCS buffer and resuspended in approximately 
500 µL of the FCS buffer. Live and dead cells discrimination was made using water soluble 
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Hoechst 33258 dye (Sigma Aldrich, Germany) added (0.1 µg/10 µL) approximately 1 minute 
before acquisition of each tube. 
The cells were then analyzed on LSR Fortessa
TM
 cell analyzer (BD Biosciences, CA, USA) at 
the Flow Cytometry Core Facility at the Institute of Molecular Medicine, University of Bonn. 
The flow cytometer settings were validated using 8 peaks SPHERO
TM
 Calibration Particles 
(Catalog # 559123, BD Biosciences, CA, USA). For both panels, around 350 – 400 thousand 
CD45+ leucocyte events were acquired for stained cells and 100 thousand CD45+ events for 
FMO controls. About 10000 all events were acquired for single stained compensation 
controls. The gating strategy for both the panels is given in appendices 10.5 and 10.6. BD 
FACSDiva
TM
 v6.2 for windows 7 (BD Biosciences, USA) software was used during 
acquisition on LSR Fortessa, while the data was analyzed afterwards using FlowJo software 
version 10.2 for Microsoft Windows 7 (Treestar, Ashland, OR). 
3.9. Statistical analysis 
The normality of the data was assessed by Shapiro-Wilk test or Kolmogrov-Smirnov test. 
Normally distributed data were expressed as mean ± SEM, whereas non-normally distributed 
data was displayed using box plots with whiskers representing median, interquartile range 
and minimum and maximum values. Student’s t test or Mann Whitney U test was used for 
comparison between controls and aSAH patients depending upon the data distribution. For 
subgroup analysis, the data was dichotomized into two groups and compared by using 
appropriate test as described by Mathiesen et al., 1997 and Faasbender et al., 2000. 
Correlations between different measured analytes and aSAH associated characters were 
assessed by Pearson correlation or Spearmann’s rho depending on data distribution. A p value 
less than 0.05 was considered as a significant difference between the two groups being 
compared. The data was analyzed by using GraphPad Prism 5.00 for windows (CA, USA) 
and SPSS 21 (IBM, NY, USA). 
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4. Results 
4.1. Role of DAMPs after aSAH 
We have determined the following selective DAMPs members including HMGB1, IL-1α, IL-
33 and mtDNA in the systemic circulation of the patients after aSAH. 
4.1.1. HMGB1 in systemic circulation 
High mobility group box-1 (HMGB1), a non-histone DNA binding protein, is expressed in 
almost all nucleated cells where it stabilizes DNA and facilitates transcription (Andersson 
and Tracey, 2011). However, extracellular HMGB1, released either passively from necrotic 
cells or actively from immune cells, serves as a damage-associated molecular pattern 
molecule (DAMP) and triggers inflammation via binding to toll-like receptor 4 (TLR4), 
TLR2 and receptor for advanced glycation end products (RAGE) (Wang et al., 1999; 
Muhammad et al., 2008; Qiu et al., 2008). HMGB1 is an early mediator of inflammation in 
experimental cerebral ischemia and its interaction with RAGE contributes to brain damage 
(Muhammad et al., 2008). HMGB1 is expressed in brain tissue and released early after 
experimental SAH (Murakami et al., 2011; Sun et al., 2014b). Here, we have investigated the 
temporal profile of systemic release of HMGB1 over a period of two weeks in aSAH patients.  
4.1.1.1. Temporal profile of serum HMGB1 release 
This study included 79 consecutive patients with a mean age of 57 years, 37% males and 
63% females, who were admitted to hospital after aneurysmal SAH with Hunt and Hess 
grade I – V. Twenty-eight control patients with spinal stenosis undergoing myelographic 
examination were enrolled in the study. The detailed characters of these patients are 
presented in Table 2. The time course of HMGB1 release over 13 days after aSAH is 
represented in Figure 2. The HMGB1 serum levels were significantly increased from day 1 
after aSAH until day 13 when compared to non-SAH controls (Fig. 2). HMGB1 
concentration was initially strongly elevated and reached almost double the level found in 
controls. However, it dropped slowly, but remained significantly high compared to controls 
until day 13. Up till now, no study showing elevated serum HMGB1 levels over almost two 
weeks in patients after aSAH covering the peak interval of CVS development has been 
conducted. 
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4.1.1.2. HMGB1 is differentially expressed in patients developing CVS 
To analyze the time course of HMGB1 release and its association with CVS, we compared 
HMGB1 concentration of patients who developed CVS with non-CVS on different days after 
aSAH. HMGB1 concentrations were significantly increased on day 1 in patients who 
developed CVS compared to patients from the non-CVS group (Fig. 4F). HMGB1 
concentrations remained significantly higher until day 13, showing a significant association 
of HMGB1 with development of CVS starting from day 1 to day 13 (Fig. 4F). However, we 
did not find any significant difference in a group of patients who developed chronic 
hydrocephalus except on day 13 (Fig. 4D). Serum HMGB1 concentration showed some 
significant elevation in patients with DIND only at day 11 and day 13 (Fig. 4E). Similarly, 
HMGB1 serum concentration in patients who suffered from seizures did not differ 
significantly than those without seizures (Fig. 4C). There was also no significant increase in 
HMGB1 concentration in patients who had cerebral ischemia or contracted infections (Fig. 
5A, D). Further dichotomization of the cerebral ischemia into interventional cerebral 
ischemia (interventional CI) or delayed cerebral ischemia (DCI) also revealed no significant 
difference in serum HMGB1 concentration (Fig. 5B, C). However, such a dichotomy in 
infections group showed only significant increase of HMGB1 concentration at day 13 in 
other infections group (presence of UTI, osteomyelitis or in combination with Pneumonia or 
Meningitis, Fig. 6A), but no significant increase was associated with Pneumonia or 
Meningitis (Fig. 5E, F). Interestingly, comparison of aSAH patients with Pneumonia and 
other infections, although showed only at day 1 a significant increase in HMGB1 
concentration in Pneumonia patients, represented a non-significant gradual fading pattern of 
HMGB1 concentration in patients with Pneumonia and a non-significant gradual rise in 
patients with other infections (Fig. 6B). Intriguingly, different parameters, including sex, 
aneurysm localization and presence of intracerebral and/ or intraventricular bleeding, in 
addition to aSAH did not influence serum HMGB1 concentrations (Fig. 3A, C, E, F, 4A). 
Furthermore, patients with less severe aSAH grades (H&H grades I-II, good grade) differed 
in HMGB1 levels only on day 11 (Fig. 3D). Interestingly, treatment modality also did not 
influence serum HMGB1 levels (Fig. 3B). A previous study has shown a correlation of serum 
HMGB1 on admission with clinical outcome after one year (Zhu et al., 2012b). We, however, 
did not find any association of serum HGMB1 with clinical outcome at discharge (Fig. 6C, D, 
7A, B).  
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4.1.1.3. Correlation of systemic HMGB1 with leukocytes and IL-6 
The source of serum HMGB1 might be peripheral leukocytes or brain via disrupted blood-
brain barrier. Hence, we quantified peripheral leukocytes to analyze association with serum 
HMGB1. Interestingly, serum HMGB1 concentrations significantly correlated with 
peripheral leukocytes (Fig. 7D) indicating the leukocytes as possible source of systemic 
HMGB1. Systemic HMGB1 can potentially induce release of other cytokines including IL-6. 
We quantified IL-6 serum levels to analyze its correlation with HMGB1. Serum IL-6 levels 
showed a significant correlation with HMGB1 (Fig. 7C), indicating the possibility of a 
pleiotropic effect of HMGB1.  
4.1.1.4. ROC Curve analysis of peripheral HMGB1 for CVS prediction 
As serum HMGB1 levels displayed a significant association with CVS, we performed an 
ROC curve analysis for the prediction of CVS using serum HMGB1 levels. The ROC curves 
showed significant area under the curve (AUC) almost approaching to 70% on day 1, 3, 5 and 
7 (Fig. 8). ROC analysis revealed that serum HMGB1 on day 1, with a cutoff value of 4.8 
ng/ml, could predict CVS with a sensitivity of 55% and a specificity of 72%. This suggests 
that systemic HMGB1 levels may be a predictor of CVS after aneurysmal subarachnoid 
hemorrhage. 
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Table 2. Baseline characteristics of the control and aSAH patients 
Spinal stenosis control patients (n) 28 
Age (mean ± SD) 67.42 ± 13.68 
Female gender, n (%) 15 (53.57%) 
aSAH patients (n) 79 
Age (mean ± SD) 56.72 ± 11.84 
Female gender, n (%) 50 (63.29%) 
Aneurysm treatment modality 
Surgical clipping, n (%) 
Endovascular coiling, n (%) 
 
39 (49.37%) 
40 (50.63%) 
Intracerebral bleed (ICB), n (%) 15 (18.99%) 
Intraventricular hemorrhage (IVH), n (%) 10 (12.66%) 
IVH+ICB, n (%) 11 (13.92%) 
Cerebrovascularspasm, n (%) 44 (55.70%) 
Delayed Ischemic Neurological Deficits, n (%) 28 (35.44%) 
Infarcts (Cerebral Ischemia, CI), n (%) 32 (40.51%) 
Interventional CI, n (%) 16 (20.25%) 
Delayed Cerebral Ischemia (DCI), n (%) 16 (20.25%) 
VP shunt dependent hydrocephalus, n (%) 25 (31.65%) 
Seizures, n (%) 23 (29.11%) 
Infections, n (%) 
Pneumonia, n (%) 
Meningitis, n (%) 
Others (UTI, Osteomyelitis etc), n (%) 
28 (35.44%) 
15 (18.99%) 
7 (8.86%) 
6 (7.59%) 
Hess and Hunt Grade, median 
1: Asymptomatic/mild headache, n (%) 
2: Moderate/severe headache, n (%) 
3: Drowsiness/confusion, n (%) 
4: Stupor, n (%) 
5: Coma/decerebrate posturing, n (%) 
3 
5 (6.33%) 
24 (30.38%) 
22 (27.85%) 
13 (16.46%) 
15 (18.99%) 
Fischer Grade, median 
1: No blood detected, n (%) 
2: Diffuse SAH, <1 mm thick, n (%) 
3 
1 (1.27%) 
2 (2.53%) 
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3: Diffuse SAH, ≥1 mm thick, n (%) 
4: Clot in ventricle/parenchyma, n (%) 
67 (84.81%) 
9 (11.39%) 
Glasgow outcome scale (GOS), median 
5: Good recovery, n (%) 
4: Moderate disability, n (%) 
3: Severe disability, n (%) 
2: Vegetative state, n (%) 
1: Death, n (%) 
3 
33 (41.77%) 
6 (7.59%) 
24 (30.38%) 
10 (12.66%) 
6 (7.59%) 
Modified Rankin scale (mRS), median 
0: No symptoms at all, n (%) 
1: No significant disability, n (%) 
2: Slight disability, n (%) 
3: Moderate disability, n (%) 
4: Moderately severe disability, n (%) 
5: Severe disability, n (%) 
6: Death, n (%) 
3 
2 (2.53%) 
25 (31.65%) 
8 (10.13%) 
7 (8.86%) 
17 (21.52%) 
14 (17.72%) 
6 (7.59%) 
 
 
 
Figure 2: Elevated serum HMGB1 levels in patients over two weeks after aSAH when 
compared to controls, Mann Whitney U test, p < 0.05 was considered as a significant 
difference, controls n = 28, aSAH n = 79. 
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Figure 3: A. Comparison of serum HMGB1 levels in patients with localization of aneurysm 
in anterior (n = 68) vs. posterior circulation (n = 11); B. clipping (n = 39) vs. coiling (n = 40); 
C. males (n=29) vs. females (n=50); D. good aSAH grade (H&H I-II, n = 29) vs. poor grade 
(H&H III-V, n = 50); E. no intraventricular hemorrhage and intracerebral bleeding (No 
IVH+ICB, n = 43) vs. intraventricular hemorrhage (IVH, n = 10); F. No IVH+ICB (n = 43) 
vs. intracerebral bleeding (ICB, n = 15); Mann Whitney U test, p < 0.05 was considered as a 
significant difference. 
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Figure 4: A. Comparison of serum HMGB1 levels in patients with: No IVH+ICB (n = 43) 
vs. both intraventricular hemorrhage and intracerebral bleeding (ICB, n = 11); B. IVH (n = 
10) vs. ICB (n = 15); C. no seizures (n = 56) vs. seizures (n = 23); D. no ventriculoperitoneal-
shunt dependent chronic hydrocephalus (n = 54) vs. ventriculoperitoneal-shunt dependent 
chronic hydrocephalus (n = 25); E. no  delayed ischemic neurological deficits (DIND, n = 51) 
vs. DIND (n = 28); F. no cerebral vasospasm (CVS, n = 35) vs. CVS (n = 44); Mann Whitney 
U test, p < 0.05 was considered as a significant difference. 
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Figure 5: A. Comparison of serum HMGB1 levels in patients with no cerebral 
infarction/ischemia (CI, n = 47) vs. CI (n = 32); B. no CI (n = 47) vs. interventional CI (n = 
16); C. no CI (n = 47) vs. delayed cerebral ischemia (DCI, n = 16); D. no infections (n = 51) 
vs. infections (n = 28); E. no  infections (n = 51) vs. pneumonia (n = 15); F. no  infections (n 
= 51) vs. meningitis (n = 7); Mann Whitney U test, p < 0.05 was considered as a significant 
difference. 
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Figure 6: A. Comparison of serum HMGB1 levels in patients with no infections (n = 51) vs. 
others (other infections either in combination with pneumonia, meningitis or alone such as 
UTI, osteomyelitis etc., n = 6); B. pneumonia (n = 15) vs. others (n = 6); C. poor clinical 
outcome (GOS 1-3, n = 40) vs. good clinical outcome (GOS 4-5, n = 39) as assessed by 
Glasgow Outcome Scale (GOS); D. good clinical outcome (mRS 0-2, n = 35) vs. poor 
clinical outcome (mRS 3-6, n = 44) as assessed by modified Rankin Scale (mRS); Mann 
Whitney U test, p < 0.05 was considered as a significant difference. 
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Figure 7: A. Correlation of cumulative serum HMGB1 levels vs. Glasgow Outcome Scale 
(GOS) (Spearman’s rho = 0.006, p = 0.896, n = 524); B. Correlation of cumulative serum 
HMGB1 levels vs. modified Rankin Scale (mRS) (Spearman’s rho = 0.025, p = 0.572, n = 
524); C. Correlation of cumulative serum HMGB1 levels vs. serum log IL-6 levels 
(Spearman’s rho = 0.105, p < 0.017, n = 517); D. Correlation of cumulative serum HMGB1 
levels vs. leucocyte counts (Spearman’s rho = 0.288, p < 0.000, n = 461). 
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Figure 8: ROC curves for predicting CVS on day 1, 3, 5 and 7 after aSAH.  
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4.1.2. Serum IL-1α and IL-33 
Both IL-1α and IL-33 are dual action cytokines with transcriptional properties inside cellular 
milieu, while DAMPs activity in the extracellular environment. We have initially screened 
both serum IL-1α and IL-33 in the sera from 10 aSAH patients at days 1, 3, 5, 7, 9, 11 and 13 
and in controls as well. Both the cytokines were either non-detectable or measured below the 
lowest standard of the standard curve standards ran during the ELISAs. This prompted us to 
precluded further analysis of the sera from remaining patients. Savarraj et al. (2017a) have 
also shown that serum levels of IL-33 are non-detectable after aSAH. 
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4.1.3. Mitochondrial DNA 
Tissue damage during early brain injury may lead to release of damage associated molecular 
pattern molecules (DAMPs) that may play a key role to initiate and sustain inflammation 
during the course of aSAH. Mitochondrial DNA (mtDNA) shares homology to bacterial 
DNA owing to unmethylated CpG motifs and acts as a DAMP (Zhang et al., 2010). 
Mitochondrial DNA can bind to TLR 9 on immune cells and upregulate systemic 
inflammation (Zhang et al., 2010). In this part of the study, we investigated the cell free 
circulating mtDNA in the peripheral blood of aSAH patients and its association with post 
aSAH complications and clinical outcome. Systemic levels of cell free circulating mtDNA 
fragments such as mt Cytochrome B (mt CytB), mt Cytochrome c oxidase subunit-1 (mt 
COX-1) and mt D-Loop were quantified in the DNA isolated from the serum of aSAH and 
control patients by real time PCR using Taqman probes. The baseline characters of aSAH 
patients are represented in Table 3. 
4.1.3.1. Mitochondrial Cytochrome B (mt CytB) 
The mt CytB levels were higher initially at day 1, 3, and 5, but did not reach significance as 
compared to healthy controls (HC) (Fig. 9A). However, at day 7 mt CytB levels were 
significantly raised in aSAH patients as compared to HC and remained significantly high till 
day 13 (1.4, 1.4, 1.6, 1.7, 2.1, 1.9, and 1.8 folds at days 1, 3, 5, 7, 9, 11 and 13, respectively). 
The mt CytB DNA appeared to be slowly released into systemic circulation, peaking at day 9 
and then started to decline (Fig. 9A). 
For further analysis, mt CytB levels were dichotomized based on gender, severity of aSAH, 
treatment modality, location of aneurysms, development of different complications and 
clinical outcome. Serum levels of mt CytB tended to be higher in male patients with 
occasional significant differences seen on day1, day 3 and day 9 (Fig. 10A). A significant 
difference existed only on day 1 between the patients who have ICB as compared to No 
IVH+ICB and on day 3, although the levels were still high, but did not reach significance (p 
= 0.075, Fig. 10B). There was no impact of infections on mt CytB levels and further, 
subgrouping based on the development of pneumonia, meningitis, and other infections 
(presence of other infections such as UTI or in combination with pneumonia or meningitis) 
revealed only significant difference at day 9 between aSAH patients with pneumonia (Fig. 
10D). Similarly, patients who developed cerebral infarction, here referred to as cerebral 
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ischemia (CI), did not display any significant changes in mt CytB levels. However, upon 
further subgrouping into interventional CI (aSAH patients who developed CI due to 
aneurysm repair) or DCI (aSAH patients where CI cause can be ascribed to CVS) showed 
significant difference between patients with Interventional CI compared to No CI at day 3, 
day 9 and day 13, while on day 11 p value was 0.05. This suggests that mt CytB levels are 
sensitive to CI resulting from neurosurgical clipping or endovascular coiling. 
4.1.3.2. Mitochondrial D-Loop (mt D-Loop) 
A region of mitochondrial D-Loop approximately 132 bp was amplified. The levels of mt D-
Loop were significantly higher from day 1 and remained high till day 13 in aSAH group as 
compared to HC (2.2, 2.2, 2.4, 2.3, 3.1, 2.7, and 2.4 folds on days 1, 3, 5, 7, 9, 11 and 13, 
respectively) (Fig. 9B).  
An analysis analogous to mt CytB was performed with serum mt D-Loop levels. Serum mt 
D-Loop levels were only significantly high on day 9 in males and on day 13 in patients with 
severe aSAH (H&H III-V) (Fig. 11A, B). Like mt CytB, serum mt D-Loop levels were only 
downregulated in patients with pneumonia on day 9 compared to patients without infections 
and on day 1 there was a non-significant difference (p = 0.088) (Fig. 11C). Patients who 
experienced post aSAH seizures have lower levels of mt D-Loop DNA levels with significant 
differences on day 3 and day 7 (Fig. 11D). A similar trend was seen in patients who required 
ventriculoperitoneal shunt (VP-Shunt) placement due to development of chronic 
hydrocephalus on day 1 and day 9 (Fig. 11E). Interestingly, mt D-Loop DNA levels seem to 
be higher with significance difference only on day 9 in patients with good clinical outcome 
(mRS 0-2) (Fig. 11F). 
4.1.3.3. Mitochondrial Cytochrome c oxidase subunit-1 (mt COX-1)  
A third mitochondrial gene fragment about 136 bp was selected from mtDNA encoding mt 
COX-1. Similar to mt D-Loop, mt COX-1 levels were significantly increased after aSAH 
compared to HC early at day 1 and remained elevated till day 13 (2.3, 1.8, 2.1, 2.5, 3.2, 3.2, 
2.7 folds on days 1, 3, 5, 7, 9, 11 and 13, respectively) (Fig. 9C). The release pattern of mt 
COX-1 in systemic circulation after aSAH was almost identical to mt D-Loop, however, all 
the gene fragments reached peak levels at day 9 and then, started to decline. Interestingly, this 
Results 
60 
 
represents an important time period during which complications arise and lead to 
deterioration of aSAH patients. 
Patients with ICB and who have DIND showed significantly higher mt COX-1 levels on day 
1 and day 11, respectively (Fig. 12A & B). Seizures have a similar impact on mt COX-1 
levels as was evident with mt D-Loop, however, only significant difference existed at a single 
time point (day 7) (Fig. 12C). Levels of mt COX-1 were significantly downregulated at day 3 
and day 9 in patients developing CI and further, dichotomy of CI patients revealed significant 
downregulation of mt COX-1 levels in patients with interventional CI compared to No CI at 
day 3, day 9 – 13 (Fig. 12D, E). 
4.1.3.4. Correlations 
Some significant correlations were observed for serum mtDNA genes measured at different 
days with aSAH patient associated characters, ensuing complications and clinical outcome at 
discharge (Table 4). Cumulative levels measured over two weeks of mt CytB, mt D-Loop and 
mt COX-1 DNA showed some weak, but significant correlations with different aSAH patient 
characters, complications and clinical outcome represented in table 5. 
Results 
61 
 
Table 3. Baseline characters of aSAH patients recruited for mtDNA quantification 
aSAH  (n) 80 
Age (years) (mean±SD) 56.97 
(±12.00)  
Females (%) 62.5% 
Treatment modality 
Neurosurgical clipping (%) 
Endovascular coiling (%) 
 
48.8% 
51.3% 
Intraventricular hemorrhage: IVH (%) 12.5% 
Intracerebral bleeding: ICB (%) 20.0% 
ICB and IVH (%) 13.8% 
Hunt and Hess grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
6.3% 
30.0% 
28.8% 
16.3% 
18.8% 
Fischer grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
3 
1.3% 
2.5% 
85.0% 
12.5% 
CVS (%) 55.0% 
Cerebral Ischemia (%) 
Intervention related CI (%) 
DCI (%) 
41.3% 
21.3% 
20.0% 
Seizures (%) 30.0% 
VP-Shunt dependent hydrocephalus (%) 31.3% 
Infections (%) 
Pneumonia (%) 
Meningitis (%) 
Others (%) 
Pneumonia+Meningitis (%) 
Pneumonia+UTI (%) 
Meningitis+UTI (%) 
Misc. (Osteomyelitis, sepsis) (%) 
36.3% 
18.8% 
8.8% 
8.8% 
2.5% 
2.5% 
1.3% 
2.5% 
DIND (%) 35.0% 
Aneurysm location 
Anterior circulation (%) 
Posterior circulation (%) 
 
86.3% 
13.8% 
GOS (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
8.8% 
12.5% 
30.0% 
7.5% 
41.3% 
mRS (median) 3 
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 0 (%) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
6 (%) 
2.5% 
31.3% 
10.0% 
8.8% 
21.3% 
17.5% 
8.8% 
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Table 4. Correlations of different mtDNA genes (mt CytB, mt D-Loop and mt COX-1) 
with different aSAH associated parameters 
Sr. 
# 
Log 
mtDNA 
aSAH characters No. of 
XY 
pairs 
Spearman 
rho 
P value 95% CI 
1 CytB D1 Female 80 -0.254 0.023 -0.454 to 0.030 
2 CytB D1 Leucocytes D13 61 -0.315 0.014 -0.531 to -0.061 
3 CytB D3 Female 79 -0.221 0.051 -0.427 to 0.007 
4 CytB D3 Leucocytes D5 76 0.323 0.005 0.098 to 0.516 
5 CytB D5 Female 77 -0.243 0.033 -0.448 to -0.014 
6 CytB D5 CRP D13 32 -0.381 0.031 -0.650 to -0.027 
7 CytB D7 Female 79 -0.225 0.046 -0.431 to 0.002 
8 CytB D9 Female 78 -0.2316 0.041 -0.437 to -0.003 
9 CytB D9 CI 78 -0.239 0.035 -0.444 to -0.011 
10 CytB D3 Interventional CI 79 -0.243 0.031 -0.446 to -0.017 
11 CytB D9 Interventional CI 78 -0.326 0.004 -0.517 to -0.105 
12 CytB D9 Leucocytes D11 57 0.306 0.020 0.042 to 0.531 
13 CytB D9 β-Blockers 78 0.240 0.034 0.012 to 0.444 
14 CytB D11 β-Blockers 73 0.237 0.044 0.000 to 0.448 
15 CytB D11 CaCBs 73 0.264 0.024 0.029 to 0.471 
16 CytB D11 Leucocytes D11 55 0.375 0.005 0.114 to 0.588 
17 CytB D13 β-Blockers 70 0.257 0.032 0.016 to 0.470 
18 CytB D13 Interventional CI 70 -0.284 0.017 -0.492 to -0.045 
19 CytB D13 CRP D1 36 -0.392 0.018 -0.645 to -0.063 
20 CytB D13 CRP D13 28 -0.426 0.024 -0.696 to -0.052 
21 D-Loop D1 Chronic 
Hydrocephalus 
80 -0.280 0.012 -0.476 to -0.058 
22 D-Loop D1 CRP D1 43 -0.309 0.044 -0.564 to 0.000 
23 D-Loop D1 Leucocytes D13 61 -0.278 0.030 -0.501 to -0.020 
24 D-Loop D5 CRP D9 38 -0.337 0.038 -0.599 to -0.010 
25 D-Loop D7 CRP D11 33 0.360 0.040 0.008 to 0.632 
26 D-Loop D9 Chronic 78 -0.289 0.010 -0.486 to -0.065 
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Table 5. Correlations of cumulative mtDNA levels of mt CytB, D-Loop and COX-1 
measured over two weeks with different aSAH patient associated characters, 
complications and clinical outcome. 
Log mt 
DNA 
Complications & 
outcome 
Spearman 
r 
P value 95% CI 
D-Loop GOS 0.113 0.010 0.024 to 0.200 
D-Loop mRS -0.104 0.019 -0.191 to -0.015 
D-Loop  Female Gender -0.152 0.001 -0.238 to -0.064 
D-Loop Pneumonia -0.1330 0.003 -0.219 to -0.044 
Hydrocephalus 
27 D-Loop D9 GOS 78 0.288 0.011 0.063 to 0.485 
28 D-Loop D9 mRS 78 -0.274 0.015 -0.473 to -0.048 
29 D-Loop D9 Leucocytes D1 77 0.230 0.045 -0.001 to 0.437 
30 D-Loop 
D11 
CaCBs 73 0.240 0.041 0.003 to 0.451 
31 D-Loop 
D13 
CRP D1 35 -0.405 0.016 -0.656 to -0.073 
32 COX1 D1 Leucocytes D13 61 -0.276 0.032 -0.499 to -0.018 
33 COX1 D3 CRP D3 41 -0.328 0.036 -0.584 to -0.013 
34 COX1 D3 Seizures 79 -0.224 0.047 -0.430 to 0.003 
35 COX1 D5 CRP D1 41 -0.319 0.042 -0.577 to -0.003 
36 COX1 D7 Seizures 79 -0.246 0.029 -0.448 to -0.019 
37 COX1 D9 CI 78 -0.234 0.039 -0.439 to -0.005 
38 COX1 D3 Interventional CI 79 -0.297 0.008 -0.491 to -0.075 
39 COX1 D9 Interventional CI 78 -0.323 0.004 -0.514 to -0.101 
40 COX1 D11 Interventional CI 73 -0.336 0.004 -0.531 to -0.108  
41 COX1 D11 DIND 73 0.242 0.039 0.006 to 0.453 
42 COX1 D11 Leucocytes D11 55 0.305 0.024 0.0353 to 0.534 
43 COX1 D13 Interventional CI 70 -0.335 0.005 -0.534 to -0.102 
44 COX1 D13 CRP D1 36 -0.351 0.036 -0.616 to -0.016 
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D-Loop 
Chronic 
hydrocephalus 
-0.128 0.004 -0.215 to -0.039 
D-Loop Seizures -0.152 0.001 -0.238 to -0.064 
D-Loop Leucocytes 0.120 0.0110 0.025 to 0.212 
CytB CVS 0.101 0.019 0.014 to 0.187 
CytB CI -0.105 0.020 -0.190 to -0.018 
CytB Interventional CI -0.179 <0.000 -0.262 to -0.094 
CytB Pneumonia -0.149 0.001 -0.233 to -0.062 
CytB Others 0.1013 0.019 0.014 to 0.186 
CytB Fischer 0.113 0.009 0.026 to 0.198 
CytB Female Gender -0.2012 <0.000 -0.283 to -0.116 
CytB Leucocytes 0.123 0.008 0.030 to 0.213 
COX-1 CI -0.150 0.000 -0.232 to -0.066 
COX-1 Interventional CI -0.208 <0.000 -0.288 to -0.125 
COX-1 Fischer 0.100 0.018 0.015 to 0.183 
COX-1 Infections -0.117 0.005 -0.201 to -0.033 
COX-1 Pneumonia -0.107 0.011 -0.191 to -0.022 
COX-1 Meningitis -0.0834 0.049 -0.168 to 0.002 
COX-1 Seizures -0.094 0.026 -0.178 to -0.009 
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Figure 9: Comparison of serum mtDNA among healthy controls (HC, n =18) and aSAH 
patients (n = 80). A. Serum mt CytB levels among healthy controls and aSAH patients. B. 
Serum mt D-Loop levels among healthy controls and aSAH patients. C. Serum mt COX-1 
levels among healthy controls and aSAH patients. Student’s t test, p < 0.05 was considered as 
a significant difference. 
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Figure 10: Comparison of mt CytB levels among different aSAH subgroups. A. Comparison 
of mt CytB levels among male (n = 30) and female (n = 50) aSAH patients. B. Comparison of 
mt CytB levels in patients showing No IVH+ICB (n = 43) and only ICB (n = 16). C. 
Comparison of mt CytB levels among patients developing infections (n = 29) and no 
infections (n = 51). D. Comparison of mt CytB levels among patients with no infections (n = 
51) and Pneumonia (n = 15). E. Comparison of mt CytB levels in aSAH patients showing CI 
(n = 33). F. Comparison of mt CytB levels among patients who have no CI (n = 47) and 
interventional CI (n = 17). Unpaired t test, p < 0.05 was considered as a significant 
difference. 
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Figure 11: Comparison of mt D-Loop levels among different aSAH subgroups. A. 
Comparison of mt D-Loop levels among male (n = 30) and female (n = 50) aSAH patients. B. 
Comparison of mt D-Loop levels among patients with severe aSAH (H&H III-V, n = 51) and 
less severe aSAH (H&H I-II, n = 29). C. Comparison of mt D-Loop levels among patients 
with no infections (n = 51) and Pneumonia (n = 15). D. Comparison of mt D-Loop levels 
among patients who developed seizures (n = 24) and no seizures (n = 56). E. Comparison of 
mt D-Loop levels among patients who developed chronic hydrocephalus (n = 25) and who do 
not (n = 55). F. Comparison of mt D-Loop levels among patients with good clinical outcome 
(mRS 0-2, n = 35) and poor outcome (mRS 3-6, n = 45). Unpaired t test, p < 0.05 was 
considered as a significant difference. 
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Figure 12: Comparison of mt COX-1 levels among different aSAH subgroups. A. 
Comparison of mt COX-1 levels in aSAH patients with No IVH+ICB (n = 43) and only ICB 
(n = 16). B. Comparison of mt COX-1 levels among patients with No DIND (n = 52) and 
with DIND (n = 28). C. Comparison of mt COX-1 levels among aSAH patients developing 
seizures (n = 24) and no seizures (n = 56). D. Comparison of mt COX-1 levels in aSAH 
patients showing CI (n = 33) and no CI (n = 47). E. Comparison of mt COX-1 levels among 
patients who have no CI (n = 47) and interventional CI (n = 17). Unpaired t test, p < 0.05 was 
considered as a significant difference. 
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4.2. Investigation of systemic cytokines after aSAH 
Selected cytokines that were either not previously investigated or scarce information was 
available relating to their association with post-aSAH complications and clinical outcome 
were also included in this study. We have determined the systemic levels of IL-23, IL-17, IL-
10, and CXCL5 at day 1 and at day 7 post aSAH, while IL-6 levels determination was carried 
out on days similar to HMGB1 and mtDNA. 
4.2.1. Serum IL-23  
The baseline characters of aSAH patients whose sera were employed for IL-23, IL-17 and 
CCL5 determination are represented in table 6. We analyzed serum IL-23 levels in aSAH 
patients at two different time points, at day 1 as an early time point and at day 7 as a late time 
point during the course of the disease. Serum IL-23 levels were significantly raised in aSAH 
patients on both time points as compared to control patients (Fig. 13). The mean (±SEM) 
serum IL-23 levels among controls, aSAH patients at day 1 and day 7 were 8.23 (± 1.99) 
pg/ml, 28.07 (± 3.40) pg/ml and 31.70 (± 3.83) pg/ml respectively. 
4.2.1.1. Serum IL-23 in post-aSAH complications 
 For further analysis, we dichotomized the aSAH patients based on their clinical severity 
(Hunt and Hess grade), treatment modality (clipping and coiling), aneurysm location (anterior 
or posterior circulation), and post-aSAH complications. There was no significant difference 
in IL-23 levels between good grade (Hunt and Hess I-II) vs poor grade (Hunt and Hess grade 
III-V) aSAH patients at day 1, but serum IL-23 levels were significantly raised at day 7 in 
good grade aSAH patients (Fig. 14A). Serum IL-23 levels were raised significantly at day 1 
in aSAH patients presenting with intracerebral bleeding and this difference non-significantly 
persisted at day 7 compared to aSAH patients without ICB (Fig. 14B). Serum IL-23 levels 
were significantly higher in patients who were treated with neurosurgical clipping compared 
to endovascular coiling at day 7 (Fig. 14C) showing the possibility that craniotomy and 
operative manipulation may induce the IL-23. Serum IL-23 levels were slightly lower in 
patients who developed seizures at day 1, however, at day 7 serum IL-23 levels were 
significantly lowered in aSAH patients with seizures (Fig. 14D). In other post-aSAH 
complications such as CVS, DIND, CI, and infections, no significant changes in serum IL-23 
levels were observed (data not shown). Further subcategorizing the patients who developed 
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CI into interventional CI and DCI groups showed that serum IL-23 levels were significantly 
higher early at day 1 in DCI group compared to interventional CI, whereas serum IL-23 
levels at day 7 were non-significantly higher in DCI group (Fig. 14E). Similarly, we 
subcategorized the patients who developed infections into pneumonia, meningitis and others 
(other infections or a co-occurrence with pneumonia and meningitis). Serum IL-23 levels 
were significantly reduced in patients who developed other infections or their co-occurrence 
with pneumonia and meningitis at both days of assessment (Fig. 14F).  
4.2.1.2. Serum IL-23 and post-aSAH clinical outcome 
Assessment of clinical outcome using Glasgow outcome scale (GOS) and modified Rankin 
scale (mRS) at discharge from the hospital showed no difference in serum IL-23 levels in 
patients with good clinical outcome (GOS 5-4; mRS 0-2) as compared to patients with poor 
clinical outcomes (GOS 3-1; mRS 3-6) (Fig. 15). However, at day 7, serum IL-23 levels were 
inclined to non-significantly rise in good outcome patients. 
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Table 6. Characteristics of control and aSAH patients 
Controls (n) 24 
Age (years) (mean±SD) 67.06 (±13.54) 
Females (%) 45.8% 
aSAH  (n) 80 
Age (years) (mean±SD) 58.29 (±11.8)  
Females (%) 61.3% 
Treatment modality 
Neurosurgical clipping (%) 
Endovascular coiling (%) 
 
48.8% 
51.3% 
Intraventricular hemorrhage: IVH (%) 13.8% 
Intracerebral bleeding: ICB (%) 18.8% 
ICB and IVH (%) 13.8% 
Hunt and Hess grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
7.5% 
30.0% 
28.8% 
16.3% 
17.5% 
Fischer grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
3 
1.3% 
2.5% 
83.8% 
12.5% 
CVS (%) 56.3% 
Cerebral Ischemia (%) 
Intervention related CI (%) 
DCI (%) 
42.5% 
21.3% 
21.3% 
Seizures (%) 28.8% 
VP-Shunt dependent hydrocephalus (%) 31.3% 
Infections (%) 
Pneumonia (%) 
Meningitis (%) 
Others (%) 
Pneumonia+Meningitis (%) 
Pneumonia+UTI (%) 
Meningitis+UTI (%) 
Misc. (Osteomyelitis) (%) 
36.3% 
18.8% 
10.0% 
7.5% 
2.5% 
2.5% 
1.3% 
1.3% 
DIND (%) 35.0% 
Aneurysm location 
Anterior circulation (%) 
Posterior circulation (%) 
 
86.3% 
13.8% 
GOS (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3.5 
8.8% 
11.3% 
30.0% 
7.5% 
42.5% 
mRS (median) 3 
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0 (%) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
6 (%) 
2.5% 
32.5% 
10.0% 
8.8% 
21.3% 
16.3% 
8.8% 
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Figure 13: Serum IL-23 levels in control patients (n = 24) and aSAH patients (n = 80) at day 
1 and day 7. Mann-Whitney U test; p value <0.0001 at day 1 and <0.0001 at day 7. SAH D1= 
Subarachnoid hemorrhage at day one, SAH D7= Subarachnoid hemorrhage at day seven.
Results 
75 
 
 
Figure 14: A. Serum IL-23 levels at day 1 and day 7 after aSAH in patients: with good grade 
aSAH (Hunt and Hess I-II, n = 30) and poor grade aSAH (Hunt and Hess III-V, n = 50); B. 
with Intracerebral bleeding (ICB, n = 15) compared to who had no intraventicular and 
intracerebral bleeding (No ICB+IVH, n = 43); C. treated by neurosurgical clipping (n = 39) 
and endovascular coiling (n = 41); D. developing seizures (n = 23) and no seizures (n = 57); 
E. who had interventional CI (n = 17) and DCI (n = 17); F. with other infections (n = 6) 
compared to no infections (n = 51); Mann-Whitney U test; *p value < 0.05 was considered as 
significant difference. 
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Figure 15: A. Serum IL-23 levels at day 1 and day 7 after aSAH in patients presenting with 
good outcome (GOS 4-5, n = 40) and poor outcome (GOS 1-3, n = 40) as assessed by GOS; 
B. Serum IL-23 levels at day 1 and day 7 after aSAH in patients presenting with good 
outcome (mRS 0-2, n = 36) and poor outcome (3-6, n = 44) as assessed by mRS; Mann-
Whitney U test, *p value <0.05 was considered as significant difference. C and D. No 
significant Spearman correlation of serum IL-23 (pg/ml) with GOS (n = 160, Spearman’s rho 
= 0.063, p = 0.429) and mRS (n = 160, Spearman’s rho = -0.006, p = 0.955) was observed. 
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4.2.2. Serum IL-17 
Serum IL-17 levels were significantly raised in aSAH patients on day 1 and day 7 as 
compared to control patients (Fig. 16). Serum IL-17 levels among control and aSAH patients 
at day 1 and day 7 were found to be 1.33 (±0.27) pg/ml, 3.23 (±0.20) pg/ml and 4.54 (±0.43) 
pg/ml respectively. Serum IL-17 levels, unlike serum IL-23 levels, were significantly higher 
at day 7 as compared to day 1 (Fig. 16). 
4.2.2.1. Serum IL-17 in post-aSAH complications 
An analysis of serum IL-17 after dichotomy in different subgroups showed some significant 
differences (Fig. 17). Serum IL-17 levels were non-significantly higher at day 7 in poor grade 
aSAH (H&H III-V, Fig. 17A). Serum IL-17 levels were also significantly higher at day 1 in 
aSAH patients involving aneurysms of anterior circulation compared to posterior circulation 
aneurysm rupture (Fig. 17B). Interestingly, serum IL-17 levels were significantly reduced at 
day 1 in patients having additional intracerebral bleeding and intraventricular hemorrhage, 
but at day 7 they were significantly higher compared to patients without ICB and IVH (Fig. 
17C). The patients who developed CVS, chronic hydrocephalus and seizures did not show 
any significant difference in serum IL-17 levels (data not shown). Interestingly, serum IL-17 
levels were significantly decreased at day 7 in patients who developed delayed ischemic 
neurological deficits (DIND, Fig. 17D). Furthermore, serum IL-17 levels were significantly 
elevated in aSAH patients who had interventional CI compared to DCI later on day 7 (Fig. 
17E). In contrast to serum IL-23 levels, serum IL-17 levels were significantly elevated in 
other infections group at both day 1 and day 7 as compared to patients who did not contract 
any infections (Fig. 17F). Further dissection of the data revealed that serum IL-17 levels were 
also significantly higher in patients who developed other infections compared to those with 
pneumonia at day 1 and day 7 and with meningitis at day 7 (Fig. 18A, B). 
4.2.2.2. Serum IL-17 and post-aSAH clinical outcome 
To analyze if serum IL-17 has a correlation with clinical outcome, we evaluated clinical 
outcome with two well known scales including Glasgow outcome scale and modified Rankin 
scale. The dichotomy of patients in good outcome and poor outcome showed no difference in 
serum IL-17 levels among the patients with good clinical outcome (GOS = 4–5; mRS = 0–2) 
and poor outcome (GOS = 1–3; mRS = 3–6) as shown in Fig. 18C, D. Pooled serum IL-17 
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levels did not show any significant correlation with GOS and mRS (Fig. 18E, F, 
respectively). However, at day 7, serum IL-17 levels tended to non-significantly decrease in 
patients with good clinical outcome and vice versa. 
4.2.2.3. Correlations between serum IL-23 and IL-17 with different baseline 
characteristics of aSAH patients and post-aSAH complications 
The significant correlations of serum IL-23 and serum IL-17 with different aSAH associated 
parameters at day 1 and day 7 were assessed by non-parametric Spearman’s correlation and 
are shown in Table 7. 
 
 
 
Figure 16: Serum IL-17 levels in control patients (n = 24) and aSAH patients (n = 80) at day 
1 and (n = 79) day 7. Mann-Whitney U test, p value <0.0001 at day 1 and <0.0001 at day 7. 
Wilcoxon signed rank test for comparison at day 1 and day 7, p value <0.0001. SAH D1= 
Aneurysmal Subarachnoid hemorrhage at day one, SAH D7= Aneurysmal Subarachnoid 
hemorrhage at day seven. 
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Figure 17: A. Serum IL-17 levels at day 1 and day 7 after aSAH in patients with: good grade 
SAH (Hunt and Hess I-II, n = 29) and poor grade SAH (Hunt and Hess III-V, n = 50); B. 
anterior circulation aneurysms (n = 68) vs. posterior circulation aneurysms (n = 11); C. No 
ICB+IVH (n = 43) and IVH+ICB (n = 11); D. DIND (n = 27) and no DIND (n = 52); E. 
interventional CI (n = 17) and DCI (n = 16); F. other infections (n = 6) compared to no 
infections (n = 51); Mann-Whitney U test, *p value <0.05 was considered as significant 
difference. 
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Figure 18: A. Serum IL-17 levels at day 1 and day 7 after aSAH in patients with: Pneumonia 
(n = 15) compared to other infections (n = 6); B. Meningitis (n = 8) compared to other 
infections (n = 6); C. good outcome (GOS 4-5, n = 40) and poor outcome (GOS 1-3, n = 40) 
as assessed by GOS; D. good outcome (mRS 0-2, n = 36) and poor outcome (mRS 3-6, n = 
44) as assessed by mRS. Mann-Whitney U test, *p value <0.05 was considered as significant 
difference. E and F. No significant Spearman correlation of serum IL-17 (pg/ml) with GOS 
(n = 159, Spearman’s rho = 0.007, p = 0.932) and mRS (n = 159, Spearman’s rho = -0.03, p = 
0.710) was observed. 
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Table 7. Correlations of different aSAH associated parameters with serum IL-23 and 
IL-17 levels 
Sr. 
# 
Serum IL-23/IL-17 
at Day 1 & Day 7 
aSAH characters No. of XY 
pairs 
Spearman’s 
rho 
P value 
1 Serum IL-23 day 1 Interventional CI 80 -0.238 0.033 
2 Serum IL-23 day 7 H&H grade 80 -0.256 0.022 
3 Serum IL-23 day 7 Fischer grade 80 -0.313 0.005 
4 Serum IL-23 day 7 Age 80 -0.268 0.016 
5 Serum IL-23 day 7 Endovascular coiling 80 -0.245 0.028 
6 Serum IL-23 day 7 Seizures 80 -0.222 0.048 
7 Serum IL-17 day 1 Posterior circulation 80 -0.249 0.026  
8 Serum IL-17 day 7 H&H grade 79 0.261 0.020  
9 Serum IL-17 day 7 DIND 79 -0.292 0.009 
10 Serum IL-17 day 7 Interventional CI 79 0.236 0.036  
11 Serum IL-17 day 7 DCI 79 -0.229 0.042  
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4.2.3. Serum IL-6 
IL-6 is a well-known pro-inflammatory cytokine that is secreted early after aSAH (Helbok et 
al., 2015; Niwa and Osuka, 2016). IL-6 levels in cerebrospinal fluid (CSF) of patients after 
aSAH have been shown to be associated with occurrence of cerebral vasospasm and clinical 
outcome (Osuka et al., 1998; Schoch et al., 2007; Sarrafzadeh et al., 2010; Helbok et al., 
2015; Niwa and Osuka, 2016; Wu et al., 2016a; Zeiler et al., 2017). Moreover, elevated early 
serum IL-6 levels predict the unfavourable clinical outcome (Muroi et al., 2013; Hollig et al., 
2015b; Hollig et al., 2015a; Kao et al., 2015). However, detailed studies exploring the 
kinetics of IL-6 release in systemic circulation over the 2 weeks after aSAH and its 
association with post-aSAH complications and its impact on early clinical outcome prediction 
are lacking. Here, we analyzed the systemic IL-6 levels over two weeks (covering the peak 
time to develop the post-aSAH complications) after bleeding and its role in post-aSAH 
complications. We have determined the serum IL-6 levels in aSAH patients and healthy 
controls. The detailed characters of aSAH patients are shown in Table 8. Serum IL-6 levels 
were significantly raised in systemic circulation after aSAH as compared to healthy controls 
and remained persistently high till day 13 of assessment (Fig. 19). For further analysis, the 
data was dichotomized as described above for other cytokines. Serum IL-6 levels remained 
significantly raised in patients presenting with poor H&H grade, reflecting severity of aSAH 
(Fig. 20E). There was no significant difference in IL-6 levels among patients undergoing 
neurosurgical clipping or endovascular coiling (Fig. 20A) and same was true for gender 
comparison reflecting the fact that gender and craniotomy do not alter the systemic IL-6 
levels (Fig. 20B). Serum IL-6 levels, only at day 1 and day 5, were significantly higher in 
patients having anterior circulation aneurysms (Fig. 20C). Most of the studies describe mean 
age of aSAH patients around 55 years (Fassbender et al., 2001; Macedo et al., 2010; Galea et 
al., 2017b). So, we have dichotomized patients above or below 55 years of age and found that 
serum IL-6 levels tend to be higher in patients with age above 55 years. This tendency 
reached to a significant difference at day 5 – day 7 reflecting the possibility of more severe 
systemic inflammation at higher age (Fig. 20D). Serum IL-6 levels were significantly raised 
in aSAH patients who present with additional intraventricular or intracerebral bleeding or 
both simultaneously at several days in comparison to patients who only had subarachnoid 
bleed (Fig. 20F, 21A, B). 
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4.2.3.1. Serum IL-6 in post-aSAH complications 
To analyze the influence of systemic IL-6 levels on the occurrence of post-aSAH 
complications, we dichotomized the patients into groups who developed the complications 
and those without these complications. Serum IL-6 levels were found to be significantly 
raised after aSAH in patients who displayed DIND (delayed ischemic neurological deficits) 
throughout the assessment days (Fig. 21C). Similarly, patients who were diagnosed with 
angiographic vasospasm had significantly elevated serum IL-6 levels (Fig. 21D). Except at 
day 1 and day 5, serum IL-6 levels were significantly increased in patients who developed 
seizures as compared to those who didn’t (Fig. 21E). Similarly, IL-6 levels were upregulated 
in patients who developed chronic hydrocephalus and required ventriculoperiotoneal shunt 
placement (Fig. 21F). A significant proportion of aSAH patients confront with nosocomial 
infections after the initial bleeding showing the possibility of immunosupression after SAH 
(Frontera et al., 2008; Sarrafzadeh et al., 2011). We found that serum IL-6 levels were 
significantly raised in aSAH patients who contracted infections (Fig. 22A). Further, 
dissecting the data into pneumonia, meningitis and other infections (having other infections 
such as UTI or in addition to pneumonia or meningitis) groups revealed distinct differences in 
serum IL-6 levels among these groups. Interestingly, aSAH patients contracting pneumonia 
infection or other infections had significantly higher serum IL-6 levels as compared to non-
infectious aSAH patients (Fig. 22B&D). However, presence of meningitis did not elevate 
serum IL-6 and the levels remained parallel to aSAH patients without infections (Fig. 22B). 
Finally, we have evaluated serum IL-6 levels among patients who developed cerebral 
infarction and found a delayed significant elevation of serum IL-6 at day 9 – day 13 (Fig. 
22E). Further dichotomy of CI group into interventional CI and DCI showed that serum IL-6 
levels were non-significantly raised lately in interventional CI group. However, interestingly 
serum IL-6 levels were significantly lower at day 1 in DCI group compared to No CI group, 
but were impaired early at day 3 and remained elevated with occasional significant difference 
existing only at day 9 (Fig. 22D). 
4.2.3.2. Serum IL-6 and post-aSAH clinical outcome 
The clinical outcome of the aSAH patients at discharge was assessed by GOS and mRS. 
Dichotomy into good clinical outcome and poor clinical outcome by both scores revealed a 
significant difference in serum IL-6 levels. Serum IL-6 levels were significantly higher early 
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at day 1 till day 13 in aSAH patients with poor clinical outcome (GOS 1-3) as assessed by 
GOS (Fig. 23A). Although, there was no significant difference at day 1, but later on till last 
day of assessment was marked with significant elevation of serum IL-6 levels in patients with 
poor clinical outcome (mRS 3-6) assessed by mRS compared to good outcome patients (mRS 
0-2, Fig. 23B). 
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Table 8. Clinical characteristics of aSAH patients whose serum IL-6 levels 
were determined 
Number of aSAH patients 80 
Age (years) (mean±SD) 56.97 (±12.00)  
Females (%) 62.5% 
Treatment modality 
Neurosurgical clipping (%) 
Endovascular coiling (%) 
 
48.8% 
51.3% 
Intraventricular hemorrhage: IVH (%) 12.5% 
Intracerebral bleeding: ICB (%) 20.0% 
ICB and IVH (%) 13.8% 
Hunt and Hess grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
6.3% 
30.0% 
28.8% 
16.3% 
18.8% 
Fischer grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
3 
1.3% 
2.5% 
83.8% 
12.5% 
CVS (%) 55.0% 
Cerebral Ischemia (%) 
Intervention related CI (%) 
DCI (%) 
41.3% 
21.3% 
20.0% 
Seizures (%) 30.0% 
VP-Shunt dependent hydrocephalus (%) 31.3% 
Infections (%) 
Pneumonia (%) 
Meningitis (%) 
Others (%) 
Pneumonia+Meningitis (%) 
Pneumonia+UTI (%) 
Meningitis+UTI (%) 
Misc. (Osteomyelitis, wound infection) (%) 
37.5% 
18.8% 
8.8% 
10.0% 
2.5% 
3.8% 
1.3% 
2.5% 
DIND (%) 35.0% 
Aneurysm location 
Anterior circulation (%) 
Posterior circulation (%) 
 
86.3% 
13.8% 
GOS (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
8.8% 
12.5% 
30.0% 
5.0% 
41.3% 
mRS (median) 
0 (%) 
1 (%) 
3 
2.5% 
31.3% 
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2 (%) 
3 (%) 
4 (%) 
5 (%) 
6 (%) 
10.0% 
8.8% 
21.3% 
17.5% 
8.8% 
 
 
 
 
 
Figure 19: Comparison of serum IL-6 levels among healthy controls and aSAH patients. HC 
= Healthy controls (n = 10) SAH = Aneurysmal Subarachnoid hemorrhage (n = 80), D1 – 
D13 = Day 1 – Day 13, Unpaired t test, p < 0.05 was considered as a significant difference. 
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Figure 20: A. Comparison of serum IL-6 levels among aSAH patients with: aneurysm repair 
by neurosurgical clipping (n = 39) or by endovascular coiling (n = 41); B. male sex (n = 30) 
and female sex (n = 50); C. anterior circulation aneurysms (n = 69) and posterior circulation 
aneurysms (n = 11); D. age below 55 years (n = 37) and equal to/above 55 years (n = 43); E. 
with good H&H grades (n = 29) and poor H&H grades (n = 51). F. no IVH+ICB (n = 43) vs. 
IVH (n = 10). Unpaired t test, p < 0.05 was considered as a significant difference. 
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Figure 21: A. Comparison of serum IL-6 levels among aSAH patients with: no IVH+ICB (n 
= 43) and ICB (n = 16); B. no IVH+ICB (n = 43) and both IVH+ICB (n = 11); C. DIND (n = 
28) and No DIND (n = 52); D. CVS (n = 44) and No CVS (n = 36); E. seizures (n = 24) and 
no seizures (n = 56); F. chronic hydrocephalus (n = 25) and no chronic hydrocephalus (n = 
55). Unpaired t test, p < 0.05 was considered as a significant difference. 
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Figure 22: A. Comparison of serum IL-6 levels in aSAH patients with: infections (n = 30) and 
without infections (50); B. only pneumonia (n = 14) and no infections (n = 50). C. only 
meningitis (n = 7) and no infections (n = 50); D. other infections (n = 9) and no infections (n = 
50); E. cerebral ischemia (CI = 33) and no CI (n = 47); F. DCI (n = 16) and no CI (n = 47). 
Unpaired t test to compare the two groups, p < 0.05 was considered as a significant difference. 
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Figure 23: A. Comparison of serum IL-6 levels among aSAH patients with: good clinical 
outcome (GOS 4-5, n = 39) and poor clinical outcome (GOS 1-3, n = 41) as assessed by GOS; 
B. good clinical outcome (mRS 0-2, n =35) and poor clinical outcome (mRS 3-6, n = 45) as 
assessed by modified Rankin scale. Unpaired t test, p < 0.05 was considered as a significant 
difference. 
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4.2.4. Serum IL-10 
The baseline characters of aSAH patients whose serum IL-10 levels were determined are 
shown in Table 9. The median H&H and Fischer scores were 3, while median GOS score was 
4 and mRS score was 3. Serum IL-10 levels were significantly raised after aSAH at day 1 as 
compared to controls (Fig. 24). Determination of serum IL-10 levels at day 7 after aSAH 
showed significant elevation of serum IL-10 levels as was obvious on day 1, while there was 
no significant difference between day 1 and day 7 serum IL-10 levels in aSAH patients (Fig. 
24). 
The dichotomization of the data into two groups for the analysis of aSAH patients with a 
specific character and without that character was carried out as described above for other 
cytokines and revealed some interesting differences in serum IL-10 levels. There was no 
significant difference in serum IL-10 levels based on gender, aneurysm location, or treatment 
modality based dichotomy (data not shown). Serum IL-10 levels were non-significantly 
elevated in poor grade aSAH (H&H III-V) patients at both days compared to less severe 
grade aSAH (H&H I-II), (Fig. 25B). Serum IL-10 levels were non-significantly elevated at 
day 1 in patients older than 55 years of age and reached to a significant difference at day 7 
compared to their younger counterparts (Fig. 25A). Patients presenting with additional 
intraventricular hemorrhage (IVH) showed significantly elevated serum IL-10 levels at day 7 
(Fig. 25C). Presence of intracerebral bleeding alone did not lead to significant elevation of 
serum IL-10 levels unless accompanied by IVH simultaneously (Fig. 25D).  
4.2.4.1. Serum IL-10 in post-aSAH complications 
Dichotomy of the patients presenting with different aSAH associated complications and those 
without these complications revealed some intriguing findings. Aneurysmal SAH patients 
who developed delayed ischemic neurological deficits (DIND) did not show any significant 
difference in serum IL-10 levels and same was true for patients experiencing seizures 
although serum IL-10 levels tend to be higher at both days in patients with seizures (data not 
shown). However, patients who developed cerebral vasospasm (CVS) and shunt-dependent 
chronic hydrocephalus showed significant elevation in serum IL-10 levels at day 7 post-
aSAH respectively (Fig. 25E, F). There was no significant difference among the patients who 
developed cerebral ischemia/infarction (CI) compared to those who did not. Although levels 
of IL-10 did not differ significantly, however, serum IL-10 levels tended to be higher in 
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patients with delayed cerebral ischemia (DCI) compared to no CI or interventional CI (Fig. 
26E, F). Serum IL-10 levels were significantly increased at day 7 in aSAH patients who 
contracted different infections (Fig. 26A). Further exploration based on the type of contracted 
infections showed that serum IL-10 levels were significantly raised at day 7 in patients who 
developed pneumonia and other infections compared to no infections, respectively (Fig. 26B, 
C). Comparison among different infections only showed significantly elevated serum IL-10 
levels at day 1 after pneumonia compared to meningitis (Fig. 26D).  
4.2.4.2. Serum IL-10 and post-aSAH clinical outcome 
The most interesting finding was the existence of difference in serum IL-10 levels in patients 
achieving good clinical outcome and poor clinical outcome at discharge as assessed by 
Glasgow outcome scale and modified Rankin scale. Serum IL-10 levels measured on day 1 
and day 7 were significantly higher in aSAH patients with poor outcome (GOS 1-3) as 
compared to good clinical outcome (GOS 4-5) as assessed by GOS (Fig. 27A). Assessment of 
clinical outcome by mRS also revealed similar results with higher serum IL-10 levels at both 
days in patients with poor clinical outcome (mRS 3-6) compared to those ones with good 
outcome (mRS 0-2) (Fig. 27B). 
 
 
 
Results 
93 
 
Table 9. Characters of aSAH patients whose serum IL-10 levels were determined 
Number of aSAH patients 76 
Age (years) (mean±SD) 59.14 (±11.93)  
Females (%) 60.53% 
Treatment modality 
Neurosurgical clipping (%) 
Endovascular coiling (%) 
 
48.7% 
51.3% 
Intraventricular hemorrhage: IVH (%) 13.2% 
Intracerebral bleeding: ICB (%) 18.4% 
ICB and IVH (%) 14.5% 
Hunt and Hess grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
3 
7.9% 
31.6% 
28.9% 
15.8% 
15.8% 
Fischer grade (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
3 
1.3% 
2.6% 
82.9% 
13.2% 
CVS (%) 57.9% 
Cerebral Ischemia (%) 
Intervention related CI (%) 
DCI (%) 
43.4% 
22.4% 
21.1% 
Seizures (%) 28.9% 
VP-Shunt dependent hydrocephalus (%) 30.3% 
Infections (%) 
Pneumonia (%) 
Meningitis (%) 
Others (Pneumonia, Meningitis in combination with 
UTI, or Osteomyelitis, wound infection) (%) 
35.5% 
19.7% 
7.9% 
7.9% 
 
DIND (%) 34.2% 
Aneurysm location 
Anterior circulation (%) 
Posterior circulation (%) 
 
85.5% 
14.5% 
GOS (median) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
4 
7.9% 
11.8% 
27.6% 
7.9% 
44.7% 
mRS (median) 
0 (%) 
1 (%) 
2 (%) 
3 (%) 
4 (%) 
5 (%) 
6 (%) 
3 
2.6% 
34.2% 
9.2% 
9.2% 
19.7% 
17.1% 
7.9% 
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Figure 24: Serum IL-10 levels in control patients (n = 24) and aSAH patients (n = 76) at day 
1 and day 7. Mann-Whitney U test; p value = 0.011 at day 1 and 0.037 at day 7. SAH D1= 
Aneurysmal Subarachnoid hemorrhage at day one, SAH D7= Aneurysmal Subarachnoid 
hemorrhage at day seven. 
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Figure 25: A. Comparison of serum IL-10 levels in aSAH patients with: age <55 years (n = 
29) and ≥ 55 years (n = 47); B. less severe aSAH (H&H I-II, n = 30) and severe aSAH (H&H 
III-V, n = 46); C. no intracerebral bleeding and intraventricular hemorrhage (No ICB+IVH, n 
= 41) vs. IVH (n = 10); D. no ICB+IVH (n = 41) vs. ICB+IVH (n = 11); E. no CVS (n = 32) 
and CVS (n = 44); F. no VP-Shunt dependent chronic hydrocephalus (n = 53) and VP-Shunt 
dependent chronic hydrocephalus (n = 23). Mann Whitney U test; p value < 0.05 was 
considered as a significant difference. 
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Figure 26: A. Comparison of serum IL-10 levels in aSAH patients with: no infections (n = 
49) and infections (n = 27); B. no infections (n = 49) and pneumonia (n = 15); C. no 
infections (n = 49) and others (n = 6); D. pneumonia (n = 15) and meningitis (n = 6); E. no CI 
(n = 43) and DCI (n = 16); F. interventional CI (n = 17) and DCI (n = 16). Mann Whitney U 
test; p value < 0.05 was considered as a significant difference. 
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Figure 27: A. Comparison of serum IL-10 levels in aSAH patients with: good clinical 
outcome (GOS 4-5, n = 40) vs. poor outcome (GOS 1-3, n = 36) as assessed by GOS; B. 
good clinical outcome (mRS 0-2, n = 35) vs. poor outcome (mRS 3-6, n = 41) as assessed by 
mRS. Mann Whitney U test; p value < 0.05 was considered as a significant difference. 
Results 
98 
 
4.3. Chemokine response after aSAH 
4.3.1. Serum CCL5 (RANTES)  
Serum CCL5 levels were quantified in aSAH patients at day 1 and day 7 and were compared 
to a control group of spinal stenosis patients undergoing diagnostic myelography. Serum 
CCL5 levels were significantly increased early after aSAH on day 1 compared to controls 
(Fig. 28). Similarly on day 7 after aSAH, serum CCL5 levels were still significantly high 
compared to the controls (Fig. 28). The median CCL5 levels at day 7 appeared to be slightly 
higher than day 1 in aSAH patients, nevertheless did not reach significant difference (Fig. 
28). 
Further subgrouping for detailed analysis of serum CCL5 in different aSAH patient 
associated characters was carried out. Serum CCL5 levels did not show any significant 
difference in aSAH patients based on gender, age, aneurysm location, aneurysm treatment 
modality or the severity of aSAH as assessed by H&H grades (data not shown). However, 
serum CCL5 levels tended to be lower in aSAH patients with age ≥ 55 years (Fig. 29A). 
Serum CCL5 levels were significantly decreased at day 7 in patients with intracerebral 
bleeding (ICB) compared to those without any additional bleed except aSAH (Fig. 29B). 
4.3.2. Serum CCL5 and post-aSAH complications 
Similar analysis for aSAH associated complications was performed. There was no significant 
impact of the development of CVS, DIND or seizures on serum CCL5 levels (data not 
shown). However, serum CCL5 levels were significantly lower in aSAH patients who 
developed chronic hydrocephalus and required the placement of ventriculoperitoneal shunt as 
compared to who did not develop this complication (Fig. 29C). Serum CCL5 levels at both 
day 1 and day 7 tended to be lower in aSAH patients who contracted infections (data not 
shown), however, on further dichotomization, only serum CCL5 levels were shown to be 
significantly reduced at day 7 in patients contracting pneumonia compared to those without 
any infection (Fig. 29D). Similarly, there existed no significant difference in aSAH patients 
who developed cerebral ischemia and further dissection into intervention related cerebral 
ischemia or DCI also revealed no any significant difference (data not shown). 
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4.3.3. Serum CCL5 and post-aSAH clinical outcome 
Serum CCL5 levels were analyzed in aSAH patients with dichotomy into good and poor 
clinical outcome at discharge as assessed by both GOS and mRS. Interestingly, serum CCL5 
levels were non-significantly higher at day 1 in patients with good clinical outcome (GOS 4-
5) and further, on day 7 they were significantly higher compared to poor clinical outcome 
(GOS 1-3) patients as assessed by GOS on discharge (Fig. 29E). Assessment of clinical 
outcome by mRS reflected the same trend as observed with GOS, i.e., non-significantly 
higher serum CCL5 levels at day1 and significantly higher serum CCL5 levels on day 7 (Fig. 
29F). 
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Figure 28: Comparison of serum RANTES/CCL5 levels among controls (n = 24) and aSAH 
patients (n = 80). Mann Whitney U test; p value = 0.004 at post SAH day 1 and p = 0.003 at 
post SAH day 7.  
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Figure 29: A. Comparison of serum RANTES (CCL5) levels in aSAH patients with: <55 
years of age (n = 31) and ≥55 years of age (n = 49); B. only intracerebral bleeding (ICB; n = 
15) compared to patients without intracerebral and intraventricular hemorrhage (No 
IVH+ICB; n = 43); C. no chronic hydrocephalus (n = 55) and with chronic hydrocephalus (n 
= 25) requiring VP-Shunt placement; D. no infections (n = 51) and Pneumonia (n = 15); E. 
good clinical outcome GOS 4-5 (n = 40) and with poor clinical outcome GOS 1-3 (n = 40) as 
assessed by Glasgow Outcome Scale; F. good clinical outcome (mRS 0-2; n = 36) and with 
poor clinical outcome (mRS 3-6; n = 44) as assessed by modified Rankin scale. Mann 
Whitney U test; p value <0.05 was considered as a significant difference. 
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4.4. Cellular immune response after aSAH 
The elevated levels of DAMPs (HMGB1, mtDNA) and different cytokines may involve the 
activation and polarization of immune cells. Therefore, we have characterized the different 
subsets of peripheral blood monocytes and CD4+ T helper cells during first 72 hours 
(hereafter represented as day 1) covering the time course of early brain injury and at day 7 
during the phase of delayed brain injury by polychromatic cell surface based flow cytometric 
immunophenotyping. 
4.4.1. Monocyte response after aSAH 
Monocytes were identified based on their intermediate side scatter (SSC) and CD45 
expression, and expressed as percentage of CD45+ leucocytes and were non-significantly 
higher at day 1 and at day 7 in aSAH patients in comparison to healthy controls. Interestingly, 
monocyte number was significantly increased at day 7 as compared to day 1 in aSAH patients 
(Fig. 30A). However, monocytes recognized as CD14+ CD15- cells when expressed as 
frequency of CD45+ leucocytes showed a non-significant increasing trend after aSAH as 
compared to healthy controls (Fig. 30B). Monocytes can be categorized into three subsets 
based on differential expression of CD14 and CD16 into classical (CD14++ CD16-), 
intermediate (CD14+ CD16+), and nonclassical (CD14-CD16++). There was no significant 
difference in classical monocytes among healthy controls and aSAH patients at both times of 
assessment (Fig. 30C). There was no significant difference in intermediate monocytes among 
controls and aSAH patients at day 1. Interestingly, a significant decrease in the frequency of 
intermediate monocytes was observed at day 7 as compared to day 1 in aSAH patients (Fig. 
30D). Intriguingly, nonclassical monocytes were significantly lower at day 1 in aSAH 
patients compared to healthy controls, but this significance did not persist at day 7 due to 
slight increase in nonclassical monocytes (Fig. 30E). 
Additionally, we have assessed the chemokine markers such as CX3CR1, CCR2, and 
activation and maturation marker HLA-DR on these subsets of monocytes. The CX3CR1+ 
classical monocytes remained unaltered among controls and aSAH patients (Fig. 31A). The 
frequency of intermediate CX3CR1+ monocytes was non-significantly higher at day 1 and 
then, non-significantly reduced at day 7 in aSAH patients compared to healthy controls. 
Interestingly, a significant reduction in intermediate CX3CR1+ monocytes was seen on day 7 
after initial rise at day 1 in aSAH patients (Fig. 31B). The proportion of nonclassical 
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CX3CR1+ monocytes was reduced significantly at day 1 and non-significantly at day 7 in 
aSAH patients as compared to controls (Fig. 31C). It was interesting to note that the classical 
CCR2+ monocytes were significantly increased early after aSAH compared to healthy 
controls, but later on at day 7, no significant difference persisted (Fig. 31D). The frequency 
of intermediate CCR2+ monocytes was significantly increased early at day 1 as compared to 
day 7 in aSAH patients (Fig. 31E) and no significant difference was observed in nonclassical 
CCR2+ monocytes among controls and aSAH patients (Fig. 31 F). It was noteworthy to 
observe that the classical HLA-DR+ monocytes were significantly reduced at day 1 and day 7 
in aSAH patients in comparison with healthy controls (Fig. 31G). However, a significant 
decrease in intermediate HLA-DR+ monocytes occurred at day 7 compared to day 1 in only 
aSAH patients (Fig. 31H). Finally, HLA-DR+ nonclassical monocytes were significantly 
reduced at day 1 after aSAH and at day 7 an upsurge resulted in a non-significant difference 
compared to healthy volunteers (Fig. 31I). 
4.4.2. CD4+ T cell response after aSAH 
Lymphocytes in the peripheral blood of aSAH patients and healthy controls were identified 
by their low SSC and high CD45 expression and were expressed as percentage of CD45+ 
leucocytes. A lymphopenic response was observed in aSAH patients at both days of 
assessment compared to healthy controls (Fig. 32A). The same was reflected for CD4+ T 
cells when expressed as percentage of CD45+ leucocytes (Fig. 32B). However, a significant 
increase in CD4+ T cells was observed at day 1 and day 7 after aSAH compared to healthy 
controls when expressed as frequency of lymphocytes (Fig. 32C). Further, we investigated 
Tregs (CD25
hi
 CD127
lo
) and different subsets of CD4+ T cells (Th1, Th2 and Th17) based on 
differential surface expression of chemokine receptors CXCR3 and CCR6 as described by 
Maecker et al., (2012). 
Th1 (CXCR3+ CCR6-) cells were non-significantly reduced at day 1 after aSAH compared to 
healthy controls and were non-significantly higher at day 7 compared to day 1 in aSAH 
patients (Fig. 33A). There was no significant difference among healthy controls and aSAH 
patients in Th2 (CXCR3- CCR6-) cells response, however, Th2 cells were significantly 
decreased at day 7 in comparison to day 1 after aSAH (Fig. 33B). Interestingly, no significant 
difference was present in Th17 (CXCR3- CCR6+) cells among healthy controls and aSAH 
patients, but a significant increase in Th17 cells was observed at day 7 compared to day 1 in 
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aSAH patients (Fig. 33C). The most striking finding was the increase in Treg cells at both 
days of assessment in aSAH patients as opposed to healthy volunteers and Treg cells were 
even significantly higher at day 7 compared to day 1 in aSAH patients (Fig. 33D). 
Like monocytes, we have investigated the activation markers HLA-DR and CD38 on these 
different CD4+ T cell subsets. Among Th1 cells, only HLA-DR- CD38+ Th1 cells were 
significantly reduced at day 1 after aSAH compared to healthy controls, but at day 7 no 
significant difference was observed (Fig. 34A). Similarly, HLA-DR- CD38+ Th2 cells were 
also reduced significantly at day 1 after aSAH compared to healthy controls (Fig. 34C). 
Interestingly, HLA-DR- CD38- Th2 cells were significantly increased at day 1 after aSAH 
compared to healthy controls and this was followed by a significant decrease at day 7 
compared to day 1 (Fig. 34B). The frequency of HLA-DR+ CD38- Th2 cells was also 
significantly reduced at day 7 compared to day 1 in only aSAH patients (Fig. 34D). A 
significant increase in HLA-DR- CD38+ Th17 cells was revealed on day 7 compared to day 1 
in aSAH patients (Fig. 34E). Analysis of CD38 and HLA-DR activation markers on Treg 
cells also revealed some interesting significant differences. The HLA-DR- CD38- subset of 
Treg cells was significantly outnumbered at day 1 and day 7 after aSAH compared to healthy 
controls (Fig. 34F). Similarly, Treg cells showing the simultaneous expression of CD38 and 
HLA-DR were also significantly increased at day 1 and day 7 after aSAH compared to 
healthy controls (Fig. 34I). Treg cells expressing only HLA-DR (HLA-DR+ CD38-) were 
significantly raised at day 1 after aSAH compared to healthy controls, but at day 7 decrease 
in their number led to a non-significant difference (Fig. 34H). Finally, HLA-DR- CD38+ 
Treg cells were significantly increased after aSAH at both days compared to healthy controls 
and there existed a significant increase also at day 7 compared to day 1 in aSAH patients 
(Fig. G). 
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Figure 30: A. Comparison of peripheral blood monocytes (intermediate SSC and CD45 
expressing cells) expressed as percentage of CD45+ leucocytes after aSAH with healthy 
controls; B. Comparison of peripheral blood monocytes (CD14+ CD15- cells) expressed as 
percentage of CD45+ leucocytes after aSAH with healthy controls. C. Comparison of: 
classical (CD14++ CD16-) monocytes expressed as percentage of CD14+ CD15- monocytes 
after aSAH with healthy controls; D. intermediate (CD14+ CD16+) monocytes expressed as 
percentage of CD14+ CD15- monocytes after aSAH with healthy controls; E. nonclassical 
(CD14- CD16++) monocytes expressed as percentage of CD14+ CD15- monocytes after 
aSAH with healthy controls (n = 10). Unpaired t test for comparison among healthy controls 
and aSAH patients, paired t test for comparison at day 1 and day 7 in aSAH patients; p value 
<0.05 was considered as a significant difference. HC = Healthy controls (n = 10), SAH = 
aSAH (n = 15), D1 = day 1 post-aSAH; D7 = day 7 post-aSAH. 
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Figure 31: A. Comparison of peripheral blood CX3CR1+: classical monocytes after aSAH 
with healthy controls; B. intermediate monocytes after aSAH with healthy controls; C. 
nonclassical monocytes after aSAH with healthy controls. D. Comparison of peripheral blood 
CCR2+: classical monocytes after aSAH with healthy controls; E. intermediate monocytes 
after aSAH with healthy controls; F. nonclassical monocytes after aSAH with healthy 
controls. G. Comparison of peripheral blood HLA-DR+: classical monocytes after aSAH 
with healthy controls; H. intermediate monocytes after aSAH with healthy controls; I. 
nonclassical monocytes after aSAH with healthy controls. Unpaired t test or Mann Whitney 
U test for comparison among healthy controls and aSAH patients, paired t test or Wilcoxon 
signed rank test for comparison at day 1 and day 7 in aSAH patients; p value <0.05 was 
considered as a significant difference. HC = Healthy controls (n = 10), SAH = aSAH (n = 
15), D1 = day 1 post-aSAH; D7 = day 7 post-aSAH. 
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Figure 32: A. Comparison of peripheral blood: lymphocytes (low SSC and high CD45 
expressing cells) after aSAH with healthy controls; B. CD4+ T cells after aSAH with healthy 
controls; C. CD4+ T cells expressed as percentage of lymphocytes after aSAH with healthy 
controls. Unpaired t test for comparison among healthy controls and aSAH patients, paired t 
test for comparison at day 1 and day 7 in aSAH patients; p value <0.05 was considered as a 
significant difference. HC = Healthy controls (n = 10), SAH = aSAH (n = 15), D1 = day 1 
post-aSAH; D7 = day 7 post-aSAH. 
 
Figure 33: A. Comparison of peripheral blood CD3+ CD4+ T cell subset: Th1 (CXCR3+ 
CCR6-) cells after aSAH with healthy controls; B. Th2 (CXCR3- CCR6-) cells after aSAH 
with healthy controls; C. Th17 (CXCR3- CCR6+) cells after aSAH with healthy controls. D. 
Treg (CD25
hi 
CD127
lo
) cells after aSAH with healthy controls. Unpaired t test for comparison 
among healthy controls and aSAH patients, paired t test for comparison at day 1 and day 7 in 
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aSAH patients; p value <0.05 was considered as a significant difference. HC = Healthy 
controls (n = 10), SAH = aSAH (n = 15), D1 = day 1 post-aSAH; D7 = day 7 post-aSAH. All 
subsets were expressed as percentage of CD4+ T cells. 
 
Figure 34: A. Comparison of peripheral blood: Th1 HLA-DR- CD38+ cells after aSAH with 
healthy controls; B. Th2 HLA-DR- CD38- cells after aSAH with healthy controls; C. Th2 
HLA-DR- CD38+ cells after aSAH with healthy controls; D. Th2 HLA-DR+ CD38- cells 
after aSAH with healthy controls; E. Th17 HLA-DR- CD38+ cells after aSAH with healthy 
controls; F. Tregs HLA-DR- CD38- cells after aSAH with healthy controls; G. Tregs HLA-
DR- CD38+ cells after aSAH with healthy controls; H. Tregs HLA-DR+ CD38- cells after 
aSAH with healthy controls; I. Tregs HLA-DR+ CD38+ cells after aSAH with healthy 
controls. Unpaired t test or Mann Whitney U test for comparison among healthy controls and 
aSAH patients, paired t test or Wilcoxon signed rank test for comparison at day 1 and day 7 
in aSAH patients; p value <0.05 was considered as a significant difference. HC = Healthy 
controls (n = 10), SAH = aSAH (n = 15), D1 = day 1 post-aSAH; D7 = day 7 post-aSAH. All 
subsets were expressed as percentage of CD4+ T cells. 
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4.5. Modulation of systemic inflammation with spinal cord stimulation 
In another study, we determined the effects of burst spinal cord stimulation (Burst SCS) on 
modulation of systemic cytokines in Failed Back Surgery Syndrome (FBSS) patients. 
Interestingly, Burst SCS increased systemic circulating anti-inflammatory IL-10, in addition 
to improvements in FBSS back pain and back pain associated co-morbidities like disrupted 
sleep architecture and depressive symptoms in FBSS patients. Thus, suggesting a possible 
relationship between burst SCS and burst-evoked modulation of peripheral anti-inflammatory 
cytokine IL-10 in chronic back pain (Fig. 35A).  
Potential associations among refractory chronic lower back pain and metabolic disorders such 
as obesity, diabetes, hypertension and metabolic syndrome have been sought and these 
metabolic disorders are characterized by a low grade systemic inflammation (Muhammad et 
al., 2017). Further investigations for obesity and metabolic disorder related 
adipokines/cytokines such as adiponectin, ghrelin and leptin were also carried out in FBSS 
patients. Non-significant lower levels of Ghrelin were found in pre-SCS compared to healthy 
controls, which were slightly increased after 3 months of Burst SCS comparable to that of 
controls, but non-significantly (Fig. 35B). Systemically elevated leptin levels have been 
implicated in low grade chronic inflammation (Iikuni et al., 2008). Interestingly, leptin levels 
were significantly high in pre-SCS compared to controls and even after post-SCS, but it was 
interesting to note that the Burst SCS led to non-significantly decrease leptin levels compared 
to pre-SCS (Fig. 35C). These pieces of evidence suggest that spinal cord stimulation may be 
used as a potential therapeutic intervention to modulate the systemic inflammatory response 
after aSAH. A recent study sought the feasibility to manage CVS in aSAH patients after 
cervical spinal cord stimulation (Slavin et al., 2011). 
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Figure 35: A. Anti-inflammatory cytokine IL-10 serum levels in FBSS patients (n = 12) at 
baseline, after three months of Burst spinal cord stimulation (SCS) and in healthy controls (n 
= 10). B. Anti-obesity ghrelin serum levels in FBSS (n = 12) patients at baseline, after three 
months of Burst spinal cord stimulation (SCS) and in healthy controls (n = 10). C. Pro-
obesity adipokine serum levels in FBSS patients (n = 12) at baseline, after three months of 
Burst spinal cord stimulation (SCS) and in healthy controls (n = 10). Unpaired t test or Mann 
Whitney U test for comparison among healthy controls and aSAH patients, paired t test or 
Wilcoxon signed rank test for comparison at day 1 and day 7 in aSAH patients; p value <0.05 
was considered as a significant difference. 
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5. Discussion 
Aneurysmal subarachnoid hemorrhage, a morbid and lethal subtype of hemorrhagic stroke, is 
characterized by an intracranial bleed into subarachnoid space due to rupture of an 
intracranial aneurysm usually located at bifurcation of cerebral arteries (Suarez  et al., 2006; 
Macdonald, 2014). The consequent transient global cerebral ischemia and extravasated blood 
toxicity leads to early brain injury that comprise all the events occurring within 72 hours of 
aSAH (Cahill and Zhang, 2009; Munoz-Guillen et al., 2013). Since the bleeding aneurysm 
can be obliterated from circulation by microsurgical clipping or endovascular coiling, but 
majority of the aSAH patients experience a delayed deterioration phase after surviving the 
initial ictus (Macdonald, 2014). This delayed deterioration is the result of post-aSAH 
complications such as cerebral vasospasm (CVS), hydrocephalus, rebleeding from the 
ruptured aneurysm, seizures, cortical spreading depression (CSD), and most importantly 
delayed cerebral ischemia (DCI) (Suarez  et al., 2006; Iadecola, 2009; Macdonald, 2014). The 
failure of the past aSAH research focused solely on the reversal of CVS (a major contributor 
to DCI) to improve clinical outcome, led to explore additional mechanisms of brain injury. In 
the recent decade, there is renewed interest in the role of inflammation both at CNS and 
systemic levels after aSAH. A great body of evidence suggests that aSAH is characterized by 
a systemic inflammatory response (Yoshimoto et al., 2001; Smithason et al., 2012; McMahon 
et al., 2013; Chaudhry et al., 2017; Da Silva et al., 2017; Savarraj et al., 2017a; Savarraj et al., 
2017b). 
Inflammation is the consequence of recognition of danger signal molecules or alarmins by the 
pattern recognition receptors (PRRs) on the immune cells. Such danger signal molecules are 
referred to as damage associated molecular patterns (DAMPs) or pathogen associated 
molecular patterns (PAMPs) depending on whether they are derived from stressed, injured 
and necrotic cells or from invading pathogens, respectively (Chen and Nuñez, 2010; 
Takeuchi and Akira, 2010). Here, we have investigated two prototypical DAMPs molecules 
(HMGB1 as a prototype for DAMP proteins and mtDNA, a classical DAMP from nucleic 
acid family) to identify possible associations with post-aSAH complications and clinical 
outcome at discharge. 
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5.1. DAMPs 
5.1.1. High mobility group box 1 (HMGB1) 
 We have showed elevated serum concentrations of the danger signal molecule HMGB1 over 
the two weeks following aSAH in humans. Importantly, our analysis covered the peak 
interval of CVS development. Our findings show that the nuclear protein HMGB1 was 
detectable early after aSAH and remained high over the peak time period of CVS when 
compared to non-SAH controls (Fig. 2). Interestingly, HMGB1 levels in patients who 
developed CVS were significantly higher than those found in aSAH patients without CVS 
(Fig. 4F). HMGB1 was already higher on day 1 (Fig. 4F) and the divergence between the 
CVS and the non-CVS group started very early on day 1, peaked over days 5, 7, 9, 11 and 
was still higher at day 13 covering the peak time of the development of CVS (Fig. 4F). 
Interleukin-6 has been intensively investigated in aSAH and it is known to be a prognostic 
marker for clinical outcome after aSAH (Muroi et al., 2013; Helbok et al., 2015; Hollig et al., 
2015b). We quantified plasma IL-6 concentrations in the serum of our patients on day 1 until 
day 13. Interestingly, serum HMGB1 concentrations showed a significant correlation with 
serum IL-6 concentrations (Fig. 7C). Although a recent report demonstrated serum HMGB1 
increase on admission that correlated with clinical outcome after one year (Zhu et al., 2012b), 
our data over the two weeks did not show any correlation with clinical outcome at discharge 
from hospital (Fig. 6C, D, 7A, B).  
HMGB1 is a non-histone DNA binding protein that can be released either during cell death 
by damaged cells or actively by immune cells. Cell death occurs as early as 10 minutes after 
SAH favouring the possibility of passive release of HMGB1 (Friedrich et al., 2012; Sun et 
al., 2014b). However, there is also an active early release of HMGB1 during brain injury after 
SAH (Sun et al., 2014b). Both, the actively and the passively released HMGB1 have the 
potential of cytokine-like activity to trigger inflammation (Scaffidi et al., 2002). HMGB1 has 
been shown to be a late mediator of inflammation in sepsis and an early mediator of 
inflammatory response in cerebral ischemia (Wang et al., 1999; Qiu et al., 2008). It has been 
previously shown that HMGB1 leads to ischemic brain damage via activation and recruitment 
of peripheral macrophages (Muhammad et al., 2008) by binding to the receptor for advanced 
glycation end products (RAGE). A recent report showed that CSF of patients exhibited 
increased HGMB1 levels after SAH and that HMGB1 concentration in CSF correlated with 
unfavorable outcome (Nakahara et al., 2009; King et al., 2010). Increased blood brain barrier 
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permeability after brain injury allows the passively released HMGB1 to enter the systemic 
circulation (Muhammad et al., 2008), where it can induce an inflammatory response by 
binding to its receptors, including TLR4, TLR2 and RAGE. Our results suggest that early 
serum HMGB1 elevation could be due to its active release by peripheral bone marrow-
derived cells (Fig. 7D) or it is being passively released from cells that were damaged during 
early brain injury. This is in agreement with experimental studies which confirmed early 
passively released HMGB1 from neurons after SAH (Sun et al., 2014b). Receptors of 
HMGB1 are expressed in a variety of cells, including monocytes and endothelial cells. 
Recently, experimental studies showed expression of HMGB1 and its receptors TLR4 and 
RAGE in brain tissue following SAH in animal models (Murakami et al., 2011; Li et al., 
2013b; Sun et al., 2014b). The interaction between HMGB1 and its receptors leads to 
activation of nuclear factor kappa B (NF-κB) and expression of various pro-inflammatory 
genes, including IL-1β, TNFα and IL-6. In circulating monocytes/ macrophages, HMGB1 can 
induce its own synthesis in an active manner and enhance synthesis of other pro-
inflammatory cytokines, including IL-6, IL-1β and TNF-α (Andersson et al., 2000; Agnello et 
al., 2002; Harris et al., 2012). We found elevated IL-6 in serum after aSAH (Fig. 19). 
Moreover, serum IL-6 levels showed a significant correlation with serum HMGB1 levels 
after aSAH (Fig. 7C). However, TNF-α can induce HMGB1 production (Rendon-Mitchell et 
al., 2003) suggesting the possibility of a vicious cycle of pro-inflammatory response.  
Although it is difficult to investigate whether HMGB1 release precedes the increase of other 
cytokines in humans, it has, nevertheless, been proven in experimental settings (Sun et al., 
2014b). Pro-inflammatory cytokines are damaging for neurovascular units, e.g. IL-1β and 
TNF-α induce apoptosis of endothelial cells (Kimura et al., 2003), whereas IL-6 can induce 
vasospasm in the cerebral artery (Hendryk et al., 2004). Interestingly, HMGB1 serum 
concentrations showed a significant correlation with serum IL-6 levels indicating the 
possibility of a pleiotropic effect of both molecules. The influence of systemic inflammatory 
cytokines suggests their importance in causing endothelial dysfunction, which, in turn, may 
contribute to development of CVS. Receptors of HMGB1, including TLRs and RAGE, are 
widely expressed on endothelial cells and are readily available for interaction with circulating 
HMGB1 (Li et al., 2013a; Shang et al., 2016). Pharmacological strategies blocking HMGB1 
release revealed neuroprotection and attenuated CVS in an animal model of SAH (Chang et 
al., 2014; Sun et al., 2014a). CVS has been reported in around 70% of patients and it is the 
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main cause of delayed neurological decline (Carr et al., 2013). Systemic HMGB1 levels and 
their association with CVS may be of significant importance in the screening of patients at 
risk of CVS. The presented results clearly demonstrate the association of serum HMGB1 with 
CVS by showing that patients, who developed CVS, exhibited significantly higher HMGB1 
levels than non-CVS patients (Fig. 4F) during the peak time of CVS development. Serum 
HMGB1 levels on day1 with a cut off value of 4.8 ng/ ml could predict CVS with a 
specificity of 72% and a sensitivity of 55% (Fig. 8A). Comparison of patients who were 
neurosurgically operated with patients treated with endovascular coiling did not find any 
difference of HMGB1, excluding the effect of craniotomy on HMGB1 release. Similarly, 
aneurysm localization and infection did not alter the HMGB1 significantly. The presented 
data demonstrate that HMGB1 might be involved directly or indirectly (via induction of other 
cytokines such as IL-6) in the pathophysiology of CVS. Sterile inflammation is a complex 
process, that is why single molecule targeted therapeutic options have not shown much 
success to date. It is important to find the source of molecular inflammation and identify its 
driving molecules. HMGB1 could be an early mediator and one of the driving molecules of 
post-aSAH inflammation giving rise to post-aSAH complications and delayed deterioration. 
In conclusion, serum HMGB1 is differentially elevated after aSAH. Serum HMGB1 levels 
were elevated early after aSAH (day 1) and remained significantly high until day 13 in 
patients who developed CVS. 
5.1.2. Mitochondrial DNA (mtDNA) 
An array of different DAMPs molecules originating from different compartments of the cell 
undergoing stress, injury or necrosis have been discovered (Schaefer, 2014). Over the past, 
mitochondria have gained value as a potential host of different DAMPs. A great body of 
evidence supports the role of mtDNA as a DAMP mediating inflammation via different PRRs 
such as TLR-9, NLRP3-, NLRC4-, AIM2-inflammasome complex and cGAS-STING 
(Boyapati et al., 2017; West and Shadel, 2017). Hence, we aimed to investigate the temporal 
profile of systemic release of mtDNA after aSAH and assess its association with post-aSAH 
complications and clinical outcome. 
The systemic levels of mtDNA were elevated in aSAH patients compared to healthy controls. 
Interestingly, mtDNA for D-Loop and COX-1 were significantly higher from day 1 until day 
13 in aSAH patients, however, mt CytB levels were significantly elevated later on at day 7 
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(Fig. 9). This suggests that different mtDNA gene fragments are differentially released into 
systemic circulation after aSAH. Interestingly, all of investigated mtDNA gene fragments 
showed a secondary delayed increase with a peak at day 9, which coincides with the delayed 
deterioration phase. Our results are in agreement with the findings of Wang and coauthors 
who observed elevated mitochondrial ND2 levels in a small group of aSAH patients (Wang et 
al., 2013).  
Further subgroup analysis was based on dichotomization of aSAH patients into two groups 
for different base line characters, development of different complications and clinical 
outcome. Interestingly, serum mtDNA levels of CytB and D-Loop were differently regulated 
in male and female aSAH patients (Fig. 10A, 11A and Table 4, 5). CytB and COX-1 mtDNA 
levels were sensitive to intracerebral bleeding in addition to primary subarachnoid bleed, but 
they were no more significant beyond the first day. There was no significant impact of 
infections on mtDNA levels. However, further subgrouping based on the type of infections 
revealed that mtDNA levels followed different trends and a significantly lower mt CytB and 
mt D-Loop levels were observed only at day 9 in patients with pneumonia infection, which is 
in contrast to the mtDNA levels in aSAH group. Another interesting trend was seen in CytB 
and COX-1 mtDNA levels where mtDNA levels were downregulated in patients who 
developed interventional CI as opposed to patients developing DCI or no CI. Whether this 
difference has some implications from immune paralysis may require further thorough 
investigations as immune depression is observed after aSAH and it is also known that 
mtDNA leads to immunosuppression via TLR-9 dependent mechanisms in cytotoxic T cells 
and deletion of cross presenting dendritic cells (Sarrafzadeh et al., 2011; Schafer et al., 2016). 
The aSAH patients experiencing seizures tended to have lower levels of both mt D-Loop and 
mt COX-1 levels, whereas in chronic hydrocephalus only mt D-Loop levels were 
downregulated. Another interesting difference, although significant at day 9, was seen in mt 
D-Loop levels where patients with poor clinical outcome (mRS 3-6) tended to have lower mt 
D-Loop levels compared to those with good outcome (mRS 0-2). However, this was in 
contrast to the findings of Wang et al., (2013) who found significant elevation of mtDNA at 
day 8 in poor outcome patients, but this difference does not exist anymore after controlling 
for the aneurysm treatment effects (Wang et al., 2013). Furthermore, the study of Wang et al. 
(2013) was comprised of a small population of patients (n = 21) with more patients in the 
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poor outcome group (n = 15), which might be the reason for divergence from the current 
findings.  
The increasing levels of mtDNA in peripheral circulation may likely involve mtDNA release 
from necrotic cells or probably the impairment of the DNA clearance mechanisms owing to 
systemic inflammation mediated organ damage in critically ill patients (Tsai et al., 2011). 
Inflammation can lead to increased leucocyte counts (Neil-Dwyer and Cruickshank, 1974) 
and interestingly, mtDNA levels showed associations with leucocyte counts (Table 4). 
However, cumulative levels of CytB and D-Loop mtDNA were positively correlated with 
leucocyte count (Table 5), which is in agreement with previous findings (Tsai et al., 2011) 
and it suggests that mtDNA may probably lead to leukocytosis owing to its DAMP nature. A 
negative correlation was found at different days among mtDNA and CRP levels. It is already 
known that systemic DNA levels correlate with cerebral hematoma; however, we found a 
weak, but significant correlation among Fischer grade, cumulative mtDNA levels of CytB 
and COX-1 (Table 5) (Rainer et al., 2003). It was also noteworthy that the use of β-blockers 
and Ca2+ channel blockers was positively correlated with mtDNA levels and whether it was 
by chance or has some clinical significance may require further investigations. 
It has already been mentioned that mtDNA levels are upregulated after CNS insult and TLR-
9 is the major receptor mediating inflammatory effects of mtDNA (Boyapati et al., 2017). 
Therefore, TLR-9 represents an important target and different strategies based on 
oligodeoxynucleotides (ODN) aimed at antagonizing the inflammatory effects of TLR-9 
activation are under development through preclinical or early clinical studies (Hennessy et 
al., 2010; Hoque et al., 2013; Savva and Roger, 2013). Another approach based on molecular 
scavenging of the free nucleic acids by nuclear acid binding polymers has been shown to 
limit the inflammation in preclinical studies (Holl et al., 2013; Holl et al., 2016). Therefore, 
further dissection of the inflammation associated with mtDNA and TLR-9 axis in animal 
models of SAH is warranted to unveil the therapeutic potential of this axis. 
5.2. Systemic Cytokine response after aSAH 
Circulating cytokines load play critical role in determining the health status of the individuals 
(Oke and Tracey, 2009). Cytokines mediate the immune or inflammatory response after 
injury and are also known to possess neuroregulatory properties with potential implications in 
various CNS diseases (Osuka et al., 1998). As already mentioned, inflammation plays an 
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indispensable role in early brain injury and also in the development of complications over the 
course of aSAH (Provencio, 2013; Miller et al., 2014; Moraes et al., 2015; Lucke-Wold et al., 
2016). A great body of evidence supports the upregulation of different cytokines secreted by 
immune cells in aSAH (Fassbender et al., 2001; Takizawa et al., 2001; Hopkins et al., 2012). 
These inflammatory cytokines do not only exist in the CSF reflecting local response at the 
CNS level, rather are also increasingly documented in the systemic circulation and some of 
these cytokines have been associated with a late inflammatory response and poor outcome 
(Miller et al., 2014).  
5.2.1. IL-23 
IL-23 is a heterodimeric cytokine composed of p40 (shared with IL-12 p40) and p19 subunits 
and signals by binding to IL-23R and IL-12Rβ1 (Oppmann et al.; Parham et al., 2002). The 
p19 subunit of IL-23 shares structural homology with IL-6 and TNF-α (Oppmann et al., 
2000). IL-23, released by activated monocytes and dendritic cells, plays a distinct role in 
Th17 cell polarization and amplifying IL-17 response (Uhlig et al., 2006; Lyakh et al., 2008; 
Ghoreschi et al., 2010). Serum IL-23 has been shown to be elevated in numerous 
inflammatory diseases (Ciprandi et al., 2012; Wen et al., 2012; Atwa et al., 2014; Chen et al., 
2014; Du et al., 2014; Borovcanin et al., 2015; Fotiadou et al., 2015; Wendling et al., 2015). 
However, IL-23 has still not been investigated after aSAH in human subjects and to the best 
of our knowledge, this is the first study to investigate serum IL-23 levels in aSAH patients 
and find the association with post hemorrhagic complications and outcome. 
We observed an early elevation of serum IL-23 after aSAH that persisted till day 7 (Fig. 13). 
It suggests that systemic inflammatory response is upregulated after aSAH and may 
contribute to the early brain injury and furthermore, in the pathophysiology of post-aSAH 
complications (Miller et al., 2014). Hence, we further analyzed IL-23 levels in different 
subgroups of patients after aSAH. Interestingly, serum IL-23 levels were downregulated in 
poor H&H and Fischer grades lately (Fig. 14A, Table 7) and in patients who developed 
seizures and at both days in other infections group (Fig 14D, F, Table 7). This might be due 
to immunodepression observed after aSAH and impaired capacity of the PBMCs to release 
cytokines under enhanced sympathetic activity due to ANS dysfunction (Kinoshita et al., 
2007; Sarrafzadeh et al., 2011). Intracerebral bleeding, in addition to aSAH may present 
additional damage and is well known to be associated with poor outcome after aSAH, 
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therefore, may be leading to an early rise in serum IL-23 (Fig. 14B) (Rosengart et al., 2007). 
Endovascular coiling appeared to have less impact on IL-23 secretion as opposed to 
neurosurgical clipping (Fig. 14C, Table 7). Endovascular coiling is advocated to lead to better 
outcomes than neurosurgical clipping in small sized cohorts; and levels of CRP and S100B 
have been found to be higher postoperatively in aSAH patients undergoing neurosurgical 
clipping compared to endovascular coiling (Weiss et al., 2006; Jeon et al., 2012; Ayling et al., 
2015; Taheri et al., 2015). Increased levels of IL-1RA were observed in CSF after surgery of 
poor H&H grade aSAH patients reflecting the contribution of surgical trauma to the 
measured cytokines (Mathiesen et al., 1997). However, are there any other differences in 
inflammatory response or immunologic markers such as IL-23, still warrants further 
investigations? Although, we did not find any significant increase of IL-23 in patients with 
cerebral ischemia, however, intriguingly serum IL-23 levels significantly upregulated 
promptly after aSAH in DCI patients and non-significantly sustained at day 7 in comparison 
to patients developing interventional CI, where elevation may have resulted from the drastic 
effects of aneurysm treatment (Fig. 14E, Table 7). DCI is a multifactorial phenomenon after 
aSAH and is a well established contributor to unfavourable clinical outcomes (Kiiski et al., 
2017). However, serum IL-23 levels did not associate with the clinical outcome (Fig. 15). 
IL-23 has been proposed as a surrogate marker for multiple sclerosis disease activity (Chen et 
al.). In an experimental acute encephalomyelitis model, anti-IL-23 p19 antibody reduced the 
serum IL-17, expression of other pro-inflammatory cytokines and CNS infiltration of myeloid 
and T cells (Konoeda et al., 2010). In ischemic stroke models, serum IL-23 has been shown 
to contribute to an inflammatory response and abolishing this response conferred 
neuroprotection and improved neurobehavioural outcomes (Shichita et al., 2009; Gelderblom 
et al., 2014). IL-23 gene deletion in mice has been shown to confer remarkable recovery in 
the setting of ischemia (Shichita et al., 2009). Konoeda et al. (2010) used anti- IL-23 p40 
monoclonal antibody and JAK-kinase inhibitor to block the effects of IL-23 and its 
downstream signaling via JAK-STAT3 pathway respectively to demonstrate neuroprotection 
in ischemia/ reperfusion injury. At present, monoclonal antibodies targeting either IL-23 p40 
or IL-23 p19 in various inflammatory diseases are being investigated in different phases of 
clinical trials (Gaffen et al., 2014; Teng et al., 2015). Therefore, IL-23 and its downstream 
signaling pathways represent potential modulatable therapeutic targets to treat various 
inflammatory diseases. 
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Until now, IL-23 and its role in aSAH has not been investigated in detail. Our data, although 
descriptive in nature, however, provide novel information in human subjects to further 
evaluate the pathophysiological role of IL-23 after aSAH.  
5.2.2. IL-17 
IL-17 or IL-17A is a signature cytokine for Th17 cells which express transcription factor  
RORγt (retinoic acid receptor-related orphan receptor-γt) and require IL-23 for maturation to 
an inflammatory phenotype (Gaffen et al., 2014). In addition to Th17 cells, IL-17 is also 
secreted by other innate immune cells such as γδ T cells, NK T cells and innate lymphoid 
cells (Gaffen et al., 2014). IL-17 signals mainly through heterodimeric complex of IL-17RA 
and IL-17RC and activates downstream pro-inflammatory pathways NFκB, MAPK and 
C/EBP (Korn et al., 2009; Gaffen et al., 2014). IL-17 can upregulate inflammation by 
inducing secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and 
chemokines for recruiting neutrophils and macrophages (Mills, 2008). IL-17 plays a key role 
in many inflammatory autoimmune diseases such as psoriasis, inflammatory bowel disease, 
multiple sclerosis, rheumatoid arthritis and asthma (Korn et al., 2009; Gu et al., 2013). 
Shichita and co-authors (Shichita et al., 2009) have shown that IL-17 producing cells (mainly 
γδ T cells) mediate ischemic-reperfusion injury. IL-17 positive lymphocytes were also 
detected in post stroke autopsies and antibody mediated neutralization of IL-17 in 
experimental stroke reduced infarction and improved outcome (Gelderblom et al., 2012). 
It is well established that IL-23 plays an indispensable role in the maturation of Th17 cells 
towards an inflammatory phenotype secreting IL-17 (Gaffen et al., 2014). In line with this, 
we found significant increase of IL-17 in aSAH compared to controls and the levels of IL-17 
were significantly higher even at day 7 compared to day 1 in aSAH (Fig. 16). In contrast to 
serum IL-23 levels, severe H&H grade led to the upregulation of serum IL-17 (Table 7). A 
large number of patients develop anterior circulation aneurysms (D'Souza, 2015), the 
increased serum IL-17 in our study might be due to the greater population with anterior 
circulation aneurysms as compared to posterior circulation aneurysms (Fig. 17B). 
Interestingly, presence of both intraventricular and intracerebral hemorrhage led to significant 
downregulation of IL-17 initially and later on it was significantly upregulated (Fig. 17C), 
suggesting an initial neuroprotective anti-inflammatory response might be implicated to limit 
further damage, but later on uncontrolled inflammation led to soaring serum levels of IL-17. 
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Serum IL-17 levels showed decrease in DIND, while IL-23 in seizures (Fig. 17D). 
Interestingly, further subgroup analysis in the infarcts group showed that serum IL-17 levels 
were downregulated in DCI, while interventional CI induced increase in contrast to IL-23 
(Fig. 14E, 17E, Table 7). In contrast to IL-23, serum IL-17 levels were upregulated in the 
patients in other infections group as compared to those who did not contract any infections 
and significant elevations in serum IL-17 were present in other infections group compared to 
only pneumonia or meningitis (Fig. 17F, 18A, B). IL-17 is well known to be upregulated 
under infections and since, other infections group represent aSAH patients with infections 
such as UTI, osteomyelitis or a combination with pneumonia and meningitis infections, so it 
may be likely that the greater burden of infections in this group led to significant upregulation 
of IL-17 secreting cells (Cua and Tato, 2010). These findings suggest that both cytokines 
were differentially regulated in systemic circulation under the development of different 
complications. The existence of association with some of aSAH complications and not with 
some others might be due to the pleiotropic nature of cytokines (Bukowski et al., 1994). 
Several animal and human studies support the upregulation and involvement of IL-17 in 
cerebral ischemic injury (Kostulas et al., 1999; Li et al., 2005; Shichita et al., 2009; 
Gelderblom et al., 2012; Gelderblom et al., 2014). Shichita et al. (2009) have shown that IL-
23 mediates early, while IL-17 is implicated in delayed damage due to ischemia and the 
source of IL-17 were γδ T cells. Neuroglial cells have also been shown to be the source of IL-
17 in the ischemic brain damage (Li et al., 2005). At present, monoclonal antibodies targeting 
either IL-17 or IL-17RA in various inflammatory diseases are being investigated in different 
phases of clinical trials (Gaffen et al., 2014; Teng et al., 2015). Therefore, IL-17 represent 
potential modulatable therapeutic target to treat various inflammatory diseases. 
A complex pathophysiology of aSAH involving brain, vasculature and immune cells preclude 
the pharmacological interventions in human subjects. Further evaluation of the role of IL-
23/IL-17 axis in early brain injury and complications after aSAH is warranted by using 
neutralization monoclonal antibodies or genetic deletion in SAH animal models to provide 
valuable therapeutic options to treat aSAH. 
5.2.3. IL-6 
IL-6 represents a primary and key player in inflammation augmentation (Tang et al., 2014). 
IL-6 is a pleiotropic cytokine with hormone like activity that can influence vascular and 
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metabolic diseases (Bethin et al., 2000; Hodes et al., 2014; Kraakman et al., 2015). IL-6 
signals via IL-6R (CD126, type 1 cytokine α-receptor subunit) and gp130 (CD130, β-receptor 
subunit) and involves downstream pathways such as GTPase Ras-Raf, MAPK and JAK-
STAT (Scheller et al., 2011; Hunter and Jones, 2015). Three modes of IL-6 signaling have 
been identified: classical involving membrane bound IL-6R and gp130; trans-signaling 
dependent on soluble IL-6R whereby only gp130 expressing cells can gain response to IL-6-
sIL-6R complex; and recently identified cluster signaling in which dendritic cells harboring 
IL-6-IL-6R complex in their membranes engage gp130 on the target cell membranes 
(Scheller et al., 2011; Hunter and Jones, 2015; Quintana, 2017).  Depending on the context of 
the disease, IL-6 has both pro-inflammatory and anti-inflammatory effects (Hunter and Jones, 
2015). In acute pathological conditions including aSAH, IL-6 stimulates the 
neuroinflammatory response (Suzuki et al., 2009) that may contribute to the disease 
progression. IL-6 levels in cerebrospinal fluid (CSF) of patients after aSAH have been shown 
to be associated with occurrence of cerebral vasospasm and clinical outcome (Osuka et al., 
1998; Schoch et al., 2007; Sarrafzadeh et al., 2010; Helbok et al., 2015; Niwa and Osuka, 
2016; Wu et al., 2016a; Zeiler et al., 2017). Moreover, elevated early serum IL-6 levels 
predict the unfavourable clinical outcome (Muroi et al., 2013; Hollig et al., 2015b; Hollig et 
al., 2015a; Kao et al., 2015).  
IL-6 is one of the extensively investigated cytokine in the CSF after aSAH, but detailed 
investigations of systemic IL-6 during the course of different post-aSAH complications are 
still lacking. We have observed that systemic IL-6 levels were elevated starting from day of 
bleeding and remained high over the 2 weeks as compared to healthy controls (Fig. 19). Early 
brain injury is a complex row of events including elevation of intracranial pressure, reduction 
of cerebral blood flow, oxidative and metabolic disturbance with acute vascular reaction 
leading to transient global ischemia (Macdonald, 2014). Elevated IL-6 levels on admission 
might be the response of transient global ischemia during the early brain injury. In most of 
brain injuries including cerebral ischemia and SAH, the initial events can lead to secondary 
complications (Miller et al., 2014). Initially released cytokines link the later damage. The best 
example of cytokine mediated late damage is the High Mobility Group Box 1 (Wang et al., 
1999; Tsung et al., 2005). It has been previously shown that cytokines released from necrotic 
cells of ischemic core mediate delayed brain damage in penumbra (Muhammad et al., 2008). 
Interestingly, IL-6 signaling is known to recruit neutrophils at the site of injury in initial 
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phase and proteolytic processing of IL-6R on neutrophils ultimately switches the IL-6 
signaling to resident cells including cerebral vasculature cells (Jones, 2005). Furthermore, IL-
6 can lead to polarization of naïve T cells to Th1 or Th2 cell subpopulations (Diehl et al., 
2002; Diehl and Rincon, 2002). Both sub populations have distinct functions. Th1 type cells 
are pro-inflammatory in nature, but Th2 type cells have anti-inflammatory effects showing 
the anti-inflammatory side of IL-6.  
Elevated IL-6 levels initially after aSAH may contribute to regulate vascular inflammation at 
later stages and hence, may contribute to post-aSAH complications. Occurrence of post-
hemorrhagic complications is the key to determine clinical outcome of patients after aSAH. 
Our data demonstrate that the patients who developed cerebral vasospasm, delayed 
neurological deficits, hydrocephalus and symptomatic epilepsy showed elevated systemic IL-
6 levels (Fig. 21C-F). Interestingly, pharmacological interventions to interrupt IL-6 signaling 
reversed vasospasm in rat femoral artery vasospasm model (Bowman et al., 2004; Bowman et 
al., 2006; Kooijman et al., 2014a). Furthermore, soluble gp130 antagonizing IL-6 signaling 
has been described to follow a parallel increase with IL-6 on day 1 after aSAH in CSF and 
then gradually declines, relieving IL-6 from regulatory check and paving the way to the 
development of vasospasm (Nakura et al., 2011). Elevated serum IL-6 in most of the post-
aSAH complications seems to be a part of generalized inflammatory response rather than a 
cause of a specific post-aSAH complication (Miller et al., 2014). Similarly, the higher IL-6 in 
serum of poor grade aSAH patients (Fig. 20E) is in line with previous investigations 
(Savarraj et al., 2017b) and may reflect the unspecific upregulated inflammatory response due 
to tissue damage. The delayed elevation of IL-6 in serum of patients with cerebral ischemia 
(Fig. 22E) might be secondary to ischemia that is in line with literature from stroke research 
(Gertz et al., 2012). Nevertheless, elevated IL-6 levels showed association with poor clinical 
outcome (Fig. 23) confirming previously published findings (Hollig et al., 2015b; Hollig et 
al., 2015a). Our data suggest that IL-6 is not specific to predict post-aSAH complications, but 
could be a surrogate parameter of global inflammatory burden observed after aSAH (Miller et 
al., 2014). Interestingly, IL-6 has been regarded as the better predictor of disease activity than 
the most commonly used marker, C-reactive protein, because of its homeostatic basal 
regulation and rapid induction under different disease conditions (Panichi et al., 2004; 
Fraunberger et al., 2006; Mroczko et al., 2010). However, in line with the existing literature 
serum IL-6 levels is a predictor of clinical outcome. 
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Our study with human population has interesting findings, but with certain limitations. First 
of all, our patient population is very heterogeneous with wide age range, inclusion of both 
sexes and diverse grade of severity of subarachnoid hemorrhage with Hunt and Hess grad I-
V. All these factors may lead to increase the variation as reflected by our data showing that 
patients with age over 55 years had higher serum IL-6 levels. Hence, due to the heterogeneity 
of aSAH population the data should be interpreted carefully for any implications in the 
clinical setting. 
Moreover, in intubated patients the body temperature is artificially maintained during the 
intensive care. Elevated body temperature is known to be associated with increased IL-6 
levels in systemic circulation (Herrmann et al., 2003). Hence, a controlled body temperature 
in intubated patients may confound the systemic IL-6 levels.  
Furthermore, the assessment of clinical outcome with common test batteries including GOS 
and mRS are not sensitive and roughly reflects the neurological status and hence, the discrete 
changes in neurological status may be overlooked. Altogether the complex and pleiotropic 
nature of IL-6 biology and its elevation in multiple post-aSAH complications makes it an 
unspecific marker for post-aSAH complications. 
5.2.4. IL-10 
The neuronal injury and neurological outcome is based on a delicate balance between pro-
inflammatory and anti-inflammatory mediators (Allan et al., 2005). IL-6 and IL-10 represent 
important players in the inflammatory cascade observed after infectious or inflammatory 
diseases of the CNS (Heep et al., 2004). Serum IL-6 levels have been already known to 
correlate with serum IL-10 levels after intracerebral bleeding and IL-6 can induce an anti-
inflammatory response with upregulated IL-10 at cellular level via regulatory mechanisms 
(Dziedzic et al., 2002; Yasukawa et al., 2003). A very recent study has shown correlation 
among serum IL-6 and IL-10 under different conditions after aSAH (Savarraj et al., 2017a). 
Moreover, suppressed IL-10 expression has been shown in ruptured intracranial aneurysms 
and some SNPs in IL-10 gene have been identified to be associated with the formation of 
intracranial aneurysms (Jayaraman et al., 2005; Sathyan et al., 2015). However, 
comprehensive studies investigating the role of this pleiotropic immunomodulatory cytokine 
after aSAH are still lacking (Garcia et al., 2017). This prompted us to investigate serum IL-10 
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levels after aSAH and investigate its association with post-aSAH complications and clinical 
outcome. 
A significant increase of serum IL-10 was recorded in aSAH patients at both days of 
assessment compared to healthy controls (Fig. 24). Serum IL-10 levels tended to be lower at 
day 7 compared to day 1, but were still significantly higher compared to controls and this 
upregulation of serum IL-10 after aSAH is in agreement with a previous study (Kinoshita et 
al., 2007). Most of the previous clinical studies have evaluated the CSF, extracellular fluid 
(by microdialysis) or serum IL-10 levels without any comparative controls (Dziurdzik et al., 
2004; Mellergård et al., 2008; Mellergard et al., 2011; Hopkins et al., 2012; Savarraj et al., 
2017a). Dziurdzik and coauthors have shown that serum IL-10 levels were significantly 
following a decreasing course with the passage of time in SAH and TBI patients and 
interestingly, serum IL-10 levels were higher compared to TBI patients and similar difference 
was revealed even on microdialysis representing local brain levels of IL-10 later on 
(Dziurdzik et al., 2004; Mellergård et al., 2008; Mellergard et al., 2011). Hopkins et al. 
(2012) did not find a huge separation between CSF and plasma levels of IL-10 after aSAH 
and Mellergard et al. (2011) reported an almost sustained IL-10 in microdialysates without 
any increasing or decreasing trend or fluctuation. 
In subgroup analysis after dichotomization, no impact of patient’s gender, aneurysm location 
or treatment modality on serum IL-10 levels were observed. Mellergard et al. (2011) while 
evaluating the course of IL-10 by microdialysis after aSAH and TBI also did not find any 
gender specific significant difference. A significantly marked elevation in serum IL-10 levels 
was observed at day 7 in aSAH patients with age ≥ 55 years, although IL-10 levels were 
higher at day 1 also (Fig. 25A). This rise might be reflecting parallel IL-10 upregulation in 
response to global inflammatory response after aSAH with advanced age, as increasing age 
independently predicts poor outcome at discharge and since, no such difference exists among 
healthy young and elderly human subjects in serum IL-10 levels and nor in healthy children 
or adults (Kim et al., 2011; Kleiner et al., 2013; Miller et al., 2014; Galea et al., 2017b). 
Peripheral IL-10 levels have already been shown to elevate significantly in poor grade aSAH 
patients (H&H ≥ 4) (Chamling et al., 2017; Savarraj et al., 2017a; Savarraj et al., 2017b). 
Although the levels of serum IL-10 were higher at day 1 and day 7 in our population of poor 
grade aSAH patients, yet they did not reach significant difference (Fig. 25B) and this might 
be due to the difference in H&H grades considered for dichotomy as they have considered 
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higher H&H grades to represent clinically severe aSAH patients. Interestingly, IL-10 levels 
were significantly increased at day 7 after IVH, but presence of both IVH and ICB led to an 
early significant increase in IL-10 at day 1 (Fig. 25C, D). Previous studies investigating the 
levels of IL-10 after intracerebral bleeding have consistently shown its significant 
upregulation and interestingly, IL-10 is linked to increase the expression of CD36 in 
microglia, thereby enhancing their erythrophagocytic capability and CD36 insufficiency led 
to increased pro-inflammatory cytokines and decreased IL-10 expression (Dziedzic et al., 
2003; Oto et al., 2008; Wang et al., 2011a; Fang et al., 2014). 
Serum IL-10 levels were already higher in aSAH patients who later on developed CVS and at 
day 7, serum IL-10 showed a very significant increase in CVS patients (Fig. 25E). This is in 
agreement with the findings of Li et al. (2017) who found significant upregulation of IL-10 
expression in basilar artery showing decreased caliber and thickened walls in a rodent SAH 
model. Interestingly, increased IL-10 expression was associated with a parallel surge of pro-
inflammatory cytokines (IL-1β, TNF-α and IL-6) and increased HMGB1 expression and 
glycyrrhizic acid supplementation, not only relieved vasospasm, but also abrogated the 
expression of pro-inflammatory factors and further enhanced IL-10 expression (Li et al., 
2017). In the current study, a significant elevation of HMGB1 in aSAH patients presenting 
with CVS has also been recorded (Fig. 4F). HMGB1 is known to drive IL-10 release from 
M2-like macrophages through RAGE signaling selectively and also from PBMCs (Huber et 
al., 2016). Therefore, keeping in view these evidences it would be plausible to investigate the 
effects of glycyrrhizic acid clinically, since CVS is known to contribute majorly towards DCI 
and ultimately leading to poor clinical outcomes (Weidauer et al., 2007; Kruyt et al., 2010; 
Kooijman et al., 2014b; Macdonald, 2014; Garcia et al., 2017). 
Serum IL-10 levels were also significantly raised at day 7 in patients requiring 
ventriculoperitoneal shunt mediated diversion of CSF due to development of chronic 
hydrocephalus (Fig. 25F). In normal pressure hydrocephalus, only CSF IL-10 levels have 
been shown to significantly rise and in the context of hemorrhagic stroke, hydrocephalus and 
plasma IL-10 are significantly associated with rebleeding and hematoma expansion with 
consequent adverse outcomes (Wang et al., 2011b; Sosvorova et al., 2014). Higher 
intracranial pressure is also known to elevate CSF IL-10 levels among other cytokines 
(Shiozaki et al., 2005). Serum IL-10 levels have not reflected any impact of cerebral 
ischemia/infarction. However, in patients with DCI serum IL-10 levels seemed to be higher 
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(Fig. 26E, F). Post-aSAH nosocomial infections are commonly reported and serum IL-10 
levels showed significant elevation at day 7 (Fig. 26A) (Frontera et al., 2008; Sarrafzadeh et 
al., 2011). Further dissection of infections group showed that this significant surge in IL-10 at 
day 7 could be contributed by pneumonia or other infections (UTI, osteomyelitis or 
concomitant presence of these with pneumonia or meningitis) (Fig. 26B, C). Chamling et al. 
(2017) have also shown significant association of plasma IL-10 with pneumonia infection in 
aSAH patients. Furthermore, a significant increase at day 1 in serum IL-10 levels was 
observed in patients who developed pneumonia opposed to meningitis (Fig. 26D).  
Finally, outcome assessment at discharge using GOS and mRS showed that serum IL-10 
levels at both days of assessment were associated with poor clinical outcome (Fig. 27A, B). 
As Garcia et al. (2017) have already indicated that comprehensive and sophisticated studies 
investigating serum IL-10 post aSAH are lacking and also to the best of our knowledge, this 
is the first study indicating association of serum IL-10 with poor clinical outcome at 
discharge during the period of early brain injury (day 1) and delayed brain injury (day 7). 
Very recently, Savarraj et al. (2017a) have shown association of serum IL-10 measured 
within 48 hours of aSAH to be associated with clinical outcome at discharge with slightly 
different dichotomization of the mRS scale (Good outcome ≤ 3). These novel investigations 
showing upregulation of systemic IL-10 after aSAH, however, conforms to the previous 
investigations in ischemic stroke, intracerebral hemorrhage or traumatic brain injury 
(Shiozaki et al., 2005; Oto et al., 2008; Mellergard et al., 2011; Wang et al., 2011a; Garcia et 
al., 2017). 
IL-10 represents an important anti-inflammatory cytokine secreted by almost all immune 
cells (Wang et al., 2017). A parallel increase in IL-10 levels is always associated with the 
elevation of pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6) (Li et al., 2017; 
Savarraj et al., 2017a; Wang et al., 2017). Therefore, the significant elevation of IL-10 may 
be reflecting an upregulated inflammatory response set into play after aSAH (Kooijman et al., 
2014b; Savarraj et al., 2017a). IL-10 is known to produce anti-inflammatory effects through 
various mechanisms such as inhibition of pro-inflammatory cytokine release and upregulation 
of antioxidant and radical scavenging enzymes and downregulation of ROS generating 
enzymes (Garcia et al., 2017). Microglial secreted IL-10 activates TGF-β secretion from 
astrocytes that blunts the pro-inflammatory cytokine response of the microglia in a feedback 
mechanism (Norden et al., 2014). IL-10 administration in stroke has been shown to be 
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neuroprotective, which could be the consequence of downregulation of NFκB, upregulated 
STAT3 signaling and inhibition of histone deacetylase resulting in Foxp3 expression by 
Tregs (de Bilbao et al., 2009; Liesz et al., 2013). Autonomic nervous system dysfunction 
after aSAH leading to increased sympathetic activity has been well known to trigger IL-10 
release from peripheral blood mononuclear cells (PBMCs) and systemic IL-10 levels are 
attributed to be mainly derived from blood mononuclear cells (Pelidou et al., 1999; Kinoshita 
et al., 2007). Interestingly, IL-10 with LPS co-stimulation has been described to upregulate 
the expression of chemokine receptors (CCR1, CCR2, CCR5) and downregulate the CCR7 
on dendritic cells, potentially hindering their maturation and migration capacity and the 
upregulated receptors sequester and scavenge pro-inflammatory chemokines such as 
RANTES/CCL5 produced at local inflammatory site (D'Amico et al., 2000). Thus, IL-10 
promotes generation of functional decoy receptors on monocytes and dendritic cells to limit 
inflammatory chemokines (D'Amico et al., 2000). All these evidences highlight an 
indispensable role of IL-10 in inflammation after aSAH which may require further 
translational investigations and suggest that IL-10 has an important prognostic potential in 
aSAH associated complications and clinical outcome. 
5.3. Chemokine response after aSAH 
5.3.1. RANTES/CCL5 
Chemokines represent small soluble mediators which play a critical role in the cell to cell 
communication and leucocyte trafficking (Zlotnik and Yoshie, 2000; Dorner et al., 2002). In 
contrast to the constitutively expressed chemokines with homeostatic role, several of the 
chemokines are induced during inflammation (Mantovani, 1999; Dorner et al., 2002). 
Regulated on activation, normal T cell expressed and secreted (RANTES) or CCL5 is a pro-
inflammatory chemokine from class CC of chemokines and binds several of seven 
transmembrane GPCRs such as CCR5, CCR4, CCR3, CCR1, Syndecan (SDC)-4, SDC-4, 
and CD44 (Rollins, 1997; Xia and Hyman, 1999; Zlotnik and Yoshie, 2000; Suffee et al., 
2017). CCL5 is secreted by T-lymphocytes, endothelial cells, epithelial cells, endometrial 
cells, smooth muscle cells, platelets, eosinophils, fibroblasts, glial cells and neurons (Appay 
and Rowland-Jones, 2001; Terao et al., 2008; Levy, 2009; Tokami et al., 2013). Elevated 
CCL5 has been regarded as a risk factor for stroke in asymptomatic subjects (Canouï-Poitrine 
et al., 2011). In numerous CNS related pathologies, CCL5 has been known to play an 
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inflammatory role (Simpson et al., 2000; Bartosik-Psujek and Stelmasiak, 2005; Cartier et al., 
2005; Zaremba et al., 2006; Tang et al., 2014; Cerri et al., 2017). CCL5 expression has been 
shown to be upregulated in the rat cerebral aneurysm arterial walls (Aoki et al., 2008). Recent 
investigations in the context of SAH have demonstrated the involvement of CCL5 in ongoing 
inflammation (Smithason et al., 2012; Chang et al., 2015b). However, detailed clinical 
investigations of CCL5/RANTES have still not been performed. Here, we have evaluated the 
serum levels of CCL5/RANTES after aSAH and its association with post-aSAH 
complications and clinical outcome at discharge. 
During the current analysis, systemic levels of CCL5 were higher in aSAH patients on early 
assessment at day 1 and later on at day 7 compared to controls (Fig. 28). This is in line with 
increased plasma levels of CCL5 observed after traumatic brain injury and ischemic stroke 
(Tokami et al., 2013; Albert et al., 2017). Analysis of multiple systemic cytokines after aSAH 
has already shown that CCL5 levels peaked 6-8 days after aSAH, but were the part of the 
cluster of platelet associated cytokines that were correlated at all the times of assessment after 
aSAH and included platelet derived growth factor (PDGF)-AA, PDGF-AB/BB, sCD40L, 
CXCL1P1 and TNF-α (Savarraj et al., 2017b). Interestingly, the CCL5 levels were shown to 
be negatively correlated with FLTL3 in less severe grade aSAH patients (Savarraj et al., 
2017b). In an experimental SAH model, CCL5 levels were significantly upregulated in brain 
after 24 hours of SAH and more pronounced increase occurred if mice were pretreated with 
LPS and a very significant decrease was observed after myeloid cell depletion (Smithason et 
al., 2012). Interestingly, in another experimental SAH study, CCL5 upregulated along with 
adhesion molecules after SAH was attenuated by valproic acid supplementation and 
intrathecal administration of CCL5 reversed the valproic acid effects with increased adhesion 
molecules (ICAM-1, VCAM-1, E-selectin) expression and infiltration by CD45+ leucocytes 
(Chang et al., 2015b). 
In the subgroup analysis after data dichotomization, it was interesting to note that the levels 
of CCL5 tended to be non-significantly lower in aSAH patients with higher age (Fig. 29A). 
However, higher age has been shown to be associated with upregulation of CCL5 levels in 
healthy subjects (Mansfield et al., 2012). Dichotomy of aSAH patients based on gender, 
aneurysm location, aneurysm treatment modality, severity of aSAH (H&H grades), CVS, 
DIND, seizures, cerebral ischemia and infections did not reveal any significant difference. 
Intriguingly, serum CCL5 levels were significantly downregulated under the development of 
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intracerebral bleeding, chronic hydrocephalus and pneumonia infection at day 7 in aSAH 
patients in the current study (Fig. 29B–D). Since, intracerebral bleeding represents additional 
damage, it may be likely that delayed release of CCL5 is restricted to limit further damage 
and may involve some immunosuppression phenomenon as CCL5 levels were non-
significantly higher at day 1 (Sarrafzadeh et al., 2011). This is somehow in agreement with 
plasma CCL5 levels observed to be downregulated under severe head injury compared to 
mild to moderated head injury (Albert et al., 2017). Since, infections are associated with a 
downregulation in the levels of RANTES and also immunodepression is observed after 
aSAH, therefore, CCL5 levels were low in pneumonia affected aSAH patients (Sarrafzadeh et 
al., 2011; Albert et al., 2017). 
The serum CCL5 levels were higher in good clinical outcome aSAH patients at day 1 and 
interestingly, at day 7 they were significantly higher compared to poor clinical outcome 
patients as assessed by GOS and mRS on discharge (Fig. 29E, F). Intriguingly, low levels of 
CCL5 have been established as predictors of mortality after myocardial infarction and 
cerebral malaria (John et al., 2006; Cavusoglu et al., 2007). As mentioned above, CCL5 
levels tend to be lower in patients with severe head injury than those with mild to moderate 
head injury (Albert et al., 2017). However, in an experimental ischemic stroke model it was 
shown that knockout of RANTES was associated with relatively lower infarct volumes and 
reduced plasma levels of IL-6, IL-10 and IL-12 and furthermore, circulating blood cells as a 
potential source of RANTES that mediates BBB disruption, cerebral inflammation and 
infarction (Terao et al., 2008). In contrast to this, CCR5 knockouts had larger infarcts 
(Woiciechowsky et al., 1998). Tokami et al. (2013) have tried to answer this puzzling 
contradiction by suggesting an autocrine or paracrine role of neuron derived CCL5 which 
upregulates neuroprotective growth factors such as BDNF, EGF and VEGF and 
downregulates Caspase-3 in neurons through CCR5 and CCR3 ligation on neurons. 
Furthermore, they speculate that CCR1 expression by endothelial cells and by circulating 
blood cells may explain the acute detrimental effects of RANTES (Tokami et al., 2013). All 
these lines of evidence suggest that CCL5 which was found to be higher in good clinical 
outcome aSAH patients at discharge may have neuroprotective role. As to the best of our 
knowledge, this is the first study which investigates serum RANTES after aSAH and its 
association with clinical outcome at discharge, further investigations are strongly warranted 
to confirm these findings using experimental SAH models. 
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The CCL5 source during early brain injury after aSAH might be damaged neurons, glial cells, 
endothelial cells and infiltrating leucocytes as suggested by others in various CNS related 
pathologies (Pedrazzi et al., 2007; Terao et al., 2008; Dénes et al., 2010; Mirabelli-Badenier 
et al., 2011; Tokami et al., 2013). Pedrazzi et al. (2007) have shown that HMGB1 could lead 
to secretion of CCL5 from astrocytes and due to localization of astrocytes in close proximity 
to BBB, secreted CCL5 may play an important role in microglial and blood monocyte 
migration and activation, thus enhancing the brain damage. The systemic levels of HMGB1 
have already been mentioned above to rise robustly after aSAH in our patient population 
(Fig. 2). Promotion of leucocyte infiltration at the inflammation site is a well established 
effect of RANTES (Appay and Rowland-Jones, 2001). CCL5 has been shown to mediate the 
brain damage through increasing the infiltration of mononuclear cells through BBB and lead 
to secondary brain injury via induction of potent inflammatory cytokines (Mirabelli-Badenier 
et al., 2011). Furthermore, CCL5 produced by DCs lead to a Th1 polarized response (Lebre et 
al., 2005; Ma et al., 2007). Interestingly, monoclonal antibody targeting of CCL5 has shown 
reduced leucocyte infiltration in CNS and also prevented neurological deficits in MS mouse 
model (Chang et al., 2015b). Therefore, further translational investigations using leucocyte or 
neuron specific knockout of RANTES or RANTES neutralization are highly encouraged to 
further understand the role of RANTES in the inflammation set into play by SAH.  
5.4. Systemic immune cell response after aSAH 
It is well known that DAMPs can activate the immune cells and trigger the production of 
numerous inflammatory mediators (Castellheim et al., 2009). Therefore, an upregulated 
DAMPs and cytokine response after aSAH may have underpinnings in the activation and 
polarization of immune cells. Hence, we have characterized different monocyte and CD4+ T 
helper cell subpopulations early after aSAH (during initial 72 hours) and later on during 
delayed brain injury phase (day 7) by polychromatic cell surface based flow cytometric 
immunophenotyping.  
5.4.1. Systemic monocyte response after aSAH 
Our data shows that total monocytes (CD45+) were significantly increased at day 7 compared 
to day 1 after aSAH and non-significantly elevated in comparison to controls (p = 0.067), 
suggesting an ongoing upregulated inflammation (Fig. 30A). However, monocytes expressed 
as CD14+ CD15- events did not show any significant difference among controls and aSAH 
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patients (Fig. 30B) and is in line with a previous study (Moraes et al., 2015). In subset 
analysis, no significant changes were evident in classical monocytes, which are mainly 
known to play a phagocytic role owing to higher peroxidase activity, enhanced IL-10 and 
diminished TNF-α response to LPS challenge (Geissmann et al., 2003; Cros et al., 2010). 
Moraes et al. (2015) have shown a significant decrease in intermediate monocytes compared 
to controls. However, we have only found a significant decrease at day 7 compared to day 1 
after aSAH (Fig. 30D) and this might be due to their wider sampling time frame and 
comparatively more number of patients in the control group. However, we found a significant 
decrease in nonclassical monocytes at day 1 after aSAH compared to controls, which did not 
persist till day 7 after aSAH (Fig. 30E). Previous studies have assigned an inflammatory role 
to intermediate monocytes due to their increased IL-1β and TNF-α secretion upon LPS 
stimulation (Cros et al., 2010; Ziegler-Heitbrock et al., 2010; Ziegler-Heitbrock and Hofer, 
2013; Guilliams et al., 2014). Whereas nonclassical monocytes are known to patrol the 
endothelium of vasculature and secrete IL-1β and TNF-α in response to nucleic acids such as 
DNA or RNA (Cros et al., 2010). A recent study has advocated nonclassical monocytes to be 
the main pro-inflammatory subtype and has shown the downregulation of CD16 expression 
during isolation procedures, likely mediating transition of nonclassical into intermediate 
monocytes (Mukherjee et al., 2015). 
Chemokine receptors reflect the distinct maturity and migratory properties of the monocyte 
subsets, therefore, we have also assessed CCR2 and CX3CR1 expression on monocyte 
subsets. Interestingly, CX3CR1 expressing intermediate cells were significantly increased at 
day 1 in comparison to day 7 after aSAH, whereas nonclassical CX3CR1+ cells were 
significantly reduced immediately after aSAH compared to controls (Fig. 31B, C). The 
fractalkine receptor (CX3CR1) is intermediately expressed on intermediate monocytes, while 
highly expressed on nonclassical monocytes and by virtue of this receptor these cells crawl 
along the endothelia of the blood vessels and gain the name as patrolling monocytes 
(Cornwell et al., 2013). CX3CR1 expression is essential for monocyte homeostasis and 
survival due to inhibition of apoptosis (Landsman et al., 2009). Interestingly, the mice 
monocytes corresponding to the nonclassical human monocyte subset give rise to M2 or 
alternate tissue macrophages during inflammation (Cornwell et al., 2013; White et al., 2014). 
Conversely, CCR2 is highly expressed on classical monocytes and intermediate monocytes 
have characteristically intermediate expression and lowest on nonclassical subset. 
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Furthermore, CCR2 plays an important role in monocyte emigration from bone marrow and 
homing into sites of injury and differentiation into inflammatory macrophages (Geissmann et 
al., 2003; Tacke and Randolph, 2006; Cornwell et al., 2013). In line with this, CCR2+ 
classical monocytes were significantly increased after aSAH on day 1 compared to healthy 
controls (Fig. 31D), although no significant difference was found in classical monocytes 
among controls and aSAH patients. Similarly, CCR2+ intermediate monocytes were 
nonsignificantly higher at day 1 in aSAH patients as compared to controls and were 
significantly increased in comparison to day 7 after aSAH (Fig. 31E).  
The monocyte activation marker HLA-DR represents an analog of MHC-II and is responsible 
for antigen presentation to T cells for paving the way to adaptive immune response (Palojärvi 
et al., 2012). Interestingly, HLA-DR expression has been shown to be upregulated during 
infection, but in sepsis and severe critical illness, downregulated HLA-DR expression on 
monocytes has been observed as a part of compensatory anti-inflammatory response 
syndrome which leads to immunosuppression (Kim et al., 2010; Palojärvi et al., 2012). 
Intriguingly, HLA-DR expressing classical monocytes were significantly decreased after 
aSAH at day 1 and day 7 as compared to controls; while HAL-DR+ intermediate cells 
showed decrease on day 7 compared to day 1 after aSAH; and nonclassical HLA-DR+ 
monocytes were significantly lower on day 1 after aSAH as compared to controls (Fig. 31G – 
I). These findings are in agreement with previous observation of reduced HLA-DR 
expression on monocytes and a prevalence of pneumonia infection among aSAH patients 
(Sarrafzadeh et al., 2011). The reduction in HLA-DR expression may stem from increased 
IL-10 and cortisol levels (Kim et al., 2010). Interestingly, we have found a significant 
increase in serum IL-10 after aSAH (Fig. 24) and the greater sensitivity of classical 
monocytes to HLA-DR downregulation is in concordance with a previous study, which 
suggested increased IL-10R expression on classical monocytes to be the likely mechanism 
(Kim et al., 2010). 
To our knowledge, this is the first study in the context of aSAH analyzing monocyte subsets 
along with activation markers during early and delayed brain injury and showing differential 
expression of different monocyte subsets along with their activation markers. 
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5.4.2. Systemic CD4+ T cell response after aSAH 
Over the past, different subsets of CD4+ T cells have been characterized, differentiating from 
naïve T cells under the influence of various cytokine microenvironments and expressing 
specific signature transcriptional factors, into Th1, Th2, Th17 and Treg cells (Murphy and 
Reiner, 2002; Acosta-Rodriguez et al., 2007; Sakaguchi et al., 2010). Th1 and Th17 cells 
represent with an inflammatory profile, while Th2 and Tregs promote anti-inflammatory 
responses (Murphy and Reiner, 2002; Acosta-Rodriguez et al., 2007; Boissier et al., 2008; 
Sakaguchi et al., 2010). A limited number of studies have investigated the major lymphocyte 
subsets such as CD4+ T cells, CD8+ T cells, and B cells after aSAH (Chrapusta et al., 2000; 
Sarrafzadeh et al., 2011; Moraes et al., 2015), but to date up to the best our knowledge, no 
study investigating specifically the subsets of CD4+ T cells based solely on the cell surface 
expression of different receptors and activation markers during early and delayed phase of 
aSAH has been performed. 
Interestingly, we found significant decrease in lymphocytes and CD4+ T cells expressed as 
frequencies of CD45+ leucocytes after aSAH compared to controls (Fig. 32A, B). This 
lymphopenic response is in line with previous studies (Sarrafzadeh et al., 2011; Moraes et al., 
2015). However, CD4+ T cells among lymphocyte population were outnumbered at day 1 
and day 7 after aSAH as compared controls (Fig. 32C) which is in par with findings from 
(Moraes et al., 2015). The different subsets of CD4+ T cells showed some interesting 
significant differences and trends after aSAH. Th1 cells, which are pro-inflammatory in 
nature, were non-significantly lower at day 1 after aSAH (p = 0.087) compared to controls 
and increased non-significantly at day 7 compared to day 1 (p = 0.092) almost similar to that 
of controls (Fig. 33A). Notably, the Th2 cells were very slightly increased at day 1 after 
aSAH as compared to controls without significant difference, but this was followed by a 
significant decrease at day 7, which clearly represents an almost equal, but opposite 
behaviour of Th1/Th2 paradigm. Inhibition of Th1 response and augmentation of Th2 
response has been shown to exert a neuroprotective role and improved outcomes in 
experimental models of ischemic stroke (Ayer et al., 2013). Similar to Th1 cells, Th17 cells 
were non-significantly lower at day 1 after aSAH as compared to healthy controls, but at day 
7 after aSAH, Th17 cells significantly recovered to the levels almost similar to controls (Fig. 
33C). Strikingly, Treg cells were significantly higher at day 1 after aSAH and increased 
further at day 7 with significant difference as compared to day 1 aSAH patients and healthy 
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controls (Fig. 33D). The pattern of Treg cells response seemed to parallel the inflammatory 
response of Th1 and Th17 subtypes. The increased Treg cells response seen after aSAH in 
our study is similar to that of observed after intracerebral hemorrhage (Shi et al., 2015). 
Zhang et al., have recently adopted a similar approach to identify helper T cell subsets and 
demonstrated a significant increase in Th17 and significant reduction in Th2 cells compared 
to healthy controls, which is in contrast to our findings as we have observed similar changes 
at day 7 as compared to day 1 in only aSAH patients. The plausible explanations for this 
difference might be due to inclusion of both ruptured and unruptured intracranial aneurysm 
patients and utilization of cryopreserved peripheral blood mononuclear cells. The chemokine 
receptor expression might be sensitive to temperature changes and density gradient separation 
techniques also modify surface expression of different receptors (Jalbert et al., 2013; 
Mukherjee et al., 2015). 
Another peculiar aspect of our study of helper T cell subsets was the inclusion of permanent 
cell surface activation markers such as CD38 and HLA-DR as opposed to transient activation 
marker CD69 (Maecker et al., 2012). Assessment of CD38 and HLA-DR activation markers 
revealed that these markers are differentially expressed on different subsets of T helper cells 
(Fig. 34). CD38 expressing T cells have been shown to be larger, more granular and have 
reduced proliferative capacity, but enhanced cytokine production capability (Sandoval-
Montes and Santos-Argumedo, 2005). Both HLA-DR and CD38 expression have been used 
as markers of activation of T cells and disease progression in various inflammatory diseases 
(Funderburg et al., 2013). The HLA-DR+ subset of Treg cells has been recognized as 
terminally activated effector Treg cells equipped with profound inhibition of proliferation of  
conventional T cells and prompt cytokine production compared to their HLA-DR- 
counterparts (Sakaguchi et al., 2010). Our results represent various novel findings with 
respect to different activation states of T helper cell subsets and suggest that polarization of 
these subsets is dynamic over the course of disease. However, the major limitation is the 
small sample size and further investigations are warranted to consolidate these findings in a 
large observational study. 
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6. Conclusion 
Our data shows that damage associated molecular patterns including HMGB1 and mt 
DAMPs were elevated in the systemic circulation of patients with aSAH. Systemic HMGB1 
was significantly associated with CVS and may have the potential to be a predictive 
biomarker for CVS. Furthermore, systemic cytokines including IL-17, IL-23, IL-6, IL-10 and 
RANTES have shown significant upregulation after aSAH and are involved in various 
complications after aSAH. Different subsets of monocytes and CD4+ T cells were 
differentially regulated during early and delayed phases of brain injury after aSAH. These 
findings altogether suggest an upregulation of systemic inflammation after aSAH, which may 
have diagnostic, prognostic and therapeutic implications and warrants further investigations 
using more sophisticated multicenter clinical studies and validation employing translational 
research.
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7. Future Perspectives    
Aneurysmal SAH is a complex disease involving a systemic inflammatory response, which is 
the mainstay of the current research. A plethora of DAMPs, cytokines and other molecular 
mediators may underlie this systemic inflammatory response which contributes to the 
development of different complications and delayed deterioration. The role of these pro- or 
anti-inflammatory molecules should be investigated through translational studies by 
exploiting genetic knockout techniques, administering monoclonal antibodies, aptamers and 
oligodeoxynucleotides, downregulating the expression through administration of miRNAs or 
by using pharmacological small molecule inhibitors. 
Recently there is increasing evidence and renewed interest in the communication taking place 
at neuronal and immune interfaces with potential implications in modulating the pro-
inflammatory or anti-inflammatory responses in the periphery (Chavan et al., 2017). 
Advancements in neuromodulation is uncovering new horizons to use “electrons” as 
therapeutics to modulate innate and adaptive immune responses in different diseases (Chavan 
et al., 2017). We have recently shown that the burst spinal cord stimulation (BSCS) not only 
leads to improvements in back pain in patients with failed back surgery syndrome (FBSS), 
but can also modulate the systemic levels of different cytokines and adipokines (Kinfe et al., 
2017; Muhammad et al., 2017b; Muhammad et al., 2017a). We have found that BSCS 
increases the anti-inflammatory cytokine IL-10 systemic levels, which may underlie the 
improvements in pain and functional capacity in FBSS patients (Kinfe et al., 2017). Slavin 
and co-authors have studied the feasibility of cervical spinal cord stimulation (cSCS) over 
two weeks after aSAH for the management of CVS (Slavin et al., 2011). Neuromodulation 
represents an interesting field of research, though in infancy, has the potential to modulate the 
immune responses and may be exploited against systemic inflammation set into play after 
aSAH.
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8. Summary 
Aneurysmal subarachnoid hemorrhage (aSAH) is a dreadful disease with overwhelmingly 
high mortality and morbidity, although it accounts for only 5% of all strokes. Around half of 
the affectees are destined to death and it affects at relatively younger age. About 20% of the 
patients die before hospitalization and 40% - 60% within a month. Rupture of the intracranial 
aneurysm floods the subarachnoid space with blood and sometimes also involves brain 
ventricles and deeper brain parenchyma. Although, the obliteration of the bleeding aneurysms 
can be successfully achieved by neurosurgical clipping or endovascular coiling, but still a 
significant proportion of aSAH patients succumbs to life threatening complications such as 
CVS, DIND, seizures, chronic hydrocephalus, cerebral ischemia, infections and achieves 
poor clinical outcome. Failure of the CVS reversal paradigm to improve clinical outcome has 
led to reassess the role of inflammation in aSAH and its associated complications. Over the 
past, a role of systemic inflammation is well appreciated and the aim of our study was to 
assess systemic inflammation after aSAH and its associated complications.  
Sterile inflammation is set into play after engagement of the DAMPs with PRRs on immune 
cells leading to their activation and polarization with the consequent release of inflammatory 
mediators such as cytokines. In order to characterize the systemic inflammation after aSAH, 
we have investigated the release of prototypical DAMPs members such as HMGB1, 
mitochondrial DNA, IL-1α and IL-33 after aSAH. Different pro-inflammatory and anti-
inflammatory cytokines such as IL-23, IL-17, IL-6, IL-10 and CCL5 (RANTES) were 
analyzed at day 1 and day 7 after aSAH. The immune cells specifically monocyte subsets and 
CD4+ T helper subsets were analyzed by polychromatic cell surface based flow cytometry 
during early and delayed brain injury phases after aSAH. 
Assessment of the DAMPs response showed significant elevation of serum HMGB1 after 
aSAH from day 1 until day 13. Interestingly, serum HMGB1 levels were significantly 
elevated in aSAH patients developing CVS early from day 1 until day 13. Hence, HMGB1 
may have a prognostic potential for CVS after aSAH. Mitochondrial DNA gene fragments 
such as CytB, D-Loop and COX-1 were significantly elevated early after aSAH with 
exception of CytB, achieving significance at day 7. Serum mtDNA gene fragments showed 
differential associations with different aSAH patients’ associated characters, complications 
and clinical outcome. However, IL-1α and IL-33 were rarely detectable in the systemic 
circulation after aSAH. 
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Among the cytokines, systemic IL-23 and IL-17 inflammatory axis was significantly 
upregulated after aSAH. However, subtle associations exist among subgroup analysis based 
on data dichotomization. The well-known acute pro-inflammatory cytokine, IL-6 was also 
evaluated after aSAH and serum IL-6 levels represented as an unspecific marker of aSAH 
associated complications and clinical outcome. The pro-inflammatory chemokine and 
cytokine CCL5 (RANTES) was also significantly elevated after aSAH, but CCL5 levels were 
significantly decreased at day 7 in patients who developed chronic hydrocephalus and 
pneumonia infection. Interestingly, CCL5 levels were significantly higher in good clinical 
outcome aSAH patients at day 7 after aSAH. Serum IL-10 levels were also significantly 
elevated and showed significant association with CVS, chronic hydrocephalus and infections 
at post-SAH day 7. Intriguingly, serum IL-10 levels were significantly elevated in poor 
clinical outcome patients at day 1 and day 7 after aSAH.  
Monocytes were non-significantly increased after aSAH. Intermediate monocytes were 
significantly higher at post-SAH day 1 compared to day 7, while nonclassical monocytes 
were significantly decreased compared to healthy controls at day 1. The CX3CR1+ 
intermediate and nonclassical monocytes showed the similar significant differences as that of 
their parent populations. Intriguingly, classical CCR2+ monocytes significantly increased on 
post-SAH day 1 as compared to controls and intermediate CCR2+ monocytes compared to 
post-SAH day 7. Finally, HLA-DR+ classical monocytes were significantly reduced after 
aSAH at both day 1 and day 7 compared to controls, while intermediate and nonclassical 
HLA-DR+ monocytes showed significant differences as that of their parent populations. 
Interestingly, CD4+ T cells were significantly increased after aSAH. Interestingly, Th2 cells 
were significantly reduced at day 7, whereas Th17 cells increased compared to day 1 post-
SAH. However, Treg cells were significantly increased at both assessment days compared to 
controls. These subtypes also revealed some interesting significant differences regarding their 
activation states assessed by CD38 and HLA-DR expression. 
All these findings reflect an upregulated systemic inflammatory response after aSAH, which 
may underlie different post-aSAH complications and affect the clinical outcome. Moreover, 
the pro-inflammatory and anti-inflammatory factors are differentially regulated over time 
after aSAH during the development of complications. These investigations unveil the 
possible role of systemic inflammatory mediators as potential diagnostic and prognostic 
markers.
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10.3. Composition of solutions used 
10x Tris EDTA (TE) pH 7.4  
 100 mM Tris-Cl (pH 7.4) 
 10 mM EDTA (pH 8.0) 
Solutions were sterlized by autoclaving for 20 minutes at 15 psi on liquid cycle. Stored the 
buffer at room temperature 
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10.4. List of antibodies along with their catalog numbers and clones 
Sr. 
# 
Product Clone Catalog 
no. 
Company 
1 Anti-Human CD127 FITC HIL-7R-
M21 
560549 Pharmingen
TM
 BD 
Biosciences 
2 Anti-Human CD183 
(CXCR3) APC 
1C6 550967 Pharmingen
TM
 BD 
Biosciences 
3 Anti-Human CD196 (CCR6) 
BUV737 
11A9 564377 Horizon
TM 
BD Biosciences 
4 Anti-Human CD25 PerCP-
Cy5.5 
M-A251 
 
560503 Pharmingen
TM
 BD 
Biosciences 
5 Anti-Human HLA-DR 
BV421 
G46-6 562804 Horizon
TM
 BD Biosciences 
6 Anti-Human CD4 BV605 RPA-T4 562658 Horizon
TM 
BD Biosciences 
7 Anti-Human CD3 PE-Cy7 UCHT1 563423 Pharmingen
TM
 BD 
Biosciences 
8 Anti-Human HLA-DR PE-
Cy7 
L243(G46
-6) 
560651 Pharmingen
TM
 BD 
Biosciences 
9 Anti-Human CD16 APC B73.1 561304 Pharmingen
TM
 BD 
Biosciences 
10 Anti-Human CD15 PerCP-
Cy5.5 
HI98 560828 Pharmingen
TM
 BD 
Biosciences 
11 Anti-Human CD192 (CCR2) 
BV421 
48607 564067 Horizon
TM 
BD Biosciences 
12 Anti-Human CD45 APC-H7 2D1 560178 Pharmingen
TM
 BD 
Biosciences 
13 Anti-Human CD38 PE HIT2 555460 Pharmingen
TM
 BD 
Biosciences 
14 Anti-Human CD14 FITC M5E2 555397 Pharmingen
TM
 BD 
Biosciences 
15 Anti-Human CX3CR1 PE 2A9-1 12-6099-
42 
Affymetrix eBioscience
TM
 
 
 
List of Publications 
164 
 
10.5. Gating strategy for monocytes 
 
The initial gate was made on the events with consistent flow by bivariate plot of Forward 
Scatter (FSC) and time (1). Then, these events were shown as FSC and side scatter (SSC) plot 
and a global gate was used to select leucocytes excluding erythrocytes, platelets and debris 
(2). Next doublets were excluded based on FSC-A vs FSC-W (3). Subsequently, dead cells 
were excluded based on their Hoechst 33258 staining (4). Then, a bivariate plot of SSC vs 
CD45 was used to select the CD45+ leucocytes (5). Further, these events were displayed once 
again on a bivariate plot of SSC vs CD45 and then, monocytes were selected based on their 
intermediate SSC and CD45 expression (6). Monocytes were then displayed as CD14 vs 
CD16 plot and a global gate was placed around CD14+ CD16+ events (7). Further, 
CD14+CD16+ events were displayed as CD14 vs CD15 plot and CD15+ events were 
excluded to purify monocytes from left over granulocytes (8). Once again, CD14+CD15- 
events were displayed as a bivariate plot of CD14 vs CD16 (9). Then, three subsets of 
monocytes were identified such as classical CD14++CD16- (C), intermediate CD14+CD16+ 
(I) and nonclassical CD14-CD16++ (N). The expression of chemokine receptors CX3CR1 
(10), CCR2 (11) and HLA-DR (12) was determined on all these three subsets by employing 
respective FMO controls on histogram plots. 
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10.6. Gating strategy for CD4+ T cell subsets 
 
Gating strategy was similar to monocytes until the identification of CD45+ leucocytes. 
Lymphocytes were selected from these CD45+ events by their low side scatter and high 
CD45 expression (1). These lymphocytes were then displayed as CD3 vs CD4 plot and a 
quadrant gate was applied (2). Then, from this quadrant gate CD3+ CD4+ events were 
selected as CD4+ T cells. CD4+ T cells were then displayed on a CD25 vs CD127 plot and 
CD25hiCD127lo events were gated as Tregs and this gating strategy was based on CD25 
FMO control (3). Then, by applying a NOT gating function, events other than Tregs were 
selected and were named as Th cells. These Th cells were further displayed on a bivariate 
plot of CXCR3 vs CCR6 (4). Then, a quadrant gate was used based on FMO controls for 
CXCR3 and CCR6 to identify CXCR3+ CCR6- cells as Th1, CXCR3- CCR6- cells as Th2 
and CXCR3- CCR6+ Th17 cells. Then, HLA-DR+ and CD38+ cells were identified among 
these subsets such as Tregs (5), Th1, Th2, and Th17 cells (6) by using FMO controls and 
applying a quadrant gate. 
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